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Abstract 
Infection with the Plasmodium falciparum malaria parasite results in an immune response which includes 
the production of antibodies against the blood-stage of infection.  In recent years there has been an 
increase in the use of serological data to monitor malaria transmission intensity. Traditionally, EIR and 
parasite prevalence were the preferred tools for measuring malaria transmission intensity. Serology has 
been shown to be particularly useful in areas of low endemicity where traditional measures (EIR and 
parasite prevalence) are problematic. Transmission intensity in this case is usually described by the 
seroconversion rate obtained from fitting a catalytic model to age-stratified serological responses.  
The aim of my thesis was to better utilise the continuous measurements of antibody responses provided by 
serology studies to obtain improved estimates of transmission intensity. To do this, I developed a series of 
biologically motivated models to mimic the acquisition and decay in blood-stage antibody responses.  
In the first part of the thesis, I developed a discrete model as a direct extension of the catalytic model and 
fitted this to cross-sectional data from several sites in Cambodia to obtain an estimate of the exposure rate. 
In the second part of the thesis a series of continuous density models were developed to mimic antibody 
acquisition and loss for P. falciparum infections. These models were fitted to both the Cambodian data and 
separately validated by fitting to data from Tanzanian villages at a wider range of transmission intensities. 
In the final section I applied and extended the model to encompass a wider range of endemic transmission 
in Somalia, Bioko Island, Gambia and Uganda in order to assess the robustness of the method.  
My results show that estimates of the exposure rate obtained by fitting the density model are highly 
correlated with classic malariometric indices and that a key advantage of this approach is the increased 
precision in the estimates compared to estimates of the seroconversion rate, especially in areas of low 
transmission. This method could therefore be a useful alternative framework for quantifying transmission 
intensity which makes more complete use of serological data and shows potentials for detecting 
heterogeneity in malaria exposure. 
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Chapter 1: Introduction 
1.1 Malaria History 
The origin of malaria dates back to 50,000 years ago, as confirmed by phylogenetic studies. Humans may 
have been infected by malaria since the origin of the species [1, 2]. The malaria parasite, Plasmodium has 
evolved with humans, migrated out of Africa and adapted itself to new environments [3]. The term malaria 
originates from the Italian mala aria, signifying “bad air” while the French terminology “paludisme” 
indicating the association with swamps was later introduced. 
In 1880, a French army surgeon Laveran observed for the first time the malaria parasite in the blood of one 
of his patients suffering from malaria. But it is only in 1898 that the British Sir Ronald Ross and the Italian 
Giovanni Batista Grassi showed that malaria was transmitted by mosquitoes and established the complete 
cycle of malaria transmission [4]. Ross & McDonald introduced mathematical modelling to describe 
transmission dynamics and were pioneers in malaria control, giving hope for eradication of malaria [5].  
A Global Malaria Eradication Program (GMEP) was launched in 1950 by the World Health Organisation 
(WHO) with the objective of eliminating malaria from endemic countries. Measures for malaria control 
consisted of indoor residual spray using the newly discovered insecticide DDT and treatment with 
chloroquine. The results of the campaign, whilst successful in Western areas including Europe, USA and 
Australia, were disappointing in tropical countries where malaria transmission was highly intense and no 
real gains were made [6]. In 1969, it was generally accepted that malaria eradication would not be achieved 
and the new objective shifted to malaria control. 
Foreign soldiers infected with malaria during Korean and Vietnamese wars provided useful samples for the 
investigation of antibodies from non-immune populations. In the 1960s, serology was shown to be a useful 
tool for measuring local transmission and assessing the impact of elimination and control interventions. A 
large number of seroepidemiological studies were subsequently undertaken to assess the potential for 
elimination [7] and confirm the success of elimination [8, 9]. As the funding for malaria eradication 
decreased, the use of serology also did. But with the recent renewed interest in the elimination of malaria 
resurrected by Bill and Melinda Gates and sequentially endorsed by WHO [10], the use of 
seroepidemiological studies is back on the agenda, with improved and standardised methods [11].    
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1.2 Epidemiology and Biology of Malaria  
1.2.1 Malaria epidemiology 
1.2.1.1 Malaria burden 
Malaria is widely distributed throughout the tropical and subtropical regions of the world [12–14] and is 
estimated to be accountable for 219 million clinical cases annually. Malaria remains an important cause of 
morbidity causing an estimated 660 000 deaths annually worldwide [15], with children bearing the greatest 
burden [16]. Indeed about 85% of the deaths globally were estimated to be in children under the age of 5 
years. According to the WHO, out of the 99 countries with on-going malaria, half of them were on track to 
meet the World Health Assembly (WHA) and Roll Back Malaria (RBM) target: to achieve a 75% reduction in 
malaria cases by 2015, compared to levels in 2000. 
Malaria is caused by the protozoan Plasmodium. Four species are responsible for human malaria: 
Plasmodium falciparum, P. vivax, P. ovale and P. malariae. Among these species, P. falciparum accounts for 
most mortality and P. vivax is responsible for most of the malaria infection outside Africa. In 2007, a total of 
2.37 billion people were estimated to be at risk from P. falciparum [17] geographically wide spread (Figure 
2.1).  
 
Figure 2.1: The spatial distribution of P. falciparum malaria endemicity in 2010. The land area was defined as no risk 
(light grey), unstable risk (medium grey) and annual mean PfPR for children between the age of 2 and 10 is 
presented as a continuum of blue to red from 0%-100% (see map legend).  Reproduced from Gething et al [14]. 
Due to its high associated mortality, its resistance to some anti-malaria drugs and its widespread 
prevalence in Africa, P.falciparum has been regarded as the greatest threat [18, 19]. However, P. vivax has 
a wider geographical range and exposes more people at risk of transmission worldwide, with 2.85 billion 
people estimated to be at risk [20].The vast majority of people affected by P. vivax (91%) live in the Central 
and South East Asia region [20]. The endemic areas of P. vivax often overlap with those affected by P. 
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falciparum with the exception of temperate zones such as sub-Saharan Africa, where populations lack Duffy 
glycoprotein expression of the red-blood cells which prevents invasion of the P. vivax merozoite [20, 21]. 
There are an estimated 80 to 300 million clinical cases of P. vivax every year [21].  
1.2.1.2 Malaria control and elimination 
Malaria affects essentially poor countries and represents an enormous health as well as a huge economic 
burden on these populations. . Indeed, if elimination or even control could be achieved and sustained in 
malaria endemic countries, not only millions of malaria cases would be averted but economic benefits 
would be observed at different levels including public health, households and industry, and school 
absenteeism would certainly be reduced [22]. 
The recent resurgence of interest in malaria elimination [23, 24] along with the call from the Bill and 
Melinda Gates Foundation [10] for worldwide malaria eradication has proactively engaged the attention of 
the international health community concerning the global fight against malaria. The target is no longer to 
control malaria – i.e. to treat disease but rather to eradicate malaria (See Table 2.1 for definitions) or as 
stated “to reach a day when no human being has malaria, and no mosquito on earth is carrying it". Funds 
have become available not only to prevent disease and death but to move towards eradication by reducing 
transmission [25, 26]. Lessons learned from the past have shown that if malaria control activities are 
reduced after aggressive scale-up, it can have a catastrophic impact [22]. In order to achieve and maintain 
malaria elimination/control, existing interventions need not only to be scaled up but new interventions and 
monitoring systems need to be developed [27, 28]. As a result, as transmission intensity decreases, the 
need for efficient surveillance tools becomes crucial [29], particularly for areas with low levels of 
transmission. Serological methods are therefore increasingly used for this purpose [30]. 
Table 2.1: Definition of Control, Elimination and Eradication [31] 
 Term Definition 
Control Reducing the disease burden to a level at which it is no longer a public health problem 
Elimination Interrupting local mosquito-borne malaria transmission in a defined geographical area, i.e 
zero incidence of locally contracted cases, although imported cases will continue to 
occur. Continued intervention measures are required 
Eradication Permanent reduction to zero of the worldwide incidence of malaria infection 
 
1.2.1.3 Malaria interventions 
The unsuccessful Global Malaria Eradication Program (GMEP), discontinued in 1969, has shown that 
malaria elimination cannot be tackled with a global single intervention. Combinations of interventions 
would be required to be sustainable but firstly, in addition to successful impact of the interventions on 
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transmission, this program would need long term commitments and the development of efficient 
surveillance systems [6]. 
Financial support for malaria research has helped to introduce or scale-up specific interventions to 
decrease the malaria morbidity and mortality [17, 32]. Clinical malaria can be treated with anti-malarial 
drugs that target blood-stage infection and clear parasitaemia. Historically, Quinine was used to treat 
malaria patients. Subsequently Chloroquine was considered first-line therapy until parasite resistance 
developed against the drug. Today, artemisinin combination therapies (ACT) are currently the 
recommended first-line treatment in many countries [15]. Malaria burden can also be reduced with the use 
of chemoprophylaxis and intermittent preventive treatment (IPT) targeting high risk groups, i.e. young 
children and pregnant women. Additionally, Mass Drug Administration (MDA), in which involves repeatedly 
treating the entire population and Mass Screening and Treating (MSAT), in which only those diagnosed as 
parasite positive are treated, can be used to support malaria elimination [33]. In addition to treating or 
preventing clinical malaria, antimalarials can also reduce transmission. Artemisinin can have some effect in 
reducing the number of circulating gametocytes. Primaquine and Tafenoquine are also efficient drugs 
against mature gametocytes [34, 35] but can cause haemolysis in individuals who are glucose-6-phosphate 
dehydrogenaze (G6PD) deficient [26]. 
Above all, the most efficient interventions for reducing transmission intensity remain vector control 
interventions, either by preventing contact between human and vector or by killing the mosquitoes. Use of 
insecticide treated nets (ITN) or long lasting insecticide-treated nets (LLIN) within households has increased 
in many African countries [32, 36–38]. Additional vector-control measures have been deployed in some 
locations, including indoor residual sprays (IRS) and larval control [39]. These interventions have already 
been associated with encouraging progress in some areas [15]. For instance, in Bioko, following the 
implementation of a control program with IRS, a successful decrease of 42% of the number of infection was 
recorded between 2002 and 2004. Also, Langeler conducted a review examining 22 studies and concluded 
that ITNs had a 17% protection efficacy against mortality in children [40]. Additionally, in southern Africa, 
Somalia, Eritrea, Rwanda as well as coastal Kenya, The Gambia and on the islands of Zanzibar, and Sao 
Tome and Principe, declining trends of malaria have been observed following the implementation of vector 
control interventions [39, 41–48]. Planning, implementing and measuring the impact of malaria 
interventions, however, depends on the transmission settings. 
As the number of new diagnostics, drugs, vaccine and insecticides is increasing, the number of challenges 
to achieve malaria elimination is unfortunately also increasing [28]. With a call for full coverage with 
insecticide-treated nets and the roll-out of artemisinin combination therapy (ACT), resistance to insecticide 
and tolerance/resistance to drugs is rapidly spreading [49, 50], threatening the effectiveness of 
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interventions. Additionally, P. vivax, which has been under less attention, represents an important 
challenge that needs to be tackled for successful elimination of malaria. 
1.2.2 Malaria biology 
1.2.2.1 Life cycle 
An infected mosquito injects sporozoites into the host (Figure 2.2); these reach the bloodstream and make 
their way to the liver. Sporozoites invade hepatocytes and differentiate into trophozoites. Trophozoites 
subsequently undergo schizonic development and mitotic replications. After thousands of replications, 
hepatocytes release merozoites into the bloodstream. For P. vivax, some of these differentiate into the 
dormant stage, termed hypnozoites, that will stay in the liver and can cause relapse weeks, months or years 
later. Merozoites are released in the bloodstream and quickly invade red blood cells (erythrocytes); further 
asexual reproduction takes place in 48 hour cycles for P. falciparum, releasing more merozoites by rupture 
of red blood cells. This stage gives rise to the majority of malaria symptoms. In P. vivax infection, 
merozoites can differentiate into mature gametocytes before any clinical infection and illness develops. 
Some merozoites develop into male or female gametocytes which initially mature while sequestered in the 
vasculature. Gametocytes are then taken in a mosquito’s blood meal and sexual reproduction occurs in the 
mosquito midgut, forming diploid zygotes (ookinetes). These penetrate the midgut walls and form oocysts. 
Meiosis occurs and produces haploid sporozoites which migrate to the salivary glands to form sporozoites 
and complete the cycle.  
 
Figure 2.2: Life cycle of Plasmodium falciparum. Reproduced from Dondorp et al [51]  
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1.2.2.2 Clinical presentation 
Infections with P.falciparum or P. vivax can be asymptomatic or develop into malaria disease which can be 
uncomplicated or severe. Individuals have asymptomatic malaria when they carry parasites but do not 
develop any clinical symptoms of infection. Uncomplicated malaria is the most common presentation of the 
disease. The symptoms are usually fever, headache, weakness and nausea. Severe malaria is often 
characterised by three main syndromes, i.e. anaemia, cerebral and respiratory distress. Other disease 
syndromes include seizures and hypoglycaemia. The acute symptoms of P. vivax including fever, body ache 
and headache have resulted in P. vivax malaria being classified as a benign disease due to its inability to 
adhere to the vascular endothelium [20, 21, 52]. However, recent studies have revealed a significant risk of 
severe disease and death caused by P. vivax [18, 19, 53, 54]. Another clinical characteristics of P. vivax that 
distinguishes it from P.falciparum is “clinical relapse” - the re-emergence of parasitaemia from liver-stage 
hypnozoites - which can happen weeks or months after exposure. In endemic settings this is difficult to 
distinguish from reinfection from biting mosquitoes or re-occurrence (clinical symptoms from a previously 
subclinical parasitaemia) and hence is to date best characterised in travellers returning from endemic 
countries [18, 53]. 
1.2.2.3 Immunity to malaria 
Populations living in malaria endemic areas develop immunity to malaria. However, protection against 
malaria is rarely life-long [55] and is often only partial. Indeed, infections tend to be controlled and 
tolerated rather than eliminated or prevented [56]. There are different levels of immunity, acquired at 
different rates (Figure 2.3). Protection against severe malaria is acquired most rapidly, followed by 
immunity to febrile/uncomplicated clinical disease and finally immunity to asymptomatic blood-stage 
parasitaemia [57]. The acquisition of immunity depends on exposure [58] and age [59–61]. Infants are first 
protected by maternal immunity but then become vulnerable to malaria episodes [62]. As age increases, 
there is a decreasing probability of children experiencing a malaria attack, presented in studies in areas of 
high endemicity to be independent of cumulative exposure [63].  Also, it was shown that for non-immune 
individuals migrating to endemic areas that adults acquire a faster protection from clinical attacks than 
children [64], demonstrating an age-dependency of the acquisition of immunity.  However, adults were also 
more susceptible to severe malaria than children, inferring an exposure-dependency of the acquisition of 
immunity against severe malaria.  
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Figure 2.3: Indices of immunity to P. falciparum for severe, mild and asymptomatic malaria.  Reproduced from 
Langhorne et al. [65]. 
The effect of age on the acquisition of immunity is often difficult to distinguish from the effect of exposure 
[66] as age represents both an indicator for the duration of exposure but also determines the maturity of 
the immune system. Additionally, adults, with larger body surface area than children, tend to receive more 
infectious bites and develop a higher immunity [67].  
However, there is an age pattern in immunity to malaria that changes with malaria transmission intensity 
[58]. The risk of severe malaria in childhood is higher for areas of high intensity and a comparable trend is 
observed for clinical episodes of malaria (Figure 2.4). Indeed, in high transmission settings, morbidity and 
mortality mainly affect children at a very young age, while adults who have acquired immunity to severe 
and mild malaria tend to be asymptomatic. On the contrary, in areas of low endemicity individuals are, 
independently of their age, at risk of malaria disease (severe or mild). Immunity in these populations is 
relatively poor and it appears that continuous exposure to the parasite is required to sustain high level of 
immunity. As a result, reducing transmission intensity will interfere with the natural acquisition of immunity 
to malaria and might not provide the expected reduction of malaria burden [58, 68, 69]. 
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Figure 2.4: Incidence of clinical malaria in Dielmo (high transmission) and Ndiop (low transmission). Reproduced 
from T. Smith et al. [69]. 
1.3 Malaria transmission 
1.3.1 Malaria vector: Anopheles mosquito 
Anopheles is the genus responsible for the transmission of human malaria. Amongst the 430 Anopheles 
species, 70 of these are malaria vectors and only 40 are of major importance [70]. Anopheles gambiae s.s., 
An. Arabiensis and An. Funestus are the most prominent malaria vectors in Africa. The development of the 
mosquito consists of four stages: egg, larva, pupa and adults and initially takes place in water. Mosquitoes 
are usually not found more than 2-3 km from their breeding site. Only female Anopheles can transmit 
malaria parasites. Some characteristics of the mosquito might influence the spread of malaria, such as its 
preference to feed on animals (zoophilic) or on humans (anthropophilic), indoors (endophilic) or outdoors 
(exophilic), or the longevity of the mosquitoes. Indeed, for mosquitoes lifespans less than 10 days, the 
parasite is unlikely to have enough time to complete its cycle within the mosquito [71]. Also, temperature 
and humidity might influence the development and survival of certain species of mosquitoes [57].   
1.3.2 Heterogeneity of transmission 
Levels of malaria endemicity vary widely between settings, with prevalence of infection ranging close to 0% 
in low endemicity areas to levels higher than 40% in high endemicity areas for children between 2 and 10 
years old [13]. This variation occurs across a range of scales, from differences between and within 
continents down to variation at the village level and so-called “hotspots” of transmission [72]. Indeed 
heterogeneity in endemicity of malaria is mainly driven by heterogeneity of malaria transmission. A number 
of determinants are responsible for malaria transmission [57] and therefore any heterogeneity due to 
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those factors might result in heterogeneity of transmission. On the one hand, local ecological and climate-
based factors are important determinants of the intensity of malaria transmission. For example, 
temperature affects both vector and parasite development [73], whilst rainfall affects the availability of 
breeding sites (which vary by species). Both these environmental factors in part determine the seasonal 
patterns of malaria transmission observed in certain regions of the world [74]. Indeed, many endemic areas 
are characterised by seasonality of transmission, with low transmission during the dry season and peaks of 
transmission during the rainy season [75]. Altitude, despite a high correlation with temperature, has also 
been shown to have an effect on transmission. In addition, many human factors, including antimalarial 
interventions, socio-economic and behavioural factors, agriculture, land use, urbanization and population 
movements contribute to variation in the transmission dynamics of malaria.  
Additionally, factors related to the efficiency of an infectious mosquito bite are highly related to efficiency 
of transmission. Indeed, not all infectious mosquito bites progress to blood-stage infection.  Therefore 
heterogeneity in factors related to the efficiency of an infectious mosquito bite can also contribute to the 
heterogeneity in transmission. Immunity and heterogeneity in mosquito biting have been suggested to be 
potential causes of this inefficiency of transmission [76]. And, some studies have shown that transmission 
efficiency decreases with increasing number of infectious mosquito bites per person. Therefore, the 
hypothesis of heterogeneous biting might be the most plausible to explain the inefficiency of transmission 
[76] and therefore heterogeneity in transmission. Indeed, Smith has shown that contact between vectors 
and humans are not random [77] and Carnevale et al. have demonstrated some heterogeneity in mosquito 
biting with age-related biting patterns [78].  
1.3.3 Measuring malaria transmission intensity 
An understanding of the relationship between transmission intensity, prevalence of infection and clinical 
incidence is key for malaria epidemiology. Therefore, a number of methods that measure malaria 
endemicity have been considered as measurements for malaria transmission intensity. 
1.3.3.1 The reproduction number R0 
The basic reproduction number R0 determines the endemic level of a disease [79]. It is defined as the 
average number of secondary infections produced from one infected individual introduced in a non-
immune and fully susceptible host population [80, 81]. If R0 is greater than one, the number of infected 
people increases and if R0 is less than one then it decreases. For malaria, R0 is mathematically defined as:  
 
2
0 / ( log )
nR ma bcp p   (1.1) 
where m is the ratio of vectors to humans, a is the biting rate, p the probability that the mosquito survives 
one day, n the extrinsic incubation period, b the infectivity of mosquitoes to human and c the infectivity of 
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human to mosquitoes. R0 provides an index for transmission intensity and is used as a threshold criterion, 
but its estimation relies on direct measurements of endemicity in the area [82]. A selection of these is 
presented in Table 1.2.   
1.3.3.2 Entomological inoculation Rate (EIR) 
The main method for measuring malaria transmission intensity is the entomological inoculation rate (EIR) 
which is defined as the number of infective mosquitoes bites received per person per unit of time. This is 
expressed mathematically as:  
  EIR mas   (1.2) 
where m is the number of mosquitoes per person, a the biting rate of mosquitoes and s the proportion of 
mosquitoes with sporozoites detectable in their salivary glands [73]. EIR represents a direct measurement 
of transmission intensity [83]. Indeed, the human biting rate (ma) can be directly measured with light-traps 
or the human bait catch, which consists of collecting mosquitoes trying to feed on exposed individuals, 
dissecting them and looking for the presence of sporozoites in the salivary glands [73]. EIR data are 
expensive, difficult to replicate, and are also affected by seasonal variation and geographic over-dispersion 
of vectors. Furthermore, in areas of low transmission, sampling methods become insensitive as mosquito 
numbers are low and sometimes below the detection level [73, 84]. In these settings, only a very small 
proportion of mosquitoes are infectious and it therefore becomes challenging to measure malaria 
transmission intensity with EIR.   
1.3.3.3 Parasite Prevalence 
Alternatively, an examination of the peripheral blood for asexual malaria parasite by microscopy would 
provide more specificity for malaria infection than EIR. The parasite rate (PR) (strictly prevalence not a rate) 
is defined as the proportion of individuals in the population carrying parasites in their blood and widely 
used as a measure of endemicity. The PR is typically measured in cross-sectional surveys in communities 
with the different parasite species distinguished. However, parasite surveys are relatively invasive for 
participants (requiring blood samples) and logistically demanding. In seasonal settings, interpretation is 
further complicated as few studies undertake surveys repeatedly throughout the year. Furthermore, it is 
increasingly being recognised that microscopic methods may miss a substantial proportion of “sub-
microscopic” low density infections [85]. Therefore in low transmission settings, parasite prevalence might 
not be appropriate as it provides unreliable measures of transmission intensity [82, 84], by either missing 
low density infections or by overestimating levels of transmission due to a lack of sensitivity of the methods 
[83]. More recently, Polymerase Chain Reaction (PCR) techniques have been developed to improve parasite 
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detection [73]. Rapid Diagnostic Test (RDT) remains as cheap, easy-to-use and a quick method for detecting 
malaria antigen from small amount of blood [86]. 
A particular feature of malaria is that the prevalence of infection in a population attains saturation very 
quickly. Indeed, there is a non-linear relationship between prevalence and the incidence of infections. 
Prevalence can change little across a wide range of incidences. It appears therefore difficult to detect 
incidence from cross-sectional parasite rate surveys across the whole population. The parasite conversion 
rate for malaria, first introduced by MacDonald, is a method to estimate the force of infection using the 
infant parasite rate and is defined as the per capita rate at which susceptible individuals contract the 
infection [87]. The force of infection is defined as the rate of infectious bites successfully causing a blood 
stage infection. Several methods were suggested for its measurement [88–90]. There is a relationship 
between EIR and force of infection, although this is not always linear due to heterogeneous biting (not 
always considered in the estimates of force of infection) [78, 91] and acquisition of pre-erythrocytic 
immunity (faster in adults than children exposed to high EIR)  [60, 61, 67]. Several studies have explored the 
relationship between EIR, parasite prevalence and the force of infection [67, 83, 92, 93]. Beier et al. found a 
linear relationship for most of the studied sites (31 sites throughout Africa) between parasite prevalence 
and the logarithm of annual EIR [83] while Smith et al. developed a model to predict the force of infection 
from EIR [67].  
1.3.3.4 Serological markers 
An alternative method to estimate the force of infection is to distinguish between individuals positive to 
antimalarial antibodies and those who are not. The proportion of the population who are seropositive can 
be used to measure exposure [89, 94], but the rate of seroconversion, defined as the rate at which 
individuals become seropositive, is the preferred method to determine the force of infection from 
serological data. Models for age-specific antibody prevalence are used to estimate this rate. Serological 
methods have recently been widely applied in order to estimate endemicity [95]. Exposed individuals may 
remain seropositive many years after they have been infected [96] and thus the seroprevalence rate 
represents a tool for assessing malaria exposure over time, as it smoothes the effect of seasonal variation 
due to the persistence of the antibodies. Serological methods have been proposed as a technique to rapidly 
assess malaria exposure [95, 97, 98]. One advantage of these methods is that they are simple and cheap. 
Serological methods are easily reproducible and easily interpretable, which therefore represents a perfectly 
adequate tool to analyse data in the field. They may also provide more accurate results than parasite rates 
in areas of low endemicity [99] and therefore help to distinguish differences in exposure when malaria 
parasites are not detected [99]. Serological markers can identify asymptomatic infections, i.e. individuals at 
risk of transmitting malaria despite a lack of clinical symptoms.  
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1.3.3.5 Other methods 
Historically the first method of malariometry was introduced in India in 1848 and involved determining the 
spleen rate (the proportion of the population with an enlarged spleen) [82]. Determination of malaria 
transmission intensity using spleen rate might not provide great specificity and suggest misleading results. 
The Global Malaria Eradication Programme (GMEP), coordinated by WHO, tried in 1950 to establish a 
common nomenclature for measuring malaria.  A consensus was finally reached for characterising the 
population based on spleen rate into 4 categories: hypoendemic (<10%), mesoendemic (11-50%), 
hyperendemic (51-75%) and holoendemic (>75%) when measured in children between 2-9 years old [100]. 
Later, the classification was used in conjunction with parasite rates [101].    
Measuring clinical incidence (i.e. the number of clinical malaria episodes in a defined population over time) 
has also been considered as an option for determining transmission intensity. However, it requires a 
comprehensive surveillance system as well as active case detection and is only considered valid if the 
proportion of the target population examined is greater than 10%  [15]. Moreover, estimation of disease 
prevalence based on hospital data has been shown to be unreliable due to over-diagnosis of malaria in 
some patients and under-diagnosis in other communities who do not have easy access to health facilities. 
The distribution and transmission of malaria is strongly influenced by climatic factors. Climate-based 
methods have thus been explored to provide a proxy for malaria transmission intensity [102]. These 
methods are based on the combination of temperature and rainfall to provide a continuous scale for the 
probability of malaria infection in a particular area. These methods have been shown to provide estimates 
that corroborate with field data at regional and country level. However, their ability to estimate malaria 
transmission intensity at the level of individual communities is limited [103]. 
Recently, molecular techniques have demonstrated striking features for measuring malaria transmission 
intensity at both an individual and a population level [104–106]. The molecular force of infection (molFOI) 
can be estimated with high sensitivity by genotyping Plasmodium parasites in longitudinal studies. molFOI 
can be used to measure malaria transmission intensity in particular in areas of low endemicity where 
individual and small geographic differences might be important [104]. Malaria transmission intensity can be 
highly variable even at a small spatial scale [107, 108] and is rarely detected at an individual scale with 
traditional measures of transmission. One of the great advantages of molecular techniques is therefore that 
they can capture the microvariability in exposure. molFOI is also useful for measuring the effect of 
seasonality and age on transmission intensity. However, as natural immunity might prevent infections, 
molFOI will better estimate differences in transmission with individual with limited levels of naturally 
acquired immunity [104].   
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1.4 Seroepidemiology of malaria 
1.4.1 Immunology of malaria 
1.4.1.1 Humoral mechanisms 
When the malaria parasite invades the human host, a series of diverse immunological processes are 
triggered to protect the host from an infection [109]. The adaptive immune response is mounted as a result 
of antigen interaction with lymphocyte cells, following the activation of the initial, innate immune 
response. The T cells generate the cell-mediated immunity and B cells the humoral immunity. B cells 
differentiate into plasma cells with the help of T cells and secrete a range of immunoglobulin antibodies 
[110]. There are four main classes of immunoglobulin antibodies, called isotypes: IgM, IgA, IgG and IgE. IgM 
antibodies are the first antibodies produced by B cells upon infection. Subsequent maturation of the 
antibody response, often requiring multiple exposure to the same antigen, will trigger the production of a 
mature antibody response with expression of other isotypes (IgG in particular, being the most abundant), 
with high affinity and immunological memory. Antibodies play a crucial role in immunity to malaria by 
preventing the invasion of the parasite with various mechanisms, including opsonisation of merozoites in 
the case of malaria, to facilitate their phagocytosis by macrophage [111].  
An immune response can be triggered at any point in the life cycle of the parasite in the human. As 
sporozoites, liver stage parasites and gametocytes do not trigger any symptoms, it has been argued that 
these stages are poorly immunogenic [56]. Studies have shown that pre-erythrocyte stages present limited 
naturally-acquired immunity  [8, 56] as they are substantially short lived. For blood stages, the potential 
targets for an immune response are the free merozoite or the intra-erythrocytic parasites[65] when the 
parasite is directly exposed to host immune system. Indeed, intracellular forms (in the liver and in the red 
blood cells) tend to hide from antibodies. However, blood stage antigens display huge antigen diversity that 
challenges the immune response. 
1.4.1.2 Blood stage antibodies 
Anti-malarial antibodies have been known to be associated with malaria clinical immunity [112]. However, 
the correlation between antibodies and the protection against clinical episodes or death remains unclear. 
For epidemiological studies, only detectable antibodies used as markers of infection are of interest, and not 
their role in protection. Therefore, antibodies to the asexual blood stage merozoite antigen, which tend to 
be more abundant, are the most relevant. Merozoite Surface Protein 1 (MSP-1) is a protein synthesized 
during schizogony. MSP-1 represents a target of immune responses with antibodies against MSP-1 
neutralising the parasite by agglutinating merozoites and preventing red blood cell invasion.  Apical 
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merozoite surface antigen 1 (AMA-1) is a membrane protein located in the apical organelles of developing 
and free merozoites [113]. Antibodies against AMA-1 prevent the malaria parasite from infecting red blood 
cells. MSP-1 and AMA-1 are typically found on merozoites, however, AMA-1 can also be found on 
sporozoites. AMA-1, known to be highly immunogenic [114], is more appropriate to analyse in order to 
increase the sensitivity of the methods in areas of low endemicity [97]. It is a bigger protein than MSP-1 and 
has a higher merozoites surface expression rate. As a result, the antibody response is typically higher for 
AMA-1 compared to MSP-1. However, despite MSP-1 being less immunogenic, antibodies against MSP-1 
have been established as useful tools that allow differentiation between short term variations (seasonal) 
and long term pattern (year to year) of malaria transmission [95]. Additionally, it was shown that once 
acquired, blood stage antibodies persist for many years [115].   
1.4.1.3 Longevity of antibodies 
Antibodies appear in the blood not long after parasites invade the bloodstream and may remain there 
between a few months to a few years. The debate on longevity of antibodies remains controversial [96, 
116–120]. Studies have shown that antibody response in vaccinated children tend to be long lasting [121], 
however a better knowledge of the persistence of antibodies in absence of vaccination would help to 
differentiate individuals recently infected from those infected months or years before.  
On one hand, studies have shown that antibody titres rapidly decline in the absence of re-infection 
following the time of acute infection, suggesting that naturally acquired immunity against merozoite 
antigens is short lived following an acute infection [117]. A survey conducted in Kenya showed indeed that 
for children living in endemic areas, antibody responses against merozoites are often very short-lived [116]. 
It is widely held that immunity to malaria can be lost after a period of time in the absence of re-infection or 
when an immune person moves away from an endemic area. The underlying hypothesis put forward for 
explaining this phenomenon is that persistent or frequent exposure to malaria is required to maintain 
immunity [56]. In endemic areas, blood stage parasites are maintained at low levels by the immune 
response due to frequent exposure. Under these conditions and in absence of treatment, seropositivity is 
likely to be maintained [56, 122].  
On the other hand, other studies have shown that antibody responses could persist for a very long time 
[119, 123]. A recent study focusing on antibody responses including MSP-1 and AMA-1 has classified 
antibodies against those antigens as long-lived antibody response once acquired in asymptomatic 
infections. In such circumstances, antibody responses to those defined malaria antigens can persist for 
several years for P. falciparum and P. vivax [96, 117]. Infrequent malaria infections could therefore induce 
long-lived antibody response [96]. Surveys carried out in Madagascar after almost 30 years of absence of 
malaria demonstrated that both immune response and protection (from clinical malaria) were observed in 
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adults previously exposed to malaria and not in young children [124]. Additionally, studies have shown that 
the mortality rate from malaria is higher in naïve travellers compared to immune people revisiting endemic 
areas [56].   
Another study in a highly endemic area also showed that the antibody response in children presented was 
short-lived [117] suggesting that long lived immune responses might be acquired after a high number of 
infections [96]. Therefore the longevity of the immune response might be determined by numerous factors 
including exposure and age. Indeed, antibodies to merozoite antigens have been shown to decline more 
rapidly in younger children than in older children. The inability of young children to produce sustained 
antibody response suggests that age might be a determinant for sustaining antibody levels. The longevity of 
the antibody response might also differ between antigens and Plasmodium strains [117]. For example, in 
P.vivax infections, antibodies can wane between relapses but they rarely completely disappear [125].  
1.4.2 Detection of antibodies 
Two established immunodiagnostic techniques, introduced by Voller in the late 1970’s, are typically used 
for the detection of malaria antibodies [125]. Traditionally, the indirect method of immune fluorescent 
antibody (IFA test) was the reference for malarial antibody determination. However, the Enzyme-linked 
immunosorbent assay method (ELISA) has higher sensitivity and has become the most common test. IFA 
involves reaction of diluted test serum samples with drops of infected blood dried on microscope slides; the 
slides are then reacted with fluorescent antiglobulin and finally examined under a fluorescent microscope. 
Fluorescent antiglobulin only fixes itself to the antigen-antibody complex, indicating that the sera contain 
antibodies. The antibody level is determined by the last dilution that reacts and is given as a ‘titre’ [125]. 
The indirect ELISA method is similar to the IFA test. Antibodies to specific antigens are detected when they 
bind to a micro-titre plate using a colorimetric enzyme reaction. The amount of antibody present in the 
serum is determined as being proportional to the amount of colour produced by the test. Optical density is 
very often used as a proxy of antibody density. Both methods have the advantages of being low technology, 
easy to reproduce and antigens can be stored for long periods. However, IFA can be laborious for large 
samples and can potentially be subjective as it relies on the technician’s expertise to visually read the 
results. In contrast, ELISA results are easily interpretable for large epidemiological studies and results can 
be read with more accuracy as it is better standardised [125] with the wider use of recombinant antigens. 
Despite a remaining need for broader Quality Control and assay validation,  findings can be compared from 
different laboratories when methods are standardised [126].  
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1.4.3 Seroepidemiological studies 
The presence of anti-malarial antibodies in an individual infers that this person has been exposed to 
malaria. As a result, serology becomes a valuable tool for epidemiological studies. However, due to 
remaining maternal antibodies, cross reactivity with other pathogens or other factors, some individuals 
have detectable levels on antibodies while they have never been exposed to malaria. Defining 
seropositivity is thus essential, i.e. defining an antibody level above which individuals who have detectable 
levels of malaria antibodies are considered having been exposed to malaria. The seronegative population is 
composed of individuals who have never been exposed and those who have previously been exposed and 
have lost their antibodies. 
Conventional serology has provided useful epidemiological information in malaria control programmes and 
has contributed to define malaria transmission areas and monitor the impact of control interventions. The 
outcomes of seroepidemiological studies are typically the seroprevalence of infection, a measure of the 
intensity of transmission and the impact of control measures if the survey was carried out for this purpose. 
Serological methods are based on detection of circulating antibodies. The amount of antibodies can vary 
due to relapse, superinfection or reinfection and total exposure history. Serological surveys can be cross-
sectional surveys (most common), repeated cross sectional survey or longitudinal surveys. Results are 
typically recorded by age as the acquisition of antibodies is age dependent [60, 127, 128] and presented 
with age-seroprevalence curves (Figure 2.5). 
 
Figure 2.5: Age specific seroprevalence curve. The y-axis represents the proportion of seropositive individuals 
(seroprevalence) in each age group and the x-axis shows the midpoint of each age group. Fictitious data are 
represented by the black dots. 
The traditional indices of malaria endemicity such as EIR or parasite rate allow an assessment of current 
transmission and consequently might not reflect malaria transmission intensity over a period of time. 
Indeed, transmission intensity might be underestimated or overestimated due to false negative or false 
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positive results attributable to the fluctuating nature or low levels of parasitaemia or even caused by the 
geographic over dispersion of vectors.  Serology can give an improved picture of the intensity of 
transmission by providing period prevalence [125] and can be used to assess changes in transmission in 
areas where transmission is considered stable. Consequently, when serology was first established for 
epidemiological studies, many serological surveys were carried out in different parts of the world. Indeed 
seroepidemiological studies were performed in Mauritius and Greece to confirm malaria eradication [8], in 
Tunisia to assess the presence of residual transmission foci after interventions [129], in West Africa [130] 
and Nigeria during the Garki project [131, 132] to investigate the epidemiology of malaria and measure the 
impact of house-spraying alone and in combination with mass drug administration. Surveys carried out to 
confirm elimination of malaria [8] have been performed on children, since long persisting antibodies 
produced before interventions can confuse the results.  
Today an increasing number of studies use serological methods to assess malaria endemicity and risk [95, 
99, 133–137] or as a tool for surveillance for malaria elimination [138].  Serological surveys are an 
established tool to measure malaria transmission intensity [95, 97, 98, 137, 139, 140]. Serological methods 
can also be useful tools for measuring variation in malaria transmission over time. Studies have shown that 
such methods are capable of distinguishing between long term patterns of malaria transmission from short-
term variations [95, 97]. Similarly, a cross-sectional survey, performed in Vanuatu where malaria 
transmission had been widely reduced over the past years [135], highlighted the potential for serological 
methods to monitor changes in malaria transmission. As a result, serology has become an established tool 
to measure changes in transmission and was used for instance in Cambodia to show changes in 
transmission pattern during the rainy season [134] and in Bioko to demonstrate the heterogeneity of the 
effectiveness of the interventions [133]. Additionally, a study conducted in Somalia, showed that 
serological markers can be used to determine heterogeneity of malaria transmission in areas of low 
endemicity, where parasitaemia is undetectable [99]. 
Serological methods also have some drawbacks. Saturation of prevalence at high transmission intensity or 
very long lived antibodies can be problematic for detecting recent variations from historical trends [97, 
123]. As a result, they might not be appropriate to assess malaria exposure at the individual level.  
1.5 Mathematical models 
“Models are a useful means of collating knowledge and experience to determine whether success is 
possible under a given set of constraints and conditions, and, if not what changes are required.” [141] 
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1.5.1 Why model malaria? 
Mathematical models are routinely used in epidemiology to simulate disease transmission, identify the key 
factors of transmission and inform the underlying process that drives the transmission dynamics. A model is 
a simplified representation of the complex reality but provides a good qualitative description of the system. 
Additionally, mathematical modelling also represents a compromise between “purely applied” and “purely 
theoretical” approaches that allows extrapolation of the findings when the collection of data is expensive, 
large, ethically challenging or time-consuming.  
One of the first model for infectious disease originates with the malaria model developed by Ross during a 
trip for malaria control in Mauritius [5] and extended by MacDonald [142] during the Global Malaria 
Eradication Program (GMEP). These models were applied to guide malaria interventions and highlighted 
the importance of vector control by spraying with DDT [143].  Later, Dietz further developed the simple 
models to include immunity and superinfection during the Garki project in Nigeria [144]. This model played 
a key role in the design and analysis of the interventions. New indices to measure transmission were then 
introduced, notably vectorial capacity and the human blood index [145, 146]. Subsequent extensions of the 
basic models were developed to consider heterogeneity [147, 148], immunity [149], within host dynamics 
of the parasite [150], interventions [151], strain theory [152] and other phenomenon. Today, mathematical 
models are still developed with different levels of complexity in order to evaluate the impact of 
interventions to inform policy and guide research for control and elimination [93, 148, 153–155].  
There is an extensive literature on modelling the dynamics of malaria transmission. Most of these models 
are based on parasitological, entomological, clinical and epidemiological data. However, a much lower 
number of models are developed for serological data.   
1.5.2 Assessing transmission using models for serological data 
1.5.2.1 Catalytic models 
A variety of mathematical models for serological data have been developed [127, 156, 157], of which the 
catalytic model is most widely used in the context of seroepidemiology. This was first introduced for 
malaria by Draper, Voller and Carpenter in 1972 and termed the ‘constant infection rate model’ as it can be 
considered a catalytic model with a constant force of infection [158] . This early model was applied in east 
Africa [159], Mauritius [8] and Guyana [160] to estimate past infection rates. In these models human hosts 
were assumed to move from seronegative to seropositive with a constant seroconversion rate λ. Initially, 
the decline of antibodies was not considered and hence the proportion seropositive at age t is given by:  
 ( ) 1
ty t e    (1.3) 
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VanDruten [161] subsequently proposed a model incorporating a decay of antibodies with a reversion from 
seropositive to seronegative occurring at rate ρ (Figure 2.6). The proportion seropositive at age t is then:  
 
( )( ) (1 )ty t e  

 
  

 (1.4) 
This reversible catalytic model corresponds to Ross’s original malaria model for transmission [142].The 
seroconversion rate λ and the rate of seroreversion ρ can be obtained by fitting the model to empirical age-
prevalence curves [97].  
 
 
Figure 2.6: Flow diagram for catalytic model 
Titre data can be converted into prevalence data using control sera from Europeans who represent truly 
unexposed individuals to define a threshold. However, different genetic make-up or exposure to other 
pathogens in the local area may mean that these do not represent appropriate controls. An alternative 
method is to use the data from endemic settings and define the cut-off using mixture models [162]. For a 
mixture model, positivity is defined as a measurement more than three standard deviation above the mean 
measurement of a panel of non-exposed individuals [163, 164]. However, in high prevalence settings there 
may be insufficient truly negative responders to appropriately define the cut-off threshold. 
In catalytic models it is assumed that in a given interval of time, all individuals have the same probability of 
seroconverting (at rate λ) and this probability is a function of the immunogenicity of the antigen and the 
likelihood of being infected [97]. The outputs from such a model provide a proxy for malaria transmission. 
Indeed the seroconversion rate λ is closely related to the force of infection of malaria [165]. The 
seroconversion rate has also been shown to correlate with EIR [95]. However, note that the seroconversion 
rate is assumed to be independent of the antibody density. Indeed, the number of time an individual gets 
infected is considered unrelated to its current antibody level. 
As a result, these models fitted to seroprevalence data allow a rapid and local assessment of malaria 
transmission intensity [95, 97–99, 135]. However, even though this approach is simple and practical the 
information contained in the continuous serological titre data is only partly considered. The use of catalytic 
models to evaluate transmission intensity based on serological data requires that the population is 
discretised between seropositive and seronegative individuals. The force of infection corresponds to the 
incidence of seroconverting. However, this discretisation and therefore the force of infection consequently 
highly rely on the choice of the threshold between seropositive and seronegative individuals, which lacks 
standardisation. Under these models any seropositive individuals that get infected (and therefore produce 
Seronegative Seropositive 
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higher levels of antibodies) would not be captured in the force of infection as such discretisation does not 
account for dynamics of individuals once they are seropositive. This simplistic model is indeed a partial 
representation of the reality as it does not address the complexity of biological mechanisms including 
antibody priming and boosting. 
1.5.2.2 Other models 
Many other models have been derived from the simple catalytic models and modified to allow the 
seroconversion rate to potentially vary with time or be a function of age and exposure [127].  
Gatton presents a model [139] similar to the reversible catalytic model used in the Garki project [166] to 
estimate the impact of interventions targeted for elimination in a study area in Africa. However, unlike Van 
Druten’s model, Gatton fits antibody decay to serological data collected in longitudinal surveys and uses it 
to derive malaria transmission rates from cross-sectional surveys. The decay probability is related to the 
time the antibody persisted at a high level in the individual. It is assumed that malaria prevalence is not 
age-dependant. The output from this model is the number of people on each day with high and low 
antibody levels. Survival curves are then produced and compared with the curves from the actual data. 
Once the decay rate has been estimated, a modified catalytic model is then used to derive the transmission 
rate of malaria. 
Burattini [140, 167] developed a stochastic model to estimate malaria transmission rates from serological 
data, based on cross-sectional data. The compartmental structure of the model takes into consideration 
parasite and serological prevalence data. This model assumes an age-dependent force of infection and 
includes acquisition and exponential decay of antibodies (with mean persistence of 10 years).  The model is 
applied to data from Brazilian Indians over a period of 25 years. They suggest that changes in malaria 
transmission indices are due to age rather than changes in malaria transmission in time.  
1.5.3 Modelling antibody levels 
1.5.3.1 Malaria models 
All the models described so far have a compartmental structure and rely on fixing a cut off value for 
distinguishing seropositive from seronegative, or modelling the probability of belonging to each 
compartment accounting for misclassifications [168]. However, antibodies can persist for many years and 
individuals might stay seropositive for a while. To that extent, a binary structure does not represent the 
actual fluctuations in antibody levels. Indeed, the magnitude of the antibody response might reflect 
changes in transmission that seroprevalence might miss. Despite some occasional use of the frequency 
distribution of antibody titre to characterise malaria endemicity [169–171] or to identify risk factors for 
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malaria infections [128] , there has generally been a lack of methods developed to make full use of the 
distribution of antibody responses. Models fitted to titre data have however been used to assess the 
duration of antibody response using longitudinal data (M. White – personal communication). 
Recently, Bretscher and colleagues have further developed mixture models [168] that considers antibody 
titres to derive the seroconversion rate, without any arbitrary values in order to estimate malaria 
transmission intensity [137]. The method uses finite mixture models with a decomposition of the range of 
antibody titres. Hidden Markov Chains are applied to estimate the rates of seroconversion and 
seroreversion from individual-level longitudinal data. This method is more robust to noise in titre 
measurements than a threshold-based method and makes better use of the information in the data as 
more weight is given to large titre changes than small ones. However, as longitudinal data is required, as 
transmission intensity decreases, the number and duration of follow-ups needs increase to ensure good 
precision, and this is unlikely to be achievable. 
To my knowledge, no other studies have directly modelled antimalarial antibody titres using a mechanistic 
model which consider the underlying biological processes. 
1.5.3.2 Other pathogens 
Most mathematical models which mimic the antibody response generally assess the persistence of 
antibody response after vaccination [172, 173]. However, Wilson and colleagues used mathematical 
modelling for the generation of immune response and antibody titre in response to hepatitis B vaccines 
[174]. Their model quantifies the rate of antibody responses and the development of immunity. However, 
their model also lacks an explicit understanding of the mechanisms underlying vaccine-induced immune 
response.  
Modelling antibody titre data is commonly used to inform epidemiological parameters. For instance, the 
kinetics of pertussis antibody response was modelled to assess the incidence of pertussis and infer the 
distribution of times from infection [175]. An age structured dynamic model was also constructed to assess 
the dependence of age on the rate of decline of antibodies to pertussis [176].  
Additionally, age-stratified serological data has been modelled for Dengue to determine incidence of 
infection and its variation over time. A study carried out by Ferguson et al. [177] provides an appropriate 
method for obtaining a good estimate of the force of infection from cross-sectional serological data and will 
provide a starting point for the development of density models in this thesis.  
  Emilie Pothin | 41 
 
1.6 The scope of the thesis 
The overall aim of this PhD is to develop a density model for antibody dynamics that reproduces the age-
structured distribution of antibodies from cross-sectional data and to establish its assessment of exposure 
as a valid tool for measuring malaria transmission intensity using serological data. This model will take into 
consideration the level of exposure in the area and the kinetics of the antibodies, accounting for antibody 
priming, boosting and decay to describe the full information contained in antibody levels. The specific 
objectives and the approach taken are outlined below. 
 Chapter 2 presents, as a preliminary method, an extension of the catalytic model as a “proof of 
concept” to assess whether a model that takes into consideration multiple arbitrary levels of 
antibodies (rather than a single cut-off value) can provides estimates of the exposure rate that 
correlate with other measures of transmission.  
 Chapter 3 presents a variety of continuous density models explored for different hypotheses for 
antibody boosting and for the acquisition of antibodies for individuals who have undetected levels 
of antibodies. A unique model, which will be further used in the subsequent chapters, is selected. 
 Chapter 4 establishes the exposure rate estimated using the density model as a valid measure of 
transmission intensity by validating the method against currently used indices and additional 
seroconversion-based metrics. Methods are validated using well known data from Tanzania that 
has previously been used to demonstrate strong correlations between the seroconversion rate and 
malaria exposure [95]. 
 Chapter 5 applies the density model to a wider range of endemic settings to assess the robustness 
of the method. The density model is also further extended to account for additional complexities 
such as heterogeneity in exposure, spatial or temporal changes in transmission and an age effect 
on exposure. 
 Chapter 6 summarises the key findings of the thesis, indicates the implications of the research, 
highlights the limitations of the methods and finally points out future directions. 
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Chapter 2: Development of an antibody 
density model to assess malaria 
transmission intensity – a discrete 
framework. 
2.1 Introduction 
Better estimates of malaria transmission intensity are invaluable for planning and monitoring malaria 
control interventions. In areas of low endemicity, the limited number of infected mosquitoes and the low 
density of parasites in the human host render entomological and parasitological methods inadequate to 
measure malaria exposure. In such settings, serology has shown to be more sensitive at detecting exposure 
[97, 99], due to the longevity of the antibodies [96, 117, 124]. Serological data, reflecting past exposure 
[178], have been used in various contexts as a tool for epidemiological monitoring [7, 125]. 
In Cambodia, malaria burden is relatively low [15] but most of the malaria cases reported are through 
passive case detection, when individuals consult health facilities [179]. This does not reflect the true picture 
of malaria intensity among remote populations. More importantly, the asymptomatic carriage of parasite 
that significantly contributes to malaria transmission is poorly documented in Cambodia. Malariometric 
indices are available from a few studies that have investigated malaria exposure [179]. The results have 
shown that transmission intensity in Cambodia is heterogeneous and characterised by forest malaria that 
represents a major problem for implementing effective control interventions. The distance to the forest has 
been identified as a risk factor for malaria exposure suggesting high transmission in the deep forests and 
the male human population representing a group at high risk of malaria infection [180]. Individuals who 
move into forests and forest-fringe areas are an important at-risk group. This includes forest-fringe 
inhabitants, temporary migrants, traditional forest inhabitant or new settlers who have been relocated to 
forest area [180]. Malaria interventions need to target these particular populations to successfully 
eliminate malaria.  
In low transmission areas, malaria in one host very often consists of more than a single species. Both 
Plasmodium falciparum and Plasmodium vivax are present in Cambodia with some spatial heterogeneity, 
presumably due to a difference in ecological differences between areas [134]. Although little is known 
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about the interaction between species, P. vivax has been reported to become predominant over P. 
falciparum as malaria intensity decreases [179, 181, 182]. With the progress of P. falciparum specific 
interventions, such as vaccines, this raises some questions about the implication of reducing the prevalence 
of P. falciparum as it could result in an increase of infection with P. vivax. Nevertheless, in a 
seroepidemiological context, antibodies to both species have been used to estimate malaria exposure [95, 
134, 136].   
The outcome of serological data is often viewed as a binary event in which the host either does or does not 
present circulating antibodies. However, antibody titre is a continuous measurement. Seroprevalence, 
commonly used to summarise serological data, requires the definition of a threshold for seropositivity. The 
force of infection is typically determined using a catalytic model for the seroprevalence data [95, 97]. 
Summary statistics of antibody titres are used to describe current settings [132] but the full information 
contained in antibody titres has rarely been used to infer the force of infection [137]. Here I develop 
mathematical models to characterise the relationship between antibody levels and malaria exposure. This 
relationship is used to estimate malaria transmission intensity based on the magnitude of the antibody 
response. Models were fitted to Immunoglobulin G antibody titres to P. falciparum antigens collected in 
cross sectional study in Cambodia. 
2.2 Setting 
2.2.1 Data source  
The Mekong region and Cambodia in particular are considered to be areas of low endemicity with 
substantial heterogeneity in exposure mainly due to forest-related malaria (See Figure 2.1) and 
heterogeneity of vectors population [179, 180, 183]. Also, the presence of both P. falciparum and P. vivax in 
this region can hinder the assessment of transmission intensity. In 2004, the Cambodia Malaria Baseline 
Survey (CBMS) was conducted in more than 8,000 individuals to measure the population “Knowledge, 
Attitude, Behaviour and Practice” (KABP) towards malaria and obtain baseline estimates of transmission 
intensity across the country. This country-wide cross-sectional randomised survey was carried out by the 
National Centre for Malaria Control, Parasitology and Entomology (CNM) in Cambodia. Serological 
measurements were analysed by the London School of Hygiene and Tropical Medicine (LSHTM). Other 
covariates including age, gender of the participant and the distance to the forest were identified as risk 
factors for malaria exposure.  
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Figure 2.1: Forest cover in Cambodia   Source: sithi.org [184] 
Blood spots were collected onto filter paper in order to measure exposure to both P. falciparum and P. 
vivax. Serological analyses were performed using ELISA and Immunoglobulin G antibodies to the asexual 
stage merozoite antigens determined. Samples were tested against two antigens, Merozoite Surface 
Protein (MSP-1) and Apical Membrane Antigen (AMA-1). The ELISA technique produces measurements as 
optical densities which are subsequently translated into estimated titres [97]. Titres were log-transformed 
prior to analysis with zero (and negative) measurements arbitrarily assigned a low value of zero on the 
log10 scale. Also, measurements greater than three on a log10 scale were set to three as higher values 
were considered to be unreliable. The age range of the studied population is wide with a range from zero to 
89 years. However older people (those >60 years) represent a very small proportion of the population and 
the majority of these did not have any antibodies. As infants may present with maternal antibodies only 
individuals between 1 and 60 years were included in the analysis. 
2.2.2 Descriptive analysis 
The data collected in Cambodia included antibody titres against AMA-1 and MSP-1 antigens for both P.  
falciparum (Pf) and P. vivax (Pv). The summary results of the collated information are presented in Table 
2.1. Titres were reported on a log10 scale and the median and inter quartile range (IQR) for seropositive 
individuals only are presented together with the overall prevalence of antibodies for each antigen and 
plasmodium species. Titre values for antibodies against antigens AMA-1 are generally higher than for 
antibodies against MSP-1.  
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Table 2.1: Summary statistics for MSP-1 and AMA-1 antigens for both P. falciparum and P. vivax. 
 Log10 Titre  for seropositive individuals 
Median (IQR*) 
Seroprevalence              
 (no. positive/no. tested) 
Pf MSP-1 1.2 (0.8-1.6) 16 (1218/7577) 
Pf AMA-1 1.5 (1.1-2.1) 24 (1730/7315) 
Pv MSP-1 1.2 (0.8-1.5) 8 (626/7722) 
Pv AMA-1 1.4 (1.0-1.8) 16 (1177/7583) 
*IQR, interquartile range (25
th
-75
th
 percentile) 
Figure 2.2 shows the overall distribution of the antibodies for each antibody type and each plasmodium 
species. Seronegative individuals are represented by the peak at log titre=0. The age-structured distribution 
of the antibodies is also presented in Figure 2.2, showing how low and variable the antibody titres are for 
younger ages whilst they become higher and less variable for older individuals. 
As malaria transmission intensity was known to vary with forest malaria, the distribution of antibodies was 
categorised by the distance to the forest (see Figure 2.3). People who live in the forest tend to have higher 
antibody levels for both P. falciparum and P. vivax and both antibody types.  
 
Figure 2.3: Antibody titre distribution according to the distance to the forest for antibodies against MSP-1 and AMA-
1 antigens for both Plasmodium falciparum (Pf) and Plasmodium vivax (Pv). 
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2.3 Material & Methods 
2.3.1 Mathematical models  
The objective was to develop and fit a model to titre data and extract information about exposure to 
infection, the boosting of the antibody-mediated immune response and potentially the decay of antibodies. 
The aim is to extend the original catalytic model, typically used to analyse serological data, to one with 
multiple compartments to represent the full dynamics of acquisition and loss of antibodies in the 
population.  
2.3.1.1 Categorisation of the population 
The population was stratified into different groups according to an individual’s antibody level on a log10 
scale at the time of the survey. An arbitrary number of categories (here six) were chosen and the range of 
titre, varying from zero to three was split into equally sized intervals of 0.6 logs. An individual i is classified 
in category k if their log10 antibody titre 1( , ]i k kx X X  where {2,3,4,5,6}k  or in category 1 if 0ix  . 
The population stratification is represented schematically in Figure 2.4. 
 
Figure 2.4: Schematic representation of the discretisation of the antibody level of individuals. For each antibody 
class, its index k is presented at the top and its boundaries (Xk-1,Xk] on the x-axis. Frequency of the population in 
each class is presented in black. 
2.3.1.2 Model specifications 
A compartmental model was used to model the dynamics of the acquisition and loss of antibodies. This 
density model is an extended version of the reversible catalytic model [158] as presented in Chapter 1. The 
rate of movement from titre class j to titre class i is λkij, where λ represents the ‘force of infection’ as a 
proxy for measure of exposure and kij is the probability that once infected an individual with a titre in class j 
will be boosted to a titre in class i. ( )ijK k  is termed the transition matrix (2.1). The structure of this 
transition matrix can take different forms depending on the assumed biology. In its most general form, 
transitions can occur from any state to any other higher state (Figure 2.5).  
  
Emilie Pothin | 48 
 
 
21
31 32
41 42 43
51 52 53 54
61 62 63 64 65
0 0 0
0
0
k
k k
K
k k k
k k k k
k k k k k
 
 
 
 
  
 
 
 
  
(2.1)       
0 0 0
0
0
0 0 0
G





 
 
 
 
  
 
 
 
 
 (2.2) 
The rate of decay of antibodies is assumed to be constant over time, resulting in exponential decay ρ. The 
matrix G, representing the decay of antibodies has the form presented in (2.2).  Estimates for antibody 
decay and exposure rate might be separately identified with difficulty from cross-sectional data. Therefore, 
the antibody decay was fixed to an estimate obtained by fitting the catalytic model to the data of
0.03
0.05  

, with 0.6  the size of the interval [134]. 
 
Figure 2.5: Flow diagram illustrating the dynamics of the population building immunity upon exposure.  Population 
stratified into 6 classes. Individuals acquire antibodies at rate λkij and lose their antibodies at rate ρ. 
Let yi(t) be the proportion of individuals with categorised titre i  1, ,   at age t  1, , 0 . Age is considered 
in months as continuous time and averaged over a year.  The matrix form of the model can be written as: 
1 1
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or more generally as:  1
i
ij j i i ji i
j j
dy
k y y y k y
dt
         (2.3) 
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2.3.1.3 Parameters 
The exposure rate λ is assumed to be constant over time. The focus of the work presented here is to 
explore different parameterisations for the acquisition of antibodies which are represented by transition 
matrix K. I want to characterise the boost in antibody levels that occurs following infection. Therefore an 
understanding of the underlying mechanisms for the boost distribution is essential for an accurate model 
able to separate the effect of exposure and immunogenicity of antigens. One would ideally be able to 
directly measure the boost of antibodies upon infection. However this information cannot be captured in 
cross-sectional surveys.  I therefore explored model structures with different levels of complexity that were 
biologically motivated. 
The full model as presented in Figure 2.5 represents the least constrained scenario where, following 
infection, antibody levels can be boosted to any higher level. In this 6-compartments model, this requires 
estimating 15 parameters for the boost and 1 for exposure ( ). To avoid over-parameterisation one of the 
coefficients in the transition matrix K is set to a fixed value and therefore 15 parameters are estimated with 
the following constraints. 
1. Each parameter [0,1]ijk  ; 
2. The sum of each column of the transition matrix is 1  as it represents the total probability of the 
transition from state j.  
A simplified version of this model is also considered and represents the case where individuals once 
exposed can only boost their antibody levels to the next level of antibodies. This model is illustrated in 
Figure 2.6 with its associated matrix K. The total number of parameters to estimate in this instance is 
strongly reduced (four for the boost distribution and one for the exposure). Here the following constraint 
remains [0,1]ijk  . In addition, to avoid over-parameterisaton 43k  was set to a fixed value, chosen to be 
0.1, therefore assuming a low probability of boosting between antibody classes 3 and 4, which includes 
most of the population.  
 
Figure 2.6: Flow diagram illustrating population dynamics during acquisition of antibodies for the simplified model 
and its associated transition matrix K.  Population stratified into 6 classes. Individuals acquire antibodies at rate λkij 
and lose their antibodies at rate ρ. 
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2.3.1.4 Application to different patterns of endemicity 
The simplified model was further developed to take into consideration different patterns for endemicity. In 
this case, based on biological grounds, the parameters determining the dynamics of antibodies (kij and ρ) 
were considered to be identical for each individual regardless of the area in which they live. Only the force 
of infection  varies for the different areas. The distance to the forest is used as a proxy measurement for 
the transmission risk and was categorised into five groups. The resulting model has five parameters for the 
transition matrix, one for the decay of antibodies and five forces of infection parameters representing 
different levels of endemicity. The decay, as well as one of the parameter from the boosting matrix ( 43k ) 
was fixed, resulting in a total of 9 parameters to estimate. 
2.3.2 Model Fitting and Model Selection 
2.3.2.1 Bayesian Model 
The model parameters were estimated by fitting the models to the data using a Bayesian approach [185]. 
Let {( , )}j jD x t denote the observed data constituted of the log10 antibody level jx  and age jt of 
individual j  and { , }K  denote the model parameters. The joint density of observed data and 
parameters is:               
 ( , ) ( / ) ( )P D P D P       (2.4) 
with    /  /t tP D П P D   and ( )P   respectively the likelihood and prior of the model parameters 
and tD the data for age range t. 
2.3.2.2 Likelihood 
Let 
,
,
,
i t
i t
i t
i
n
D
n


denote the observed proportion of individuals at age t in antibody titre class i  and let ,i tn
denote the number of individuals of age t in this class. The model predicted proportion of individuals at age 
t in titre class i is denoted ,i ty solution of (2.3). The likelihood is therefore defined by: 
 ,, ,( / )
i tn
i t i tP D y   (2.5) 
Consequently, assuming observations are independent, the multinomial likelihood for the data is:  
 ,,0 ( / )
i tn
i ti t
P D y

  (2.6) 
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and the log-likelihood given by :   , ,
0
log( ( | )) log( )i t i t
t i
l P D n y

     (2.7)  
The differential equations were numerically integrated in C using the Runge-Kutta method [186]. The 
number of individuals in each compartment was derived for each time step (every second day) and the 
mean over a year was used as the predicted values. Results were validated with the R solver [187] using the 
lsoda function in the deSolve package [188] . The starting values for the algorithm were taken from the 
data when individuals were at age 0. However, for model fitting, only individuals aged above 1 year were 
included to remove the confounding effect of maternally-derived antibodies.  
When estimating multiple exposures the log-likelihood becomes: 
 
, , , ,( / ) log( )i t v i t vv i tl D n y    (2.8) 
where , ,i t vy and , ,i t vn are respectively the predicted proportion and the observed number of people in 
antibody titre class i and age t  in area v . 
2.3.2.3 Prior distribution 
Uniform priors were chosen for the different parameters. The coefficients from the boosting matrix K were 
given a prior that is uniform  0,1U .  In addition, they were subject to the constraint 1iji k  . The 
exposure rate also had an uninformative prior and was drawn from a uniform distribution  0,5U . 
2.3.2.4 MCMC Sampling  
A Monte Carlo Markov Chain (MCMC) method was used for the parameter estimation. Parameters were 
sampled using a standard random-walk Metropolis-Hasting algorithm [185, 189]. To reduce correlations in 
the chain, model parameters were updated together. At each iteration, all model parameters were 
resampled; if θ was the current value of the parameter, a candidate point * is sampled from a proposal 
distribution so that log( *) log( )    , where μ is drawn from a normal distribution  0,1N and the 
random walk rate σ was tuned to obtain optimal mixing (See Section 2.3.2.5). The candidate point is then 
accepted with probability ( , *)   where:   
   
( *) ( / )
( , *)=min 1,
( ) ( * / )
P P D
P P D
 
  
 
 
 
 
     (2.9)   
If the candidate point is accepted, the current point for the next iteration becomes *  . 
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A total of 100,000 iterations were performed for each run of the MCMC algorithm. The first 1,000 were 
discarded as the burn-in period. The output was then sampled every 250 iterations to constitute a sample 
from the posterior distribution. Multiple chains were run with different parameter starting values and 
combined to obtain an overall posterior sample of 3,600 iterations. For each parameter the posterior 
median and a 95% credible interval were computed. 
2.3.2.5 Random walk tuning 
The standard deviation of the proposal distribution, also called the random walk rate σ, was tuned in order 
to achieve appropriate mixing of the chains and an acceptance rate close to 20% [190]. During the burn-in 
period, at each iteration m the random walk rate was updated as below (Jamie Griffin, personal 
communication March 2011): 
 
1 10
1
1 1
0.001 if 0.0010.4 ( )
exp( )  and  
10 if 10
35
1
m m
m m
m m
m
M
  
 
 
 

 
  
  
 

 (2.10)  
With  the acceptance probability defined in (2.9), 0 the optimal acceptance rate equal to 23% and M
the total number of iteration. 
2.3.3 Validation of measures of exposure  
A classic catalytic model was fitted to the data with the purpose of comparing estimated measures of 
exposure. A cut-off value above which individuals were considered seropositive was defined using a 
mixture model [98, 162]. Cut-off values were generated separately for each antigen and each plasmodium 
species. The proportion of seropositive individuals who are seropositive at age t is given by:   
     
( )
( ) (1 )c c
tc
c c
y t e
 
 
  

    (2.11) 
with λc is the seroconversion rate and ρc the reversion rate for the catalytic model. 
The reversion rate was fixed to a constant value of 0.05, resulting for Pf MSP-1 from another study also 
carried out in Cambodia [134]. However, we assume that loss of antibodies is not antigen- or species- 
specific. Models were fitted with standard maximum likelihood estimation techniques [191], using optim 
function in R [188]. Denoting the maximum likelihood estimate of the force of infection λ*, a 95% 
confidence interval for the parameter λ is then determined by  * 1.96.se      with 1( )se diag H   and 
H is the Hessian matrix provided by R, corresponding to the negative of the inverse of the covariance matrix 
of the estimates. 
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2.4 Results 
2.4.1 Estimating malaria exposure and acquisition of antibodies rate  
The simplified model was fitted to data available from Cambodia. Parameters were estimated using a 
Bayesian approach. The algorithm converged and a good model fit was obtained, as demonstrated by the 
results below. 
Posterior densities of the parameters and MCMC trace are presented in Figure 2.7, demonstrating good 
convergence of the MCMC chain with smooth posterior distributions obtained for each parameter. The 
auto-correlations were small enough (between 0.2 and 0.3) to consider the observations in each parameter 
posterior sample to be independent from each other. The lowest effective sample size is around 233. 
 
Figure 2.7: MCMC trace (top row) and posterior distribution (bottom row) for measure of exposure (λ) and 
coefficients for the boosting matrix 
Correlations between parameters were examined to understand the relationship between parameters, as 
presented in Figure 2.8. A high degree of correlation was observed between parameters, as cross-sectional 
data provide limited information to distinguish between exposure and biological mechanisms for 
acquisition of antibodies. Indeed, estimates of the force of infection are negatively correlated with 
estimates of all the parameters from the boosting matrix. 
 
Figure 2.8: Bivariate plots of the marginal posterior distributions of all the model parameters.  Pearson correlation 
coefficients are presented in the upper panels. 
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Figure 2.9 and Figure 2.10 show the predicted output from model fit, illustrating a qualitatively good fit and 
a very narrow credible interval around the median fit. The model fit is constructed through simulation using 
sets of parameters, here 100, from the posterior distribution. Age specific median fit and 95% credible 
intervals of the resulting simulations are then computed and presented on the figures. Age-structured 
seroprevalence curves, categorised by antibody titre, are presented in Figure 2.9. 
At a very young age, individuals with no antibodies against Pf MSP-1 represent a high proportion of the 
population. However, with increasing age, an antibody response is first initiated and then boosted and 
people acquire higher antibody titres.  
 
Figure 2.9: Seroprevalence curves as a function of age categorised by titre values for Pf MSP-1;  the coloured lines 
correspond to the data seroprevalence and the black line the model fit median and the pink shaded area represents 
the 95% credible interval. tx represents individual’s antibody titre on log10 scale. 
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In each antibody class individuals are assumed to have, on average, the median value of the class, except 
for class 1 where individual’s log10 titre is zero. The mean titre for each age group is therefore defined as 
the mean of the proportion of individuals in each antibody class multiplied by the median value of the class 
(0 for class 1). The mean antibody titre by age is presented in Figure 2.10 for Pf MSP-1. Individuals acquire 
antibodies through their life seemingly faster at younger age than at older age. Analogous results are 
presented in Figure 2.11 for MSP-1 and AMA-1 for both P. falciparum and P. vivax. 
 
Figure 2.10: Mean antibody titre again Pf-MSP1 antigen; the coloured line represents the data and the black line the 
model. Here, median (black line) and 95% credible interval (pink shaded area) of 100 simulations of the mean log10 
titre are computed. 
Figure 2.11 compares the average antibody titre by age for both antibody types and both Plasmodium 
species. The model fit consistently reproduces the data qualitatively well. We observe higher titres for 
antibodies against AMA-1 compared to those against MSP-1. However, P. falciparum and P. vivax appear to 
have similar trend in mean antibody levels across age ranges.  
 
Figure 2.11: Individual mean antibody titre for MSP-1 and AMA-1 for P. falciparum and P. vivax.  The black lines 
correspond to the median fit for a sample of the MCMC simulation results and the colours dots correspond to the 
data. The pink shaded areas represent the narrow credible interval around the model fit. Note that the y-axes are 
on different scales. 
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Similar to the results found with the mean antibody titre, Figure 2.12 indicates that the proportion of 
individuals with high antibody levels (>2.4) appears to be higher for antibodies against AMA-1 antigens, 
consistently for both P. falciparum and P. vivax. This could be reflecting the higher immunogenicity of AMA-
1. In addition, across all ages, a higher proportion of individuals present with P. falciparum antibodies 
compared to P. vivax antibodies (the model predicts up to 20 to 40% of the population for respectively 
MSP-1 and AMA-1 for old individuals compared to 8 to 25% for P. vivax). 
 
Figure 2.12: Seroprevalence curves categorised by 6 titre ranges on log10 scale ( tx ) for antibodies against MSP-1 
and AMA-1 antigens for P. falciparum and P. vivax. The black lines correspond to the median fit of a sample of the 
MCMC simulation results and the coloured dots correspond to the data (colours are used for visual clarity). 
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Table 2.2 presents posterior median (95% equal-tailed credible interval) for model parameters for 
antibodies against MSP-1 and AMA-1 for both P. falciparum and P. vivax.  
Table 2.2: Posterior median (95% credible interval) for model parameters and transition rates λk 
Model 
Parameter 
Pf MSP-1 
Median 
(95% credible interval) 
Pf AMA-1 
Median 
(95% credible interval) 
Pv MSP-1 
Median 
(95% credible interval) 
Pv AMA-1 
Median 
(95% credible interval) 
λ 1.11 1.71 1.27 1.53 
(1.06-1.17) (1.61-1.81) (1.2-1.33) (1.45-1.61) 
k21 0.047 0.0266 0.0394 0.0415 
(0.0443-0.0499) (0.0248-0.0284) (0.0372-0.0418) (0.0391-0.044) 
k32 0.204 0.204 0.196 0.218 
(0.188-0.221) (0.185-0.225) (0.181-0.212) (0.201-0.237) 
k54 0.0424 0.0511 0.0357 0.1 
(0.0395-0.0457) (0.0471-0.0552) (0.0332-0.0383) (0.1-0.1) 
k65 0.0497 0.0552 0.0155 0.0485 
(0.0463-0.0533) (0.0513-0.0591) (0.0143-0.017) (0.0452-0.0521) 
     
λk21 0.0523 0.0454 0.05 0.0634 
(0.0507-0.0541) (0.0439-0.0469) (0.0484-0.0515) (0.0615-0.0655) 
λk32 0.227 0.349 0.249 0.333 
(0.216-0.239) (0.328-0.372) (0.236-0.261) (0.316-0.352) 
λk43 0.111 0.171 0.127 0.153 
(0.106-0.117) (0.161-0.181) (0.12-0.133) (0.145-0.161) 
λk54 0.0473 0.0872 0.0452 0.0742 
(0.0454-0.0492) (0.084-0.0905) (0.0434-0.047) (0.0716-0.0769) 
λk65 0.0554 0.0942 0.0197 0.0423 
(0.0526-0.0584) (0.0906-0.0978) (0.0183-0.0211) (0.0404-0.0443) 
     
 
 
The results suggest that the initiation of immunity, corresponding to the transition from no antibodies, 
(antibody class 1), to some antibodies (antibody class 2), is occurring at a slower rate compared with the 
acquisition of immunity during subsequent infections, consistently for both antigens and both Plasmodium 
species. The rate is around fivefold higher for second infections (from class 2 to class 3) and two to three 
fold higher for third infections (from class 3 to class 4) compared to first infection (assuming infection 
corresponds to a boost of immunity). 
Applying the full model 
Parameter estimation was also conducted using the complex full model presented in Figure 2.5. The MCMC 
algorithm was run for PfMSP-1 for 1 million iterations. Although the trace for the likelihood was converging, 
and both the seroprevalence curves and the mean antibody titre indicated a visually good fit to the data, 
the acceptance rate was still very low (around 2%) and it is clear from the MCMC trace plots for the 
parameters (not presented here) that the fitting has not converged. This is very likely due to model over-
λk54 λk65 λk43 λk32 λk21 
 ρ 
1 2 3 4 5 6 
ρ ρ ρ ρ 
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parameterisation, where multiple combinations of parameter values provide the same likelihood and are 
thus correlated in the sampling process.  
As algorithms were not converging for this more complex model, the simplified model was considered for 
the remainder of this chapter. The generalizability of the model was subsequently addressed by switching 
to a continuous model (see Chapter 3). 
2.4.2 Comparison of estimates with those from a catalytic model 
One of the objectives in developing this model was to be able to separate the effect of exposure and 
immunogenicity of antibodies. If it is to be used as a measure of transmission intensity, the ‘force of 
infection’ estimated from these models should rank different settings in the same way as other methods. A 
first step was therefore to compare the estimates from the density models with those obtained using a 
catalytic model. The data available are stratified by risk of exposure, considering the distance to the forest 
as a proxy for malaria transmission intensity.  
Figure 2.13 presents the seroprevalence curves and the fitted catalytic model when the seroreversion rate 
ρc is fixed to 0.05. The estimates of the seroconversion rates λc (Maximum Likelihood (ML) estimates and 
95% confidence interval) are presented in Table 2.3. 
 
Figure 2.13: Age-structured seroprevalence curves for MSP-1 and AMA-1 for both P. falciparum and P. vivax. 
The results suggest that fixing the seroreversion rate ρc to 0.05 is a reasonable assumption as the estimated 
values from both models are consistent, with rates for P. falciparum higher than for P. vivax consistently for 
both antigens. Similarly the conversion to seropositive is higher with AMA-1 antigen rather than MSP-1, 
consistently for both Plasmodium species (Table 2.3). 
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Table 2.3 : Parameter estimation for seroconversion rate for a catalytic model for antibodies against MSP-1 and 
AMA-1 for both P. falciparum (Pf) and P. vivax (Pv). 
 Model 
Parameter 
Pf MSP-1            
ML Estimates 
(95% conf.   interval) 
Pf AMA-1 
ML Estimates  
(95% conf. interval) 
Pv MSP-1 
ML Estimates  
(95% conf. interval) 
Pv AMA-1 
ML Estimates 
 (95% conf. interval) 
Es
ti
m
at
in
g 
ρ
c 
λc 
0.016 
(0.014-0.019) 
0.022 
(0.019-1.025) 
0.010 
(0.008-0.013) 
0.012 
(0.010-0.014) 
ρc 
0.05 
(0.04-0.06) 
0.04 
(0.03-0.05) 
0.09 
(0.06-0.12) 
0.03 
(0.02-0.04) 
Fi
xi
n
g 
ρ
c λc 
0.016 
(0.015-0.017) 
0.025 
(0.024-0.027) 
0.007 
(0.006-0.008) 
0.015 
(0.014-0.016) 
 
 
2.4.3 Estimating exposure rate in multiple endemicity settings 
As heterogeneity in malaria transmission is often believed to be related to the forest in Cambodia, the 
distribution of the antibody titre was presented in Figure 2.3 according to the distance between the 
individual’s house and the forest and showed higher antibody levels for individuals living in the forest.  
The density model applied to different transmission settings fitted the data well with convergence of the 
MCMC algorithm. Posterior distributions for the coefficients of the boosting matrix are summarized in Table 
2.4. The parameter estimates show the same patterns between antigens and between species as the model 
fitted assuming no variation in endemicity. 
Table 2.4: Parameter estimation for boosting matrix for MSP-1 and AMA-1 for both P. falciparum and P. vivax 
Model 
Parameter* 
Pf MSP-1 
Median 
(95% credible  interval) 
Pf AMA-1 
Median 
(95% credible  interval) 
Pv MSP-1 
Median 
(95% credible  interval) 
Pv AMA-1 
Median 
(95% credible  interval) 
k21 0.076 0.032 0.069 0.06 
(0.073-0.078) (0.031-0.033) (0.067-0.071) (0.058-0.062) 
k32 0.3 0.23 0.31 0.27 
(0.28-0.31) (0.21-0.24) (0.3-0.32) (0.26-0.28) 
k54 0.04 0.043 0.02 0.038 
(0.039-0.042) (0.042-0.045) (0.019-0.021) (0.036-0.039) 
k65 0.037 0.038 0.015 0.016 
(0.035-0.039) (0.037-0.04) (0.013-0.016) (0.015-0.016) 
*k43 was fixed to 0.1 
Table 2.5 shows the parameter estimates from this simple density model (median and 95% credible 
interval) alongside those from the catalytic model (MLE and 95% confidence interval) for antibodies against 
AMA-1 and MSP-1 for both P. falciparum and P. vivax. The results for the density model show a decreasing 
exposure rate with an increasing distance to the forest consistently for both antigens and both Plasmodium 
species (Figure 2.14). The same conclusions hold for the catalytic model. 
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Table 2.5: Parameter estimation measuring 5 different exposure rates λ based on the distance to the forest (1 : In 
forest, 2 : <200m, 3 : 200-500m, 4 : 500m-1km, 5 : >1km). Rates estimated by simple density model and catalytic 
model for MSP-1 and AMA-1 for both P. falciparum and P. vivax.  
 
 
 
Figure 2.14: Median force of infection estimated by density model (left) and catalytic model (right) for Pf MSP-1, Pf 
AMA-1, Pv MSP1 and Pv AMA-1.  Note that the scale is expected to be different between the two models. 
 
Figure 2.15 illustrates the relationship between the exposure parameter for the two different models 
(catalytic and density). A Pearson correlation of 0.78 and a Spearman correlation of 0.76 were found, 
indicating that both exposure rate from the density model and seroconversion rate from catalytic model 
would rank endemicity settings in an equivalent order. 
Risk 
area 
Pf MSP-1 Pf AMA-1 Pv MSP-1 Pv AMA-1 
Density 
Median 
(95% CrI) 
Catalytic 
ML Estimates 
(95% conf. int) 
Density 
Median 
(95% CrI) 
Catalytic 
ML Estimates 
(95% conf. int) 
Density 
Median 
(95% CrI) 
Catalytic 
ML Estimates 
(95% conf. int) 
Density 
Median 
(95% CrI) 
Catalytic 
ML Estimates 
(95% conf. int) 
1 1 0.038 2.32 0.055 0.99 0.021 1.51 0.023 
(0.97-1.03) (0.031-0.044) (2.27-2.39) (0.048-0.063) (0.96-1.02) (0.016-0.027) (1.47-1.54) (0.019-0.027) 
2 0.84 0.014 1.35 0.022 0.74 0.0063 1.13 0.0091 
(0.81-0.87) (0.011-0.017) (1.31-1.41) (0.018-0.026) (0.71-0.76) (0.0039-0.0087) (1.09-1.16) (0.007-0.011) 
3 0.81 0.012 1.26 0.012 0.74 0.0062 1.15 0.009 
(0.78-0.83) (0.0093-0.014) (1.22-1.3) (0.0099-0.014) (0.71-0.76) (0.0042-0.0083) (1.12-1.18) (0.0072-0.011) 
4 0.74 0.0071 1.22 0.0091 0.77 0.0071 1.21 0.0098 
(0.71-0.76) (0.0052-0.009) (1.18-1.26) (0.0071-0.011) (0.75-0.8) (0.045-0.0096) (1.17-1.25) (0.0076-0.012) 
5 0.65 0.0056 0.89 0.007 0.78 0.0072 0.83 0.0061 
(0.63-0.66) (0.0044-0.0067) (0.86-0.91) (0.0059-0.0081) (0.76-0.8) (0.0051-0.0093) (0.81-0.86) (0.005-0.0072) 
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Figure 2.15: Correlation between estimates from the catalytic model and the density model, categorised by distance 
to the forest, irrespective of Plasmodium species and antibody types. 
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2.5 Discussion 
In this chapter, I developed a compartmental model to mimic the dynamics of the acquisition and loss of 
blood-stage antibodies in the population using a discrete model.  The model separates the effect of 
exposure, antibody production and decay of antibodies as part of the wider immune response by using the 
full information contained in serological measurements. The results demonstrate that using a simple 
discretised version of a density model not only provides measurements of exposure consistent with those 
obtained with classical methods, but also gives insight into the dynamics of the acquisition of antibodies. 
The use of more complex models would ideally better inform the biological mechanisms of the acquisition 
of antibodies and help in understanding the immune responses against P. falciparum and P.vivax and their 
potential interactions.  
2.5.1 Boost of antibodies 
A key result is that the change in the rate of acquisition of antibodies is estimated to depend on current 
titre. The simplistic model showed that at lower antibody densities, rates of boosting conditional on 
exposure are slow, and then increase before slowing down again. This suggests a density dependency in the 
acquisition of antibodies for both anti-MSP-1 and anti-AMA-1 antibodies, whereby circulating antibodies 
are necessary to facilitate a faster boost of antibodies and as saturation begins, the acquisition of 
antibodies happens at a slower rate. An explanation of this mechanism could be a saturation of antibodies 
such that antibodies in subsequent infections occurring with existing high titres are boosted at a slow rate 
and eventually stop production if sufficient levels already exist. Alternatively, the existence of a threshold 
above which antibody production is triggered could explain the minimum level of circulating antibodies 
required to activate a faster boost. This assumption would therefore give weight to the choice of a cut-off 
value for the assessment of seroprevalence using the catalytic model, although what a catalytic model 
would not capture is the first infections leading to low levels of antibodies.  However, such a finding could 
also simply be an artefact of the heavily constrained model. Indeed, the simple model representing a 
gradual acquisition of antibodies forces individuals to have an arbitrary identical fixed boost upon infection, 
irrespective of the current titre or first or subsequent infections. Only the probability of developing an 
antibody boost varies according to the current level of antibodies. Additionally, I have assumed that the 
probability of boosting is independent of individual’s age. In the available dataset, age and antibody levels 
are collinear, it would be impossible to distinguish whether the boost in antibodies depend on age or on 
current antibody levels. 
The full model allows for greater flexibility in the assumptions about the acquisition of antibodies, implying 
that individuals can experience antibody boosts of different magnitudes irrespective of their current level 
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of antibodies. The interesting question this model is trying to answer is whether there is a saturated titre 
above which antibodies do not get boosted anymore or whether there is a constant or density-dependent 
boost constantly occurring. Even though conclusions cannot be made from this model, with the current 
discretisation of the population, it would still be difficult to differentiate between both hypotheses. Indeed, 
a discretised model might mask the effect of underlying threshold values and generate heterogeneity 
within discretised population. Therefore a discrete model with very small intervals (i.e. large number of 
states) or ideally a continuous model would overcome this issue and will be developed in the following 
chapters. When a higher degree of complexity was added to the model to attempt to recreate the 
biological mechanisms allowing antibodies to be boosted to any level, it was not possible to properly 
estimate the parameters due to over parameterisation. 
The lack of convergence of the MCMC algorithm limits the validity of the complex models. Increasing the 
number of states to overcome the issue of creating heterogeneous population would only increase the 
number of parameters of a model already over-parameterised. Setting a few parameters to constant values 
could help fixing the issue, but this would be tedious and would only revert back to a constrained model 
leading to a model such as the simple one developed here. Consequently, fitting a continuous distribution 
for the acquisition of antibodies would represent a trade-off for decreasing the number of parameters and 
minimizing the constraints and better mimic the biological mechanisms underlying the acquisition of 
antibodies. 
2.5.2 Measure of transmission intensity 
Serology is currently used as an indicator of malaria transmission and estimates of the rate of 
seroconversion made using catalytic models [97]. Studies have shown that these estimates of the 
seroconversion rate correlate well with EIR [95]. However it was not clear whether density models that 
utilise the full information contained in the serological measurement, i.e. titres, would provide similar 
estimates as the parameter here is meant to represent the force of infection rather than a rate of 
seroconversion. The results show that there is a positive correlation between the parameters estimated 
from both traditional catalytic and the simple density model fitted here. This suggests that the ‘force of 
infection’ estimated in the density model can represent a measure of transmission intensity and such 
models could therefore be used to measure changes in transmission intensity in a similar way to the use of 
catalytic models [99, 135]. However, an application of the model to other datasets across a wider range of 
transmission is first needed to validate the method as a tool for measuring malaria transmission intensity. 
Also, the assessment of transmission intensity based on serological data relies on the residual antibodies 
sustained by individuals after infection. The maintenance of long-term immunity is highly dependent on the 
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rate of decline of these antibodies. The model has assumed an exponential decay of antibodies by assuming 
that the number of individuals becoming seronegative is exponentially decreasing with increasing duration 
of exposure (age). The value of the rate of fading antibodies was fixed in the model. However, the 
underlying antibody response relies on antibody secreting cells (plasma cells) and memory B cells [56, 65].  
The duration of the antibody response for long term immunity remains poorly understood. The current 
literature provides, indeed, substantially variable estimates for its duration [96, 115, 117, 119, 124, 192].  
The rate chosen for this analysis, 0.03 yrs-1 represents a half-life for antibodies around 23 years. This 
estimate was chosen based on the catalytic model which assumes individuals would remain seropositive for 
this duration. However, despite the fact that the longevity of the antibody response can vary due to a 
number of factors such as age [96, 117] or treatment [118], this rate might be unrealistic and therefore a 
better estimate based on longitudinal data would be more appropriate.  
The model outlined here is subject to a number of other assumptions. In particular it assumes that the 
parameter measuring exposure is not age dependent. Both adults and children are equally exposed to 
infectious mosquitoes. However, a study conducted by Carnevale [78] has shown that the mosquitoes 
biting rate is age-dependent, with a preference three fold higher for adult. Therefore a constant force of 
infection across all age groups is unlikely to occur. The developed model would benefit from an age-specific 
force of infection based on similar concept used by Smith et al.[67] or by Griffin et al. [93] for the 
transmission model where an age-specific biting rate was fitted to the data.  
I have fitted the model to data on antibodies against MSP-1 and AMA-1 antigens, assuming they were 
similarly responding to the infection. However, the immunogenicity for these antigens is relatively different 
[97]. Antibodies to MSP-1 antigens might bind faster while antibodies to AMA-1 might produce a higher 
antibody response [114]. These differences in antibody acquisition might explain the discrepancy observed 
between the predictions of antibody levels of MSP-1 and AMA-1 antibodies, already observed in the data 
with higher prevalence and higher average titre for antibodies against AMA-1 antigens. 
The model has assumed that infections with P. vivax and P. falciparum were undergoing the same biological 
process. However, the main characteristic which differs from P. falciparum is the presence of dormant 
hypnozoites in the liver. The exposure to blood stage antigen might therefore be due to a relapse of 
hypnozoites [181]. Therefore assuming a systematic boost of blood stage antibodies following exposure to 
P. vivax might not be an adequate representation of reality. Results might underestimate antibody levels 
and consequently exposure, if hypnozoites remain in the liver upon a mosquito bite. This might therefore 
explain the lower predicted prevalence of P. vivax antibodies in comparison with P. falciparum antibodies. 
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Additionally, as demonstrated in this chapter, the model has replicated conclusions made by a classic 
catalytic model showing seroprevalence for P. falciparum was consistently higher than for P. vivax. 
However, Cook et al. published an evaluation of transmission in Cambodia using serological data [133] and 
showed that there was spatial heterogeneity of the distribution of the Plasmodium species with P. vivax 
dominating in the west and P. falciparum in the east, probably due to ecological differences. The country-
wide data used for the model in the chapter might therefore experience some heterogeneity in the 
distribution of plasmodium species that would explain differences in antibody levels. Therefore in order to 
differentiate between biological and environment hypotheses to explain differences in antibody level 
between species, it would be interesting to adjust for environmental factors (e.g. test the model where 
levels of P. falciparum and P. vivax are known to be the same). The results would help to understand the 
extent to which the model would be valid for P. vivax. 
 
2.6 Conclusion 
This chapter has summarised the development and application of a discretised density model allowing for 
separation of the effect of exposure and immunogenicity of antigens on the immune response. Correlation 
of the measures of exposure obtained with the density model and current methods was demonstrated. On 
the other hand, given the simplistic form of the model, only qualitative conclusions indicating a density- 
dependency of the rate of acquisition of antibodies were established. Complex models providing a more 
realistic insight of the biological processes could not be assessed. A continuous model is needed to better 
capture the acquisition of antibodies. 
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Chapter 3: Development of a density 
model for antibody dynamics  
In the previous chapter, I investigated the acquisition of immunity in a discrete framework assuming 
independence of the parameters responsible for the boost of antibodies. In this chapter, I extend this 
model and use a continuous distribution to model the boost of antibodies upon infection. A continuous 
framework will be more representative of the actual process, while decreasing the total number of 
parameters and providing more easily interpretable information. 
3.1 Introduction 
As presented in Chapter 1, a blood stage antibody response is initiated by the presence of the Plasmodium 
parasite at the erythrocytic stage. These antibodies have eligibly an important role in malaria immunity. 
However, the protective function of some induced antibody responses remains unclear. Indeed, some 
studies have shown a lack of correlation with lower prevalence of parasitaemia or with lower rate of 
disease [65, 110]. Also, protective immunity presents some important challenges  with antibodies which 
might not last long enough to protect from subsequent infections [115, 116, 118]. Additionally, antigenic 
variation might render naturally acquired immunity obsolete [115, 193].  
In addition to their role for protection against malaria, antibodies have a role of marker of exposure, useful 
in a seroepidemiological context. The presence of antibody titre to blood stage antigens give some 
indication on the interaction, past or present, between malaria parasite and individuals [194]. Antibody 
titres have been associated with malaria exposure and high concentrations of antibodies have been 
reported in areas of high EIR  [111, 195]. Also, in areas where transmission was reduced by insecticide 
treated nets, a decrease of concentrations of antibodies was recorded [196]. 
However, many other factors are also responsible for variation in antibody response. Despite being less 
susceptible than parasite density to seasonal variation, antibody levels have been recorded to be higher 
during peaks of malaria transmission [195, 197]. This is likely to be a consequence that concentration of 
antibodies is higher during an acute malaria infection [198, 199]. Antibody concentration peaks around one 
week after a malaria episode and decay to low levels in 6 to 8 weeks [200]. The rapid decay of antibodies, 
widely discussed [128], the unmeasured heterogeneity of exposure and the unmeasured difference in 
individual’s susceptibility to mount antibody response [200] are all important determinants for the levels of 
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antibody response and might infer some heterogeneity in the seropositive and seronegative 
subpopulations . For instance, individuals can lack antibodies because they are not under exposure or they 
have been exposed and loss their antibodies. Similarly, the seropositive population consists in a mixture of 
non-immune individuals recently treated for an episode of malaria and parasite positive or negative 
individuals with some degree of immunity. It might therefore be difficult to accurately distinguish between 
immune and susceptible and between exposed and unexposed individuals and this might lead to 
misclassification issues. 
A better understanding of the processes underlying the acquisition and loss of antibodies would greatly 
benefit the interpretation of seroepidemiological studies. In the previous chapter, a discrete framework 
was used to characterise the acquisition of antibodies. However, due to the limited number of the classes 
of antibody level, only qualitative result could be drawn on the dynamics of the antibodies. To better 
characterize the kinetics of antibodies, a much higher number of classes is required to approximate a 
continuous model. In this Chapter, I explore a number of continuous models to mimic the biological 
mechanisms responsible for antibody production. In particular, I investigate whether a model in which the 
amount of antibodies produced following exposure depends on the current individual’s antibody levels 
provides a more parsimonious fit to cross-sectional serological data than one in which the response is 
uniform. The structures of the models are based on the model presented in Chapter 2 with a higher 
number of compartments. 
3.2 Methods 
3.2.1 Data 
A cross-sectional Malaria Baseline Survey (CMBS), described in detail in Chapter 2, was conducted across 
Cambodia in 2004. Serological samples were collected and tested against blood stage antigens. In this 
chapter, only antibodies against Merozoite Surface Protein (MSP-1) antigens were analysed. Also, only 
individuals older than 1 year old (disregarding maternal antibodies) were included in the analyses. Antibody 
titres were reported on a log10 scale. The laboratory methods employed provided reliable measurement 
between -2 and 4 (Patrick Corran, personal communication), therefore values outside this range were set to 
these limits. The data for individuals at age 0 were used as the initial state to solve the equations of the 
model. 
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3.2.2 Framework for a continuous model 
The compartmental model developed here reproduces the dynamics of antibodies when individuals are 
exposed to malaria infection. It is based on the previously described model and focuses on the continuous 
aspect of the acquisition and loss of antibodies. 
3.2.2.1 Individual interpretation of antibody dynamics 
I developed a mathematical model to describe the dynamics of acquisition and loss of antibodies in the 
population. The model assumes that, following exposure to an infectious bite which occurs at rate λ, an 
individual’s antibody level is boosted by ( )tx  where tx  is the base-10 logarithm of antibody density. In 
the absence of exposure I assume antibodies decay exponentially at a constant rate  . A schematic 
representation of an individual’s dynamics of naturally acquired antibodies in presented in Figure 3.1. 
 
Figure 3.1: Schematic kinetics of antibodies in response to successive malaria infection 
 
3.2.2.2 Model description 
Let ( )y x  denote the proportion of the population with log10 antibody level x at time t and 
*( , )K x x denote 
the probability that individuals with log10 antibody level x are boosted to level
*x
*( )x x   on exposure to 
an infectious bite. Then the distribution of antibody levels in the population is given by:   
 
* * * *( ) ( )( , ) ( ) ( , ) ( )
y x y x
K x x y x K x x y x dx
t x
 
 
     
 (3.1) 
The model was numerically approximated by a version in which the log10 antibody density variable, x , was 
discretised by dividing the range of the variable into N compartments each of width , with ix denoting 
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the value of (log10) antibody density at the mid-point of antibody class i . The first class represents 
measurements below the limit of detection, minx . I used N=51, with =0.12 and 2minx   . I also 
investigated the impact of the number of states on the results by analysing the model with N=41 and N=61 
states. The resulting discrete model describes the dynamics of the proportion of the population in each 
antibody density category i, denoted iy , and is defined by the following set of ordinary differential 
equations:   1       1
i
ij j j hi i i
j i h i
dy
k y y k y y i N
dt
 
 
 
     
 
   (3.2) 
where h, i, j index the N antibody level classes. The rates of exposure and decay of antibodies, and  , 
are assumed to be independent of antibody density and age.  Multiple functions are explored to describe 
the probability that, following exposure, antibody levels are boosted to class i from class j, ijk . 
3.2.2.3 Modelling acquisition of antibodies 
There is limited knowledge of the dynamics of acquisition of antibodies and even less about the density-
dependency of the boost of antibodies following malaria infection. I explored a few hypotheses for the 
underlying mechanisms of acquisition of antibodies by testing different parameterisations of the boost of 
antibodies that individuals experience upon exposure.  
A first assumption is what occurs in individuals with no circulating antibodies. These individuals can be 
“seronegative” either because they have never been exposed or because any previous antibody response 
has decayed to below detectable levels. Such individuals are assumed to have an antibody response that 
differs from those who already have circulating antibodies. I further investigate this underlying assumption 
about the composition of the “seronegative” population in section 3.2.3.  
In order to assess the density dependency of the antibody boost size I considered the following scenarios 
(see Figure 3.2): 
 The size of the boost of antibodies upon infection is independent of the individual’s current 
antibody level (constant boost size) 
 The size of the boost of antibodies upon infection only depends on a threshold value for the 
current antibody level; above this level the antibody boost is lower than below it (step boost size) 
 The size of the boost of antibodies upon infection decreases continuously with increasing current 
antibody levels with a given parametric form (logistic, exponential or linear boost size) 
This is referred to as functions for the “boost size mean”.  
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Figure 3.2: Representation of functional forms for average boost size using the parameters in Table 3.1. 
In addition, there is likely to be variation between individuals in the magnitude of the boost even if they 
have the same current antibody level on exposure to a new infection. I therefore also compared models in 
which this between-individual variation was incorporated with either a Normal or a Lognormal distribution 
to one in which there was no between-individual variation. This is referred to as the “boost size 
distribution”. Therefore, a total of 15 models were considered for comparison encompassing 5 functions 
for the “boost size mean” and 3 different distributions for the between-individual variation in boost size 
(“boost size distribution”). These are summarized in Table 3.1. 
Mathematically, the between-individual variation in the boost size is calculated in the following way. The 
probability that following exposure, antibody levels are boosted to class i from class j, ijk , is distributed 
according to a discretised distribution: 
 
 1
0                                                                                            if  
( / 2 ; ( ), ) ( / 2 ; ( ), )  if  
1 / 2 ; ( ),                       
ij i j j i j j
N j j
i j
k F x x x S F x x x S j i N
F x x x S
 


       
  
    
                        if  i N





(3.3) 
where  , ( ),F z x S is the cumulative density function at point z of the boost distribution with mean ( )x  
and standard deviation S (see Table 3.1). Here ( )x  (the boost size mean) is a function of the current log10 
antibody level, x, assumed to be given by:   
min( ) if    
( )
otherwise
d x x x
x


 

 
with  d x  representing the function for “boost size mean” dependent on current antibody levels as shown 
in Table 3.1 and Figure 3.2 and  the boost size mean for individuals with no circulating antibodies. 
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Table 3.1: Summary of mean and distribution of boost size for each of the models 
Models 
“boost size 
distribution”1 
Function for 
“boost size 
mean"2 
“Boost size mean” 
parameterisation 
“Boost size distribution “ 
parameterisation 
1 None Constant ( )d x a  
11{ ( ) ( , ]}i iF x X x X x      
2 None Exponential ( ) exp( )d x a bx   
11{ ( ) ( , ]}i iF x X x X x      
3 None Linear ( )d x ax b   
11{ ( ) ( , ]}i iF x X x X x      
4 None Logistic ( ) / (1 *exp( ))d x a A bx   
11{ ( ) ( , ]}i iF x X x X x      
5 None Step   if ( )
0 otherwise
oa x x
d x

 

 
11{ ( ) ( , ]}i iF x X x X x      
6 Normal Constant ( )d x a  
( ( ), )F Norm mean x sd S    
7 Normal Exponential ( ) exp( )d x a bx   
( ( ), )F Norm mean x sd S    
8 Normal Linear ( )d x ax b   
( ( ), )F Norm mean x sd S    
9 Normal Logistic ( ) / (1 *exp( ))d x a A bx   
( ( ), )F Norm mean x sd S    
10 Normal Step   if ( )
0 otherwise
oa x x
d x

 

 ( ( ), )F Norm mean x sd S    
11 Log Normal Constant ( )d x a  log ( ( ), )F Norm mean x sd S    
12 Log Normal Exponential ( ) exp( )d x a bx   log ( ( ), )F Norm mean x sd S    
13 Log Normal Linear ( )d x ax b   log ( ( ), )F Norm mean x sd S    
14 Log Normal Logistic ( ) / (1 *exp( ))d x a A bx   log ( ( ), )F Norm mean x sd S    
15 Log Normal Step   if ( )
0 otherwise
oa x x
d x

 

 log ( ( ), )F Norm mean x sd S    
1 
Between-individual variation in size of the boost 
2
 Dependent on current antibody level 
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3.2.2.4 Model parameters 
The 15 models presented above are all characterised by the same following input variables: exposure rate, 
rate of decay of antibodies, mean boost for acquisition of antibodies for “seronegative” individuals. Only 
the acquisition of antibodies for those individuals with existing circulating antibodies differs. A detailed 
description of the parameters is presented in Table 3.2 and their use in each model is summarised in Table 
3.3. Literature provides a wide range of estimates of duration of immune response but based on White’s 
estimate [192], I have assumed throughout that the half-life for circulating antibodies is around 1 year, 
fixing the rate of loss of antibodies to 0.7 yr-1 using 1/2 1/ 2te   where 1/2t represents the antibody half-life. 
Table 3.2: Parameters description & associated uninformative priors 
 Parameter descriptions Prior distribution 
λ Rate of exposure U[0,100] 
ρ Rate of loss of antibodies - 
η Mean boost for individuals with no current circulating antibody U[0,10] 
a Maximum antibody boost size on exposure U[0,10] 
b Slope of dependence of antibody boost on current log10 antibody titre  U[0,10] 
xo Maximum antibody titre above which individual’s do not get a boost of antibodies  U[0,10] 
A Parameter associated with the slope in the logistic function U[0,10] 
S Standard deviation for boost size distribution U[0,100] 
 
Table 3.3: Model parameters 
Models “Boost size 
mean” 
“Boost size 
distribution” 
Model parameters Total # of 
parameters λ ρ η a b xo A S 
1 Constant None         4 
2 Exponential None         5 
3 Linear None         5 
4 Logistic None         6 
5 Step  None         5 
6 Constant Normal         5 
7 Exponential Normal         6 
8 Linear Normal         6 
9 Logistic Normal         7 
10 Step  Normal         6 
11 Constant Log Normal         5 
12 Exponential Log Normal         6 
13 Linear Log Normal         6 
14 Logistic Log Normal         7 
15 Step  Log Normal         6 
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3.2.3 Heterogeneity in the « seronegative » population 
The models presented so far considered a specific antibody response for individuals with no circulating 
antibodies, corresponding to an antibody titre equal to the limit of detection minx and termed 
“seronegative” population in this context. However, this assumption might not be valid as there is inherent 
heterogeneity between individuals presenting with no circulating antibodies. Indeed, individuals classified 
as “seronegative” could either be individuals who have never experienced an infection or individuals who 
had an infection and whose circulating antibodies have been lost or fallen below the limit of detection. As a 
result, I additionally considered parameterising the « seronegative » individuals as a mixture of sub-
populations representing these different populations. Five hypotheses about the antibody response for 
“seronegative” individuals were assessed. A schematic representation of these is presented in Figure 3.3. 
 Hypothesis H1: “Seronegative” individuals do not develop any specific antibody response and their 
mean antibody boost  is constrained to equal the maximum boost size seropositive individuals can 
experience, a   
 Hypothesis H2: “Seronegative” individuals have a specific  antibody response and so the model is 
not constrained, i.e  a   
 Hypothesis H3: A proportion (1  ) of the “seronegative” individuals have never been exposed  
and will never be exposed and therefore won’t produce any antibody response whilst a proportion 
 of the population is exposed and develop a specific antibody response 1 , therefore the overall 
mean antibody boost size for seronegative individuals is 1  . 
 Hypothesis H4: “Seronegative” individuals represent a mixed population of %w  of never infected 
individuals (and are now susceptible) and  1 %w of previously infected individuals with no 
detectable antibodies. The latter group are assumed to have a mean antibody boost 2  and the 
other group a different mean antibody boost 1 . Thus the overall mean antibody boost is 
1 2(1 )w w     . 
 Hypothesis H5: “Seronegative” individuals represent a mixed population of never exposed 
individuals and previously infected individuals with no detectable antibodies but only 80% of them 
will ever get exposed, i.e 1 20.8*( (1 ) )w w     , and 2 1 * ,    with [0,1]     . This 
hypothesis was based on the observation in the cross-sectional data from Cambodia with at least 
20% of individuals being seronegative (with antibody level below the level of detection) for all age 
classes counfounded at the time of the survey.  
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Figure 3.3: Schematic representation of the five different hypotheses to explain the composition and the antibody 
response of the seronegative population. 
For each of these 5 hypotheses, the model used has the same structure as Model 12 from above, with a 
Lognormal distribution for the boost size and an exponentially decreasing mean boost size with increasing 
current antibody level for modelling the density dependent acquisition of antibodies. The four parameters 
common to all five model variants were the exposure rate , the decay of antibodies rate  , and the 
parameters associated with antibodies kinetics ( a ,b and S ). The extra parameters associated with each 
hypothesis are presented in Table 3.4. 
Table 3.4: Model parameters for seronegative population and associated uninformative priors. 
Parameters                               Hypotheses H1 H2 H3 H4 H5 Prior distribution 
Mean boost size        η (or η1)       U[0,10] 
Mean boost size         η2      U[0,10] 
Proportion of exposed individuals γ      U[0,1] 
Proportion of previously infected individuals w       U[0,1] 
Scaling factor             β      U[0,1] 
Total number of parameters. 
 
4 5 6 7 7  
 
3.2.4 Bayesian framework for inference of model parameters 
I used a Bayesian approach to estimate the model parameters by fitting the model to the data. For anti-
MSP-1 antibodies, the rate of decay of antibodies was fixed. Using   to denote the estimated parameter 
vector and {( , )}i iD x t  the data including the observed antibody level and age of individual i, the 
multinomial log-likelihood is given by:  
, ,
0
log( ( | )) log( )i t i t
t i
l P D n y

     (3.4) 
Here  ,i tn  and ,i ty  are, respectively, the observed number and predicted proportion of individuals in 
antibody category i at age t.  
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MCMC methods were used to calculate the posterior distribution of the parameters (details in Appendix I).  
As all parameters were positive-definite I used a Log-normal random walk proposal density and assumed 
uninformative uniform priors (see Table 3.4). After a burn-in period of variable length, I performed 500,000 
iterations for each run of the MCMC algorithm. Chain convergence was checked visually. The output was 
then recorded every 100 iterations to generate a sample from the posterior distribution of a minimum size 
of 4,500. The  standard deviation of the proposal distribution was tuned in order to achieve appropriate 
mixing of the chains and an acceptance rate close to 20% [190].  
3.2.5 Model selection 
To discriminate between models one should ideally use a criterion based on a trade-off between 
complexity of the model and the fit to the data. The Deviance Information Criterion (DIC) [201] provides a 
measure of the goodness of fit weighted against the number of parameters being estimated  and is defined 
as:                              DIC = goodness of fit + complexity of the model 
The goodness of fit is evaluated through the deviance defined as: 
 ( ) 2log( ( / ))Dv P D    (3.4) 
for the likelihood P(D/θ). The complexity of the model is assessed with the estimation of the ‘effective 
number of parameters’, defined as “posterior means deviance - deviance of posterior means”: 
  / /[ ( )] [ ] ( ) ( )Dv D Dp E Dv Dv E Dv Dv          (3.4) 
  
The DIC is then defined as:             ( ) 2 DvDIC Dv p   
        ( ) DvDv p   (3.4) 
Models with smaller values better support the data. It is imperative to note that only the differences in DIC 
are important and its absolute size is irrelevant. 
In total, this Chapter presents 75 different models; 15 for the boost size (presented in Section 3.2.2) 
combined with 5 hypotheses for the heterogeneity in the “seronegative” population (presented in section 
3.2.3). However, in practice, a model selection was first performed to select the best model for the boost 
size (assuming a specific antibody response for the “seronegative” population: H2). Subsequently, based on 
this selected model, the 5 hypotheses for the heterogeneity in the “seronegative” population were 
compared to define the best model. 
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3.2.6 Fitting the model to simulated datasets 
To assess the performance of my method to reproduce estimates of transmission intensity, I designed 
simulations based on the following scenario. A population was exposed at a constant exposure rate 
λ=5.5 yrs-1 and constant rate of decay of antibodies ρ=0.7 yrs-1. I used Model 12 from the model presented 
above, assuming a Log normal distribution for the boost distribution with an exponentially decreasing mean 
boost size with increasing current antibody levels with the following values; the maximum size of the boost 
of antibodies is 0.5a  , while the decrease of boost size 0.4b   and the standard deviation 0.1S  . 
“Seronegative” individuals had a mean boost size of 0.015  . The values used for simulation were 
chosen so the model outcomes were similar to those observed in field datasets.  
I assumed that a survey sampled individuals with the same age structure that was found in the dataset 
from Cambodia. The number of individuals in each antibody level category was drawn from a multinomial 
distribution with its associated probability corresponding to ,i ty  representing the solution of the model 
described above. Individuals were assigned a same antibody level if they were from the same discretised 
interval, corresponding to the median antibody of that interval. I simulated 100 datasets and I performed 
parameter estimation for each of them by fitting the model to simulated data using MCMC methods as 
described above.  
3.2.7 Fitting the model to Cambodian datasets 
In order to determine the best model that reproduces age-specific antibody levels from a cross-sectional 
survey, I fitted the different models to data from Cambodia using MCMC methods as described above. For 
the selection of the best model, I assumed the exposure level was constant over the country. In a second 
part, I used the best selected model to assess exposure from different areas, using the distance to the 
forest as a proxy for transmission intensity. Therefore, I fitted a single model that estimates simultaneously 
exposure levels from different areas.  
When estimating multiple exposures, the log-likelihood becomes:  
 , , , ,( / ) log( )i t v i t vv i tl D n y    (3.4) 
where , ,i t vy and , ,i t vn are respectively the predicted proportion and the observed number of individuals with 
titre i and age t in area v . 
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3.3 Results 
3.3.1 Simulation study 
The simulation study assessed the ability of the fitting algorithm to estimate the parameters. The posterior 
median and credible intervals of each parameter were computed for each simulated dataset and are 
presented in Figure 3.4. As a result, the original parameter fell within the estimated posterior 95% credible 
interval on average for 82.8% of the simulations. I observed a correlation between the rate of exposure (λ) 
and the maximum boost size (a). This is not surprising since individuals at a given antibody level can be 
there either because they were recently at a slightly lower level, were exposed and as a result had a small 
boost or because they were at a lower level (having been exposed less) and recently received a large boost 
in antibodies. The proportion of times either the rate of exposure or the maximum boost size is correctly 
estimated is relatively high (74%), which suggests that, despite the underlying correlation between these 
two parameters, the model is capable of identifying the correct exposure rate (and therefore maximum 
boost size). Note that the product of the exposure rate by the maximum boost size ( *a ) is correctly 
estimated in 96% of the cases. The estimated antibody levels are shown in Figure 3.5 (see Appendix II for 
details of how these are calculated). As can be seen on the plot, the predicted values from the model 
closely match the values from the simulated datasets.  
 
Figure 3.4 : Posterior 95% credible interval for each parameter (each panel) estimated for each of the 100 simulated 
datasets.  The values used for the simulation are shown by the red line and the proportion of the intervals that 
contains the simulated value is noted below by the proportion correctly estimated. Note that when   and   are 
fixed, unbiased estimates of their values were obtained from additional simulation studies (not presented).  
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Figure 3.5 : Predicted median antibody titre.  The black lines represent the antibody titres for each of the 100 
simulated dataset. The grey shaded area correspond to the 95% credible interval for the model fit using the median 
parameters sets resulting from the estimation on each of the 100 simulated datasets and the red line corresponds 
to the associated median antibody titre. 
Note here that I made the assumption that at birth all individuals have no antibody and the size of the 
boost for seronegative individuals is chosen to be very low. This explains why individuals before 15 years 
old do not present any antibody in the simulated dataset. However, in field data, this theoretical 
assumption might not be valid. 
3.3.2 Model selection by fitting to Cambodia data 
A series of 15 models that suggest various scenarios for the acquisition of antibodies were investigated in 
order to best describe this mechanism despite the limited within-host information captured in cross-
sectional data. Each model was successfully fitted to the serological data from Cambodia and summary 
results are presented in Table 3.5. The simplest model in which there is no variation in the antibody boost 
size between individuals had a substantially poorer fit as judged by the DIC than other models (Models 1 to 
5). Allowing there to be variation between individuals (Models 6 to 15) improves the fit of the models, with 
lower values of DIC obtained assuming a Lognormal boost distribution (Models 11 to 15). Overall, with the 
exception of the constant boost size distribution model (Models 1, 6 and 11), all models provided a 
reasonably good fit to the data (not presented here). However, the estimates of exposure rate were 
noticeably sensitive to the choice of the model. Thus relative values of exposure rate would provide better 
information rather than their absolute values.  In addition, the exponential boost size distribution 
consistently provided the lowest values of DIC. As a result, the model with a Lognormal boost distribution 
and an exponential boost size distribution was retained as the best model as it provided a more 
parsimonious fit than the model with a logistic boost size distribution, which had the second lowest DIC.  
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Table 3.5 : Model comparisons & estimates of exposure 
Models Boost size 
Boost 
distribution 
Exposure estimate 
Median (95% CrI) 
# param. 
LogLik 
Median 
ΔDIC* 
1 Constant None 0.4 (0.39-0.41) 3 -11996.1 5091.1 
2 Exponential None 0.9 (0.89-0.91) 4 -9844.96 772.7 
3 Linear None 0.88 (0.87-0.9) 4 -10029 1158.8 
4 Logistic None 0.9 (0.88-0.91) 5 -9844.1 784.0 
5 Step None 0.96 (0.95-1) 5 -9983.43 1065.8 
       
6 Constant Normal 0.4 (0.39-0.41) 4 -11996.4 5092.2 
7 Exponential Normal 5.3 (4.9-5.4) 5 -9488.46 78.5 
8 Linear Normal 1.3 (1.2-1.3) 5 -9585.31 272.4 
9 Logistic Normal 5.3 (5.2-5.4) 6 -9487.9 77.8 
10 Step Normal 0.45 (0.44-0.46) 6 -10859 2814.1 
       
11 Constant Log Normal 0.4 (0.39-0.41) 4 -11996.4 5091.8 
12 Exponential Log Normal 5.6 (4.1-6.9) 5 -9495.66 0.0 
13 Linear Log Normal 1.8 (1.6-2.1) 5 -9506.79 114.7 
14 Logistic Log Normal 5.4 (3.8-6.8) 6 -9496.08 53.2 
15 Step Log Normal 2.2 (2-2.3) 6 -9516.77 132.3 
* ΔDICi=DICi-DIC12 
 
3.3.3 Best model 
The most parsimonious model (Model 12) assumes that, following a new infection, the size of the boost in 
antibody levels decreases exponentially for increasing current antibody levels. As can be seen in Figure 3.6, 
the data and the fitted antibody density curves for anti MSP-1 antibodies show an increase in antibody titre 
with age. There is a good fit to both the age-specific antibody titre and overall antibody distribution for 
individuals with circulating antibodies, despite the model over-estimating the number of individuals 
without circulating antibodies. 
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Figure 3.6 : Model fit for the overall antibody distribution (left) and age specific antibody distribution (right).  Actual 
data are represented in grey while the dashed line represent the median fit and the pink shaded area the 
associated 95% credible interval. 
Estimates of the different parameters are shown in Table 3.6. The key result here was the measure of 
exposure rate, estimated to 5.6 yr-1 (95% credible interval: (4.1-6.9)) over the whole country in Cambodia. 
This estimate might however be overestimated due to local heterogeneity in transmission intensity [202], 
not accounted for in the model.  A secondary aim was to gain insight into the parameters used to explain 
the antibody kinetics. The small antibody boost size for individuals with no current antibodies indicate that 
these “seronegative” individuals tend to produce very small amount of antibodies and multiple infections 
are therefore required to acquire higher levels of antibodies. Indeed, upon exposure, I estimated that only 
1% of the “seronegative” individuals will acquire antibodies, which would explain why the model 
overestimated the number of “seronegative” individuals. In addition, the significant difference between the 
size of antibody boost for “seronegative” individuals and the maximum boost for “seropositive” individuals 
might indicate that individuals need to be primed to achieve a high antibody response. The density-
dependent antibody boost size is illustrated in Figure 3.7. It can be seen that the uncertainty around the 
size of the boost decreases as individual’s current antibody titre decreases. 
Table 3.6 : Parameter estimates for the most parsimonious model  (Model 12) 
Param. Description Estimates 
Median [95% Credible 
Interval] 
λ Exposure Rate  5.6 (4.1-6.9) 
a Maximum antibody boost size on exposure 0.44 (0.31-0.75) 
b Slope of the decreasing boost size 0.39 (0.33-0.46) 
S Standard deviation for boost size distribution 0.11 (0.09-0.13) 
η Mean boost for individuals with no current antibody 0.016 (0.013-0.022) 
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Figure 3.7 : Antibody boost size (δ) depends on individual’s current antibody level when individual get exposed  (xt) 
Black line (and the pink shaded area) represents median boost size for individuals with circulating antibodies (95% 
credible interval). Black point indicates boost size mean for “seronegative” individuals.  
MCMC Diagnostics: 
Four MCMC chains were run in parallel, sampled every 1,000 iterations and combined to obtain a sample of 
size 1,800. The lowest effective sample size was 100. Posterior densities of the parameters and the MCMC 
trace are presented in Figure 3.8, demonstrating relatively good convergence of the MCMC chain with 
smooth posterior distributions obtained for each parameter.   
 
Figure 3.8 : MCMC trace (above) and posterior distributions (below) for the exposure rate (λ), the maximum boost 
size (a), the slope of the decreasing boost size (b), the standard deviation of the size of antibodies (S) and the mean 
of antibodies for individuals with no circulating antibodies (η).  
There was some posterior correlation between the model parameters. In particular, as expected, the 
exposure rate was negatively correlated with the size of the antibody boost (average for “seronegative” 
and maximum for “seropositive” individuals) with a correlation of 0.96 with η and 0.97 with a. Also, the 
variability amongst individuals, modelled by S, had unexpected associations, i.e. a negative correlation with 
maximum boost size for “seropositive” individuals (0.89) and a positive correlation with mean boost size for 
“seronegative” individuals (0.97).   
 
Additional analyses show that, for this specific model, changing the number of antibody categories does not 
affect the estimates of the exposure rate (See Annex III). 
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3.3.4 Heterogeneity in the “seronegative” population 
In addition to investigating the dynamics of acquisition of antibodies when individuals already had 
circulating antibodies, I was interested in better understanding the acquisition of antibodies for individuals 
that do not have any circulating antibodies. A total of 5 hypotheses were investigated. Models 
corresponding to each of these hypotheses were fitted to the data and the MCMC algorithms all converged 
reasonably well. Posterior median and 95% credible intervals are presented in Table 3.7. With the 
exception of H3 and H4 that present very similar estimates for most of the parameters, the estimates of the 
exposure rate, as well as the estimates for the biological parameters ( a , b and S ), differed substantially 
from each other between the different hypotheses. The estimate of w  for hypothesis H5 was uncertain 
(wide credible interval), giving limited information about the exact proportion of the population that gets 
their antibody level boosted upon infection. Similarly, the estimate of the variability between individuals 
was imprecise for models H1 and H5. Note that the results with H4 are consistent with those found not 
only in H3 but also in H2. Indeed, when the model assumes a mixture in the seronegative population, it 
predicts that 96% of the seronegative have an antibody response with a mean boost size around 0.016 
(similar to results found in H2 when the mixture in the seronegative population is ignored) and 4% have an 
antibody response with a mean boost size around 2.3 (similar to the results found with H3).  
Table 3.7 : Parameter estimates for of models for heterogeneity of the “seronegative” population. 
Hyp   η (or η1)  η2 (or β ) 
2  (or k) 
w  (or γ) 
a
 
b
 
S
 
H1 
0.43 
(0.4-0.45)    
3.9 
(3.8-4.1) 
0.45 
(0.43-0.47) 
0.067 
(0.02-0.21) 
H2 
5.6 
(4.1-6.9) 
0.016 
(0.013-0.022)   
0.44  
(0.31-0.75) 
0.39 
(0.33-0.46) 
0.11 
(0.09-0.13) 
H3 
1.5 
(1.3-1.7) 
2.3 
(1.8-2.6)  
0.036 
(0.029-0.043) 
4.6 
(3.3-7) 
0.75 
(0.67-0.87) 
0.26 
(0.23-0.29) 
H4 
1.5 
(1.3-1.7) 
0.016 
(0.007-0.042) 
 
2.3 
(1.7-2.6) 
 
0.96 
(0.96-0.98) 
4.7 
(3.3-7.2) 
0.75 
(0.67-0.88) 
0.26 
(0.20-0.29) 
H5 
0.8 
(0.78-0.81) 
0.0054 
(0.001-0.029) 
 
(β=) 0.49 
(0.11-0.96) 
 
0.48 
(0.04-0.97) 
5.5 
(5.3-5.8) 
0.71 
(0.69-0.73) 
0.15 
(0.07-0.21) 
The different models were compared using the DIC (see Table 3.8) and the model H2 had the lowest DIC, 
suggesting it might represent the best model.  
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Table 3.8 : Model comparison for the various hypotheses about heterogeneity of the « seronegative » population. 
Hypotheses # parms LogLik ΔDIC* 
H1 4 -10713 2498.0 
H2 5 -9495.66 0 
H3 6 -9496.65 91.1 
H4 7 -9497.23 91.7 
H5 7 -10109.2 1319.9 
* ΔDICi=DICi-DICH2 
When looking at the model outputs (see Figure 3.9), model H1 predicts that all “seronegative” individuals 
will systematically increase their antibody level when they are exposed. However, this model also predicts a 
lower number of seronegative individuals than observed in the data. In contrast, model H2 predicts the 
lowest proportion of individuals that will acquire antibodies upon an infection and also predicts the highest 
number of “seronegative” individuals.  As seen above, the estimated parameters for models H3 and H4 
were very similar and hence the predicted numbers of “seropositive” and ”seronegative” individuals were 
identical. Additionally, the predicted number of “seropositive” individuals for H2 was similar to the results 
found for H3 and H4, while the number of seronegative was different. All models provided a reasonably 
good fit to the data. However, models H1 and H5 gave the worst overall fit to the distribution of antibodies 
by underestimating the levels of antibodies for adults and overestimating it for children. Indeed, the better 
fitting models as judged by the DIC (H2, H3 and H4) visually gave the best fit for individuals and 
overestimate the number of “seronegative” individuals, in particular for H2. 
Overall, all models provide a reasonably good fit. I chose to retain model H2 as it presents the best DIC and 
represents the most parsimonious model despite marginally overestimating the number of seronegative 
individuals. 
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Figure 3.9 : Model predictions for (a) the proportion of individuals that remain seronegative/become seropositive 
upon infection, (b) the overall antibody distribution, (c) age specific antibody distribution categorised by model. The 
5 models for heterogeneity of the seronegative population are represented by the different coloured lines and the 
data are represented in grey. 
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3.3.5 Multiple regions 
In Cambodia, the distance to the forest is likely to be a proxy for exposure levels [179]. Therefore Model 12 
was extended, as presented in section 2.4, to simultaneously estimate the exposure rate in 5 regions 
categorised according to their distance to the forest. The MCMC algorithm converged well and the 
parameter estimates are presented in Table 3.9. As can be seen in the table, there is a trend where 
exposure rate, represented by λ, decreases with increasing distance to the forest. This extended model 
provided a better fit to the data according to the DIC (equal to 18311), lower than the DIC estimated from 
the homogeneous model in section 3.3.2 (DIC=18902). The estimated exposure rates were the same order 
of magnitude as those from the simpler model, with a much higher level of exposure for individuals within 
the forest. There were no significant difference in the estimate of the maximum boost size a between this 
extended and the original models which did not consider multiple exposure levels. 
Table 3.9 : Parameter estimation for model extended to account for multiple exposure 
Parameters Estimates  Median [95% Credible Interval] 
λ 
In forest 5.9 (5.8-6) 
<200m 5.3 (5.2-5.4) 
200m-500m 5.2 (5.1-5.3) 
500m-1km 5.1 (5-5.2) 
>1km 5 (4.9-5.1) 
a 
b 
S 
η 
0.65 (0.62-0.69) 
0.5 (0.48-0.51) 
0.015 (0.013-0.023) 
0.006 (0.005-0.020) 
The fit of the model to the data is presented separately for each region in Figure 3.10. The model fit for the 
“seropositive” population fit the data well for the five regions, only the predicted number of “seronegative” 
individuals appear to present some lack of fit, in particular for individuals in the forest. Overall, the model 
fits the age structured data relatively well. However a few discrepancies between regions are worth noting. 
One of the main differences between the age structured output of the model and the data lies in the 
presence of extremely small values for children below the age of 1 (used as a starting point for the 
resolution of the equation of the model). Indeed, I had assumed that individuals start their life with the 
same antibody levels than children at age 0 (taken from the data) but in regions between 200m and 1km 
away from the forest, the median antibody titre for individuals below 1 year of age is equal to -2, causing 
the model to underestimate the antibody level between 0 and 20 years old. However, by ignoring the decay 
of maternal immunity, the model underestimates by around 3 fold the number of “seronegative” 
individuals living in the forest. Also, in areas where individuals tend to be less exposed (>1km), the antibody 
level is underestimated for individuals older than 5.  
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3.4 Discussion 
The objective of this chapter was to develop a model that incorporates an exposure rate and antibody 
kinetics to determine continuous levels of antibody density in a cross sectional survey. The rationale for 
developing a density model was to better estimate malaria transmission intensity by taking into 
consideration the full information contained in serological data, i.e. antibody levels rather than just 
seropositivity as has typically been done. The model exploits the continuous characteristic of the antibody 
quantity measurements (discretised for implementation reasons) and, using a simple model of the 
acquisition and loss of antibodies following exposure, replicates the observed antibody levels measured in 
individuals during a population-wide survey in Cambodia. Given the limited understanding of the precise 
role of specific blood-stage antibodies in protection from infection and disease, I developed and tested a 
series of models assessing different hypotheses for the acquisition of antibodies. The most parsimonious 
model was one which assumes the quantity of antibodies produced is Lognormally distributed between 
individuals with a mean that depends on the antibody level individuals have when they get exposed. The 
boost is assumed to be decreasing exponentially in individuals with increasing levels of antibodies. I have 
also assumed that individuals who do not have any circulating antibodies, or are below the detection limit 
equal to xmin=-2 on a log10 scale, would have a constant specific antibody response. The validation of the 
method through simulation study demonstrates that the MCMC method used to estimate the parameters 
performs correctly. By fixing the rate of decay of antibodies, the fitting could identify all parameters with 
good chain convergence.  
In the simulation study, the model was fitted to 100 simulated datasets, produced with the same model 
and same set of parameters. This resulted in the posterior 95% credible interval for the parameters to 
include the values used for the simulation 83% of the time. There is a high level of correlation between the 
parameters. Therefore, while the model tends to slightly underestimate the exposure rate, it also tends to 
simultaneously overestimate the maximum size of the boost of antibodies. However, the proportion of 
individuals being boosted to a fixed level of antibodies (i.e. frequency x size of boost) remains constant and 
in agreement with the simulation values. The size of the boost for seronegative individuals is however 
systematically well estimated despite the correlation with other parameters.  
It is broadly agreed that antibodies to malaria infection are produced relatively quickly during an infection 
[203] with antibodies to blood stage antigens appearing within days of infection [56, 116, 128]. However, to 
my knowledge, there is no detailed description relating the amount of antibodies produced to the current 
antibody levels. The model explored here is a very simplistic representation of the true picture by ignoring 
the underlying processes responsible for the production of antibodies. Indeed, parasite antigens are first 
recognised by B cells that will proliferate. B cells will then differentiate into plasma cells (antibody secreting 
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cells) which will secrete circulating antibodies that will be measured in surveys [204]. In reality the model 
did not allow to distinguish with the available data whether individuals will produce fewer antibodies due 
to a large amount of circulating antibodies or due to any other feature about memory B cells and/or plasma 
cells [205]. Also, some studies suggest that levels of antibody are maintained due to the continuous 
production of antibodies by long- lived plasma cells that migrate to the marrow bones [96, 206]. This is not 
an assumption that I considered in the model but the fit of the model to the data could indicate that the 
model represents an approximation, averaged over a year, of the real mechanism responsible for the 
antibody response. 
The persistence of antibodies in individuals previously exposed to malaria infection is debated [56, 124, 
207]. In the model developed in this chapter, I made the simple assumption that, in the absence of 
exposure, individuals lose their antibodies at a constant rate 0.7 yr-1, corresponding to a half-life of 360 
days. This estimate was based on the results from a study on the duration of antibody response to 
Plasmodium infection. Indeed, White estimated the half-life of MSP-1 long-lived B cells to be 376 days (233-
600) days for children in Gambia [192]. These estimates were obtained from longitudinal data assuming 
that there are short- and long- lived B cells producing circulating antibodies. Therefore, I have also made 
the underlying assumption that the measured antibodies were produced from long- lived cells. However, if 
the measured antibodies are in reality short lived, the model might in consequence over-predict the 
antibody levels and consequently also overestimate the exposure level. Further analyses of the antibodies 
kinetics using longitudinal data might be necessary to better understand their duration and better inform 
the model.  
By investigating multiple models for the “seronegative” population I wanted to assess the heterogeneity in 
the immune response for the acquisition of antibodies during the first infection. There is inherent 
heterogeneity between seronegative individuals [200]. Indeed, individuals with no circulating antibodies 
are people who either have never experienced an infection or had an infection and lost their circulating 
antibodies. Thus, despite their lack of circulating antibodies, some apparently “seronegative” individuals 
may have been exposed in the past and therefore have low levels of memory cells. This immune memory 
would thus facilitate a better immune response once re-infected. Although the model that assessed 
heterogeneity in the “seronegative population” (Hypothesis 4) did not have the lowest DIC, the parameter 
estimates for this model suggest that the observed antibody levels for “seronegatives” in these data could 
be captured by a model in which those that have never previously been infected experience a small boost 
on infection while those previously-infected are already primed and experience a larger boost in antibody 
levels. If this assumption is valid, this form of a density model would better estimate the acquisition of 
antibodies for individuals who never had infection or antibodies. However with available data collected 
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from cross-sectional surveys, the model might be over-parameterised and hence any inference might be 
limited. To better estimate this I would need longitudinal data that would allow me to calibrate my model 
with the parameters that account for the antibody kinetics. I might also expect heterogeneity in the 
seronegative population to be due to the fact that some individuals might have been treated and therefore 
develop slower immune responses [200].  
Additionally, asymptomatic individuals who have not been treated are most likely to have been exposed 
before and are very likely to already have an immune memory. The age of individuals has not been 
considered as a determinant for the acquisition of antibodies but might be responsible for the 
heterogeneity in the seronegatives, as children might experience smaller boosts in antibodies than adults 
[60, 208]. Finally, measurement error or undetectable antibody titre [85] could also mislead the results by 
misclassifying individuals who actually had antibodies, as individuals with no circulating antibodies. 
The aim of this work was to develop a model that could better estimate malaria intensity levels from 
serological data. My results demonstrate that it is possible to infer differences in exposure rate. Here I used 
data from Cambodia to assess exposure in 5 different regions categorised by their distance to the forest, 
considered to be a surrogate for malaria exposure and intensity [179]. I observed a trend between 
increasing distance to the forest and decreasing exposure rate. In addition, in comparison with the results 
found for the catalytic model in chapter 2, I observed a correlation between the exposure rate estimated 
with this density model and the seroconversion rate estimated using a classic catalytic model. This indicates 
that this density model could be a novel method used to measure malaria transmission intensity. 
It is worth noting that the models considered here make numerous inferences on within host parameters 
that could not be directly measured using cross-sectional surveys. I am therefore making assumptions 
about unobservable data while, with good quality longitudinal data I could estimate parameters associated 
with the acquisition of antibodies and therefore better inform the measure of interest, i.e. transmission 
intensity. Despite limited information on the loss of antibodies, I could calibrate the model with values 
similar to the available estimates [192]. So if I could calibrate models using longitudinal data to inform the 
other biological parameters, I would also be able to consider other models that were disregarded because 
of their level of complexity. 
  
Emilie Pothin | 90 
 
 
3.5 Conclusion 
In summary, my findings show that we can use a density model that mimics individual’s antibody kinetics 
and takes into consideration exposure rate to predict age specific antibody titres collected in a cross 
sectional survey. The model assumes a constant exposure rate and loss of antibodies with a density 
dependent acquisition of antibodies. The most parsimonious model assumes that individuals will produce 
decreasing (exponentially) amounts of antibodies as their current antibody titre increases and the size of 
this boost varies between individuals which is best captured by a Lognormally distribution. The fitted model 
was able to reproduce data from a survey carried out in Cambodia and the resulting estimates of malaria 
intensity correlate with the distance to the forest used as a proxy for exposure. However, levels of 
endemicity in Cambodia are very low and some of the results might be artefacts from such data. The 
methods developed here therefore need to be tested on data with from a wider range of endemicity levels 
and where malariometric indices are available for comparison.  
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Chapter 4: Estimating transmission 
intensity across a range of transmission 
settings in Tanzania 
In the previous chapters I developed models that reproduce antibody levels based on malaria exposure and 
assumptions made on the kinetics of antibody acquisition and decay. Here, I further explore the best model 
obtained and test its ability to measure malaria transmission intensity simultaneously in multiple regions 
where exposure levels differ significantly. Additionally, I compare the results obtained by fitting my density 
model to data from a seroepidemiological study in Tanzania with estimates of the seroconversion rate and 
traditional measures of transmission intensity (EIR) from the same region. 
4.1 Introduction 
Malaria remains a leading cause of morbidity and mortality worldwide [15], with heterogeneous levels of 
endemicity across the globe [14]. Measuring malaria transmission intensity is a key element of monitoring 
changes in transmission and assessing the impact of anti-malaria interventions. The standard reference 
historically used for reporting malaria transmission intensity is the entomological inoculation rate (EIR), 
defined as the number of infectious bites per person per year (ibppy), estimated by catching mosquitoes in 
order to estimate the sporozoite (infectious) rate. Despite its usefulness in providing a direct estimate of 
the force of infection, this method is time consuming, expensive and can lack precision,   especially in low 
endemicity areas. The prevalence of individuals carrying the parasite (parasite prevalence) is an alternative 
measurement of malaria transmission intensity. This can be estimated in cross-sectional surveys using 
microscopy, rapid diagnostic tests (RDTs), or increasingly using PCR methods to detect infection in 
individuals. This approach is in widespread use, with population-level representative samples now 
undertaken in many malaria endemic areas as part of national Malaria Indicator Surveys [209]. However, 
although parasite prevalence can be estimated rapidly in populations, it is subject to seasonal variation 
(with up to 30% variation between the peak and trough in highly seasonal areas in West Africa), is affected 
by anti-malarial treatment levels, requires highly skilled staff (for microscopy and PCR), and lacks precision 
in low endemicity settings.  
Serological data, which measure antibody responses to one or more blood-stage antigens, offer an 
alternative means to estimate past exposure to malaria [125]. Serological data are typically analysed using 
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catalytic models to estimate the antibody seroconversion rate (SCR) - the rate at which seronegative 
individuals become seropositive – as a proxy for the force of infection [8,9]. However, one limitation of this 
method is that it is necessary to distinguish seropositives from seronegatives using continuous measures of 
antibody levels. For malaria this is typically achieved using sera from European (i.e. unexposed) volunteers 
to define a cut-off. However, there may be underlying differences between the immune responses in these 
unexposed volunteers and those living in endemic countries, as for instance, genetic differences is already 
observed between ethnic groups from a same country [210, 211]. An alternative approach is thus to fit 
mixture models to the bi-modal distribution of antibody levels [137, 163, 168]. This approach has the 
advantage of using only data from the study and assumes similar characteristics throughout the whole 
population, with the exception of seropositivity status. Two Gaussian distributions can be fitted for 
seropositive and seronegative sub-populations.  However, this approach can be problematic in highly 
endemic areas where a large proportion of the population are seropositive. Additionally, another caveat of 
such method is that the population is likely to be made of many distributions, rather than only two. 
A study conducted by Drakeley and colleagues in Tanzania [95] has highlighted the importance of the use of 
serological markers for estimating transmission intensity. In this study, altitude was used as a proxy for 
transmission intensity. Indeed, as transmission intensity varies with temperature affecting the development 
of the vector and of the parasite, transmission intensity is therefore affected by altitude associated with 
changes in temperature. Mosquitoes’ density and parasite prevalence are influenced by topography and 
tend to decrease with increasing altitude, causing variation in malaria transmission intensity. Drakeley et al 
showed that malaria transmission intensity can be estimated using the seroconversion rate (SCR) across 
multiple endemicity settings. 
Here I use the continuous model of the acquisition and loss of antibodies developed in the previous chapter 
and fit this to individual-level data on measured antibody levels from cross sectional surveys. An advantage 
of this approach is that it takes into consideration the full information contained in measurement of 
antibodies levels rather than reducing the data to seropositive / seronegative status. Estimates of malaria 
transmission intensity are thus derived without the use of cut-offs and with better precision than estimates 
obtained with binary seroprevalence data. I illustrate the utility of the approach by fitting the model to data 
from a cross-sectional survey in Tanzania across areas with differing endemicity and compare the results to 
traditional measures of malaria transmission intensity as well as to estimates obtained from traditional 
catalytic models. 
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4.2 Setting 
4.2.1 Data source: Tanzania cross-sectional survey 
A program investigating malaria disease burden and transmission intensity was conducted in Tanzania 
during short rainy seasons in 2001. The objective of the study was to use altitude and rainfall to predict 
malaria transmission intensity. The full study surveyed individuals from 24 villages for two age stratified 
cross sectional surveys, which were pooled for the analysis [212]. In his seroepidemiological study, Drakeley 
include a subset of 12 of these villages from West Usambara, North Pare and South Pare regions [95]. The 
studied area has mountains ranging between 300 and 1870m high. In each region, also referred to as 
transect, 4 villages were selected with different altitude: 1 at low (<600m), 2 at intermediate (600-1200m), 
and 1 at high altitude (>1200m). A map of the region is presented in Figure 4.1. The exposure in this area 
ranged from less than 1 infected bite per person per year (ibppy) for the highest villages up to ≈100 ibppy 
for low altitude villages close to the coast [95]. In each village, around 250 individuals were recruited (~32% 
between 0 and 4 years of age, ~32% between 5 and 14 years of age, ~36% between 15 and 45 years of age). 
Individuals were recruited on a first come first served basis over a period of three days until the required 
sample size was achieved. Previous publications have already described the study design and epidemiology 
of malaria in this area [212]. Ethical approval was obtained from the institutional review boards of the 
National Institute of Medical Research of Tanzania, Kilimanjaro Christian Medical Centre, and the London 
School of Hygiene and Tropical Medicine. Individuals’ sera were collected and antibodies to the asexual 
stage merozoite antigens, Merozoite Surface Protein (MSP-1) and Apical Membrane Protein (AMA-1) were 
determined using ELISA [194].  
 
Figure 4.1: Map of the studied area showing the 3 regions and 12 villages. Figure reproduced from Drakeley et al 
[95].  
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During the study, parasitaemia data were also collected for each individual and parasite rate (PR) is 
reported in Table 4.1. Direct measurements of EIR were not available for the studied area, however EIR 
could be predicted for this area based either on altitude h, according to 0.0057hEIR 331.5 e [213]  or 
based on the relationship between EIR and parasite prevalence demonstrated by Griffin et al [93] (See 
Table 4.1). 
Table 4.1: Summary of study data. PR denotes parasite prevalence measured in children 0-4 years of age. EIR
1
 is 
estimated from altitude [214]. EIR
2
 was estimated from the parasite prevalence data using a previously published 
relationship [93] . 
Transect Village 
Altitude 
(m) 
N 
PR 
(%) 
EIR1 
(ibppy) 
EIR2 
(ibppy) 
North Pare Kilomeni (Ki) 1 556  411 1 0.047 0.08 
 Lambo (La) 1 188  355 10 0.38 1.11 
 Ngulu (Ng) 832  486 8 2.9 0.84 
 Kambi ya Simba (KyS) 746  494 10 4.7 1.11 
South Pare Bwanbo (Bw) 1 598  485 3 0.037 0.26 
 Mpinji (Mp) 1 445  461 2 0.088 0.17 
 Goha (Go) 1 163  453 13 0.44 1.57 
 Kadando (Ka) 528  382 25 16 4.45 
West 
Usambara 
Kwadoe (Kw) 1 564  357 4 0.045 0.37 
Funta (Fu) 1 240  429 17 0.28 2.38 
Tamota (Ta) 1 055  449 19 0.81 2.74 
 Mgila (Mg) 375  465 34 39 8.31 
In the first part of my analyses, I selected the same 12 villages to fit the model to the data and compare 
measurements of exposure. Additionally, for validation purposes, 8 villages from Rombo and West 
Usambara regions were considered. As infants may present with maternal antibodies, only individuals 
between 1 and 45 years were included in my analyses. Data on individuals at age 0 were however used as 
initial state to solve the equations in the model. Only anti-MSP-1 antibodies were analysed. Originally, 
measurements were recorded as optical densities and I log-transformed them prior to analysis due to the 
high number of individuals with low levels of antibodies. Measurements below the limit of detection were 
assigned to approximate limit of detection (LoD) of 0.01 (i.e. -2 on a log10 scale). Also, assay results above a 
value of 4 were considered to lack accuracy and were therefore set to an upper limit of 4.  
4.2.2 Descriptive analysis 
The distribution of the antibody level, measured in optical density unit (OD) is presented for each studied 
village in Figure 4.2. The altitude of villages decreases from left to right on the graph. Hence, for higher 
altitude as in Kilomeni, Bwambo and Kwadoe, most of the population have very low antibody level. In 
contrast, in villages with lower altitude, such as Kadando and Mgila, the number of individuals with low 
antibody level is much lower while the number of individuals with a medium or high antibody level is 
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higher. Consistently for each transect, corresponding to rows on the figure, the distribution of the antibody 
density seems to shift towards higher levels of antibodies as the altitude decreases. It is worth noting that 
given their altitude, villages such as Ngulu and Funta present an unexpected distribution of antibodies (low 
number of individuals with low antibody levels and high number of individuals with higher levels) 
suggesting that factors other than altitude alone may influence exposure to malaria in this region.  
 
Figure 4.2: Distribution of optical density per village in North Pare (first row), South Pare (second row) and West 
Usambara (third row). In each transect (each row), villages are presented with decreasing altitude (left to right). 
Note y-axes are on different scales. 
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Figure 4.3 show the antibody level distribution on a log10 scale for each village. The median antibody 
density, presented in black in each box, tends to increase with decreasing altitude, with the exception of 
Ngulu and Funta, as seen in Figure 4.2. The mean antibody density, presented in red, appears to be greater 
than the median antibody density for higher altitude and lower for lower altitude. This reflects a very high 
number of individuals with low antibody levels in villages at high altitude and a high number of individuals 
with high antibody level in villages at low altitude, i.e. the distributions are over-dispersed. 
 
Figure 4.3: Summary of optical density distribution on a log10 scale, per village and categorised per region (North 
Pare, South Pare and West Usambara). The grey boxes characterize the interquartile range (25%-75%) of the optical 
density distribution while the thick black line represents the median. Error bars include all values 1.5 times the 
interquartile range. The red squares show the mean optical density.  
These observations suggest that as altitude decreases, the density of antibodies increases, consistently for 
each region. However, the acquisition of antibodies is also dependent on age. Indeed, as shown in Figure 
4.4, the level of antibodies increases with age, consistently for all villages. However, those in villages at 
lower altitude have levels of antibody that appear to saturate at high levels by 15 years of age, while for 
those residing villages at higher altitude, most individuals tend to have low levels of immunity throughout 
their life. As altitude is considered to be a proxy for exposure in this study, individuals highly exposed to 
malaria tend to build immunity at a young age and this immunity is long lasting. However, those residing in 
villages at higher altitude never reach this immunity level in their lifetime (up to 45 years). In such settings, 
it might be difficult to maintain immunity due to limited exposure, antibody levels tending to decay in the 
absence of reinfection. As noted earlier, the villages of Ngulu and Funta appear to have patterns of 
antibody density distribution that are more consistent with those residing in villages at low altitude.   
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In addition to antibody levels (OD here), the prevalence of seropositive individuals is commonly used to 
characterise serological data. Seropositivity for these individuals was previously defined as individuals 
whose antibody level is greater than 0.5 OD unit (Chris Drakeley – personal communication). Based on this 
definition, the number of seropositive and seronegative individuals is presented for each village in Figure 
4.5. The proportion of seronegative individuals is substantial in high altitude villages and the proportion of 
seropositive individuals in the population increases with decreasing altitude but is never markedly higher 
than the number of seronegative individuals. Therefore, in each altitude transect the proportion of 
seropositive individuals in the population increases as the exposure increases, as expected. Here also, 
Ngulu and Funta do not follow the trend and show high proportions of seropositive individuals despite their 
medium altitude. For those residing in areas of higher exposure, there appear to be a saturation in the 
proportion of seropositive individuals at less than the whole population, suggesting that some individuals 
might never get exposed. Another possible explanation would be that in those settings, individuals become 
seropositive at the same rate than they reverse to seronegative. The rate of acquisition of immunity for the 
exposed individuals would be similar to the rate of losing immunity if this assumption is valid.  
 
Figure 4.5: Number of seropositive/seronegative individuals for each village and categorised per region. The dark 
shaded area illustrates the number of seronegative individuals while the light shaded area represents the number 
of seropositive individuals. 
 
 
 
  
Seronegative 
Seropositive 
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4.3 Methods 
4.3.1 Density model to assess transmission from serological data 
4.3.1.1 Model formulation 
In Chapter 3, I developed a mathematical model to describe the dynamics of acquisition and loss of 
antibodies in the population. In this chapter I use the same model, i.e a discretised approximation of the 
density model, that mimics the proportion of the population in each antibody density category i , denoted
iy . The following equation is the same as the equation presented in Section 3.2.2.2: 
 1       1
i
ij j i hi i i
j i h i
dy
k y y k y y i N
dt
 
 
 
     
 
   (4.1) 
where h, i, j =1,…,N index the N antibody level classes. The rates of exposure and decay of antibodies,  
and  , are assumed to be independent of antibody density and age. The numerical approximation of the 
continuous model was achieve by categorising the log10 antibody optical density variable, x , into N=51 
compartments each of width 0.052  with the first class represents measurements below the limit of 
detection, min 2x   . 
Let ix  be the value of (log10) antibody optical density at the mid-point of antibody class i. The probability 
that, following exposure, antibody levels are boosted to class i from class j, ijk , is distributed according to a 
discretised lognormal distribution, as it was already presented in Section 3.2.2.3: 
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       
  
    
                        if  i N
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(4.2) 
where  ; ( ),F z x S  is the cumulative density function at point z of the lognormal distribution with mean 
( )x  and standard deviation S. ( )x  is the mean boost size, a function of the current log10 antibody level, 
x , assumed to be given by: 
 min
if    
( )
otherwise
bxae x x
x

 
 

 (4.3) 
where ,   and a b  are parameters. This model assumes that exposure increases the log of antibody density 
by an exponentially decreasing amount as current density increases. 
 
Emilie Pothin | 100 
 
 
4.3.1.2 Parameter estimation 
A Bayesian approach was used to estimate the model parameters, summarised in Table 4.2, by fitting the 
model to the optical density data from the 12 villages simultaneously, allowing only the exposure rate, , 
to vary by village, with local value for village v denoted v . As in Chapter 3, the rate of decay of antibodies 
was fixed to ρ=0.7 yr-1. Using { , , , , }v a b S    to denote the estimated parameter vector and 
{( , )}i iD x t  the data including the observed antibody level and age of individual i, the multinomial log-
likelihood is given by:  
 , , , ,
0
log( ( | )) log( )i t v i t v
v t i
l P D n y

   (4.4) 
where , ,i t vn  and , ,i t vy  are, respectively, the observed number and predicted proportion of individuals in 
antibody category i  in village v at age t . MCMC methods were used to sample from the posterior 
distribution of the parameters.  As all parameters were positive-definite I assumed uninformative uniform 
priors on [0, max], where max was the maximum permitted value of each parameter as listed in Table 4.2 
and I used a log-normal random walk proposal density. I performed two runs of 500,000 iterations for the 
MCMC algorithm with a burn-in period of 50,000 iterations. The output was then recorded every 200 
iterations to generate a sample of size 5,000 from the posterior distribution. 
Table 4.2: Summary of model parameter values 
Related to Param. Description Prior Distribution 
Exposure λv Annual antibody acquisition rate for village v Uniform on [0;100] 
Boost size a Maximum antibody boost size in exposure  Uniform on [0;10] 
 
b 
Slope of the dependence of antibody boost on 
current log10 Optical density 
Uniform on [0;10] 
 s Standard deviation for boost size distribution Uniform on [0;10] 
Seronegatives η Mean boost for individuals with no current antibody Uniform on [0;100] 
 
4.3.1.3 Model validation 
The density model was then validated using data from 8 additional villages in the Rombo and West 
Usambara regions [212]. The posterior distribution of the boost parameters obtained from the first 12 
villages was used to inform the model in the parameter estimation using data from 8 nearby different 
villages. The priors were assumed to be normally distributed with the previous posterior mean and a 
coefficient of variation of 1% as parameters. Priors for exposure rate were uninformative (Uniform on 
[0,100]).  
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4.3.2 Use of a mixture model for seroprevalence data 
Mixture models can be used in a number of different forms for defining seroprevalence and deriving the 
seroconversion rate for the measurement of malaria exposure. Here, I present three methods which were 
further investigated. First, a mixture model was fitted to the optical density measurements in the 
population as a whole and a cut-off chosen based on this fitted mixture model used to define seropositivity. 
In a second method, I fitted a mixture model to the data but additionally accounted for potential 
misclassification while modelling the dynamics between seropositive and seronegative individuals. Finally, 
in the third method, I developed  a Bayesian approach that provides estimates of seroconversion rates 
using augmented data for unobserved seropositivity status, based on the probability of being seropositive. 
4.3.2.1 Defining seropositivity 
Commonly, seropositivity is determined using European control populations as the seronegative 
population. Using these data, a cut-off value for seropositivity is defined as the mean plus 3 standard 
deviations of the distribution of the negative antibody density (optical density or titre) in that population. 
This cut off value was suggested to be 0.5 OD unit in Drakeley’s study (Chris Drakeley - personal 
communication).  
Here, I explore alternative methods to derive a cut-off value without resorting to external data. A mixture 
model was fitted to the normalised optical density distribution for each village to determine appropriate 
cut-offs for defining seropositivity. This method assumes that the population is composed of two 
subpopulations with proportions p and (1-p) respectively denoting seropositive and seronegative 
individuals. The optical density distribution for each sub-population is assumed to be a Normal distribution 
with parameters 1 1( , )   for seronegative and 2 2( , )  for seropositives. A cut off value that differentiates 
between seronegative and seropositive individuals is defined as 1 13  . 
The parameters of the mixture model were estimated using MCMC method (as previously described) with 
the following likelihood considering the parameter vector 1 1 2 2{ , , , , }p     and the data {( , )}i iD x t  
 
1
1
1 1 2 21
( ; ) ( / )
            ( / )
            { ( 0) ( / , 0) ( 1) ( / , 1)}
            {(1 ) ( ; , ) ( ; , )}
n
i ii
n
i i i i i i i ii
n
i ii
L D P D
P X x
P S P X x S P S P X x S
p x p x
 

 
     




 
       
  



(4.5) 
where
 
( , , )ix   represents the probability density function for an observed antibody titre ix  that is 
Normally distributed with mean μ and standard deviation σ and iS  denotes the (unobservable) individual’s 
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seropositivity state of individual i equal to 1 for seropositive and 0 for seronegative. Parameter estimation 
is performed for all villages simultaneously to determine the cut-off value.  
Once individuals have been classified based on the derived cut-off value, the standard approach using a 
catalytic model, as seen in the previous chapters, is applied to estimate seroconversion rates for each 
village. The proportion of individuals who are seropositive at age t is given by: 
 ( )( ) (1 )C C tCC
C C
y t e
 
 
  

 (4.6) 
where C is the annual mean rate of conversion (SCR) from seronegative to seropositive in a village and C  
the annual mean rate of reversion from seropositive to seronegative. A Bayesian MCMC approach as 
described above was used for parameter estimation with the following log-likelihood:  
 , log( ( ))
v
t v C
v t
l n y t  (4.7) 
where ,t vn  and ( )
v
Cy t  are, respectively, the observed number and predicted proportion of individuals in 
village v at age t .The model was fitted to all villages simultaneously allowing C to vary between villages 
but with the constraint of a single value for the reversion rate C , which was also estimated.  
 
4.3.2.2 Mixture model for estimation of SCR 
This method incorporates both the mixture model fitted to optical density as well as the catalytic model in 
a single model and therefore captures misclassification issues. As before, the population is assumed to be 
composed of two subpopulations with proportions ( )Cy t and (1- ( )Cy t ) respectively for seropositive and 
seronegative individuals for each age group t where ( )cy t is defined in (4.6). As in the previous method, the 
antibody level in each sub-population is assumed to have a Normal distribution with parameters 1 1( , ) 
for seronegative and 2 2( , )  for seropositive individuals. The log-likelihood for the model is then given by:     
 
 
1
1 1 2 2
1
log ( , )
 log( ( / ))
 log (1 ( )) ( ; , ) ( ) ( ; , )
n
ii
n
C i i C i i
i
l L D
P D
y t x y t x


     




  


 (4.8) 
with n  the total number of observations,  1 1 2 2, , , , ,C C        the model parameters and
{ , }i i iD x t  the data including the observed antibody level and age of individual i. The model was fitted to 
all villages simultaneously; parameter estimation uses MCMC methods as described above with (4.8) as the 
likelihood. 
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4.3.2.3 Use of augmented data 
In theory seronegative individuals should be those who have categorically no antibodies contained in their 
blood serum. However, due to potential cross-reactivity of the antibodies, residual maternal antibodies, 
analytical method errors and other reasons, in practice measured low levels of antibodies might be 
detected in seronegative individuals. The potential for misclassification was addressed in the previous 
method by jointly estimating the cut-off value and the model fit.  
An alternative method is to impute the unobserved “true” sero-status of each individual. To do this, I used 
MCMC sampling to explore different possibilities. As before, I define an unobserved variable Si 
corresponding to the sero-status for an individual i (Si=1 if individual is seropositive, else 0). This is imputed 
based on the probability of being seropositive. The level of antibodies measured for an individual i is 
denoted by the continuous variable ix .  
Let  1 1 2 2, , , , ,C C        denote the model parameters and ( )iS S  the vector of unobserved 
individual’s sero-status. The joint density of parameters, observed and unobserved data is given by:    
 ( , , ) ( / , ) ( / ) ( )P X S P X S P S P     (4.9) 
with,   
1
( / , ) ( / , )
n
i i
i
P X S P X S 

     (4.10) 
and, 
1
( / ) ( / )
n
i
i
P S P S 

     (4.11) 
and ( )P   prior distribution for  , n the total number of individuals. The following calculations are 
presented for a single village. 
The first part of the equation (4.9) corresponds to the observation level and ensures that augmented and 
observed data are compatible. The seropositivity status is a binary variable; individuals can either be 
seropositive (individuals have been exposed in the past) or seronegative (unexposed individuals or exposed 
individuals who have lost their immunity). There is no direct relationship between antibody level and 
seropositivity status but I assumed that antibody density distribution for each sub-population is a Normal 
distribution with parameters 1 1( , )   for seronegative and 2 2( , )   for seropositive subpopulations. 
I write,       1 1 0 2 2 1( / , ) ( ; , )1 ( ; , )1i ii i i i S i SP X x S x x            (4.12) 
with ( ; , )ix   the probability density function of a normal distribution for an observed antibody titre ix
with parameters  and  and  1 Z  the indicator function equal to 1 if Z is true, else 0. 
The second part of the equation (4.9) refers to the dynamics between seropositive and seronegative 
individuals (as allocated by the augmented data) given the parameters. The model here simply is a 
reversible catalytic model where individuals become seropositive at a rate λ and revert to seronegative 
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status at a rate ρ. The probability that individual i at age t is seropositive is ( )Cy t defined in (4.6). Hence, 
conditional on the seropositivity status: 
( ) ( )
0 1
1 1 / 1
( / ) ( / ) {(1 ( ))1 ( ) ( )1 ( )} {(1 ( )) ( ) }
t t
i i
i
n nn
n t n t
i i S i i S i
i t i t t t
P S P S y t S y t S y t y t 
 
 
   
        (4.13) 
where ( ), ( )n t n t
 
 represent the number of seropositive and seronegative individuals at age t and tn  the 
number of age groups.  Finally, the joint distribution is given by: 
 1 1 0 2 2 1
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     
 (4.14) 
MCMC sampling was used for parameter estimation so that the stationary distribution of the chain is the 
joint distribution of the parameters and the augmented data ( , , )P X S  .  
A random walk Metropolis Hasting sampling was performed. At each iteration, the following algorithm was 
performed: 
a. Independently sample model parameters  
b. Sample seropositivity status with the proposal for the candidate status 
*
iS : 
*( / ) 1i i iQ S S S   
Positive model parameters were sampled in (a) with a log Normal proposal. Only 1 2and    were sampled 
with a Normal proposal. The random walk for all parameters was tuned for better mixing. The algorithm 
was run for 50,000 iterations and I fixed a burn-in period of 1,000 steps. The output was recorded every 10 
iterations to constitute a sample for the posterior distribution of size 4,900. 
In summary, in this chapter I used not only the density model developed in the previous chapters but I also 
developed methods to improve estimation of seroconversion rate. All of the developed methods were 
compared between themselves and against EIR, derived from altitude [214] and from parasite prevalence 
[93]. Except when specified otherwise, Pearson correlations were used to assess the association between 
results. A summary of the different methods is presented in Table 4.3. 
Table 4.3: Summary of the methods applied to Tanzania dataset to measure malaria transmission intensity 
Density Model Catalytic model EIR 
Exposure rate SCR SCR SCR SCR EIR EIR 
Newly  
developed 
European 
control 
Mixture model 
defines 
seropositivity 
Mixture model 
to assess SCR 
Use of augmented 
data to assess SCR 
Derived from 
altitude 
Derived from 
parasite 
prevalence 
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4.4 Results 
4.4.1 Malaria transmission assessed using a density model 
4.4.1.1 Antibodies density 
Data from 5,227 individuals in the 12 villages were included in the analysis. The antibody levels of 
individuals in each village stratified by age are shown in Figure 4.6. The overall trend shows an increase in 
mean antibody level in adults in the village with decreasing altitude and hence increasing transmission 
intensity in this setting [214–216]. As previously noted [95], two villages - Ngulu and Funta - have higher 
than expected antibody densities, suggesting higher transmission despite being at medium altitude. As 
expected, the trend is for antibody density to increase with age in each village, representing cumulative 
exposure to infection.  
I fitted the previously developed age-structured density model to 12 villages from different altitude in 
Tanzania to estimate exposure rate based on antibody levels. The algorithm converged well (See Appendix 
IV). The fitted density model is able to capture antibody density patterns across most of the villages (Figure 
4.6).  
 
Figure 4.6: Antibody levels associated with age and village altitude. Median fits (95% credible interval) for median 
antibody levels are represeted by the red (black) lines. Dark and light shaded area represent respectively 25
th
/75
th
 
IQR and 2.5
th
/97.5
th
 IQR for the data. Individuals surveyed were between 0 and 45 years old. 
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4.4.1.2 Estimates of exposure 
In each transect, North Pare, South Pare and West Usambara, the estimate of the exposure rate increased 
with increasing transmission intensity (as indicated by decreasing altitude), with the exception, as 
expected, of Ngulu and Funta villages (See Figure 4.7 and Table 4.4). 
 
Figure 4.7: Measure of antibody acquisition rate by village 
and by region (a) North Pare (b) South Pare and (c) West 
Usambara. Estimates represented here are posterior 
median ± 95% credible intervals. 
Table 4.4: Posterior median and credible intervals for each 
estimated model parameter 
Posterior Median(95% CrI) 
Exposure parameters (λ) 
Kilomeni 3.09  ( 3 - 3.18 )  
Lambo 3.29  ( 3.2 - 3.38 )  
Ngulu 4.11  ( 4 - 4.22 )  
Kambi ya Simba 4.07  ( 3.97 - 4.17 )  
Bwanbo 3.09  ( 3 - 3.17 )  
Mpinji 3.07  ( 2.98 - 3.16 )  
Goha 3.52  ( 3.44 - 3.61 )  
Kadando 4.34  ( 4.21 - 4.48 )  
Kwadoe 3.14  ( 3.04 - 3.24 )  
Funta 4.36  ( 4.24 - 4.49 )  
Tamota 3.86  ( 3.76 - 3.95 )  
Mgila 4.33  ( 4.2 - 4.46 )  
Antibody boost size parameters 
a 
 
0.24  ( 0.24 - 0.25 )  
B 0.09  ( 0.04 - 0.12 )  
S 0.02  ( 0.01 - 0.03 )  
Η 0.026  ( 0.025 - 0.029) )  
 
4.4.1.3 Antibody boost size 
I estimated the maximum boost size, a, to be 0.24 (95% credible interval 0.24-0.25) for individuals with an 
antibody level prior to exposure above the detection threshold. The rate of decline of the boost size with 
increasing antibody level prior to exposure was b=0.09 (95% CrI 0.04-0.12). As illustrated in Figure 4.8, the 
low value of b means that the estimated mean boost size declines approximately linearly with the log10 
antibody level prior to exposure. For the previously unexposed population, I estimated the mean boost size 
as =0.026 (95% CrI 0.025-0.029). The lack of overlapping credible intervals for the estimates of a and  
suggests that there is a difference in the antibody responses of individuals who have never been exposed or 
have antibody levels below the detection threshold compared to those whose antibody levels are above 
the detection threshold at the time of exposure. With these estimates, the probability of becoming 
seropositive is negligble meaning that most of the seronegative individuals remain seronegative upon 
exposure and it therefore takes a number of exposures for individuals to become seropositive. 
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Figure 4.8: Antibody boost size (δ) depends on individual’s current antibody level when an individual get exposed 
(xt). Black line (and the pink shaded area) represents median boost size for individuals with circulating antibodies 
(95% credible interval). Black point indicates boost size mean for “seronegative” individuals. A histogram of the 
distribution of anti-MSP1 antibody OD is shown in grey.  
 
4.4.1.4 Association between measures of exposure from density and catalytic models 
A strong correlation was observed between the estimates of exposure rates obtained using the density 
model, and those estimated by fitting a catalytic model to the data, using European controls to derive the 
cut-off  (see Figure 4.9a). As anticipated, villages at high altitude (Bwambo, Kilomeni, Mpinji and Kwadoe) 
had lower estimates of exposure while villages at lower altitude (Kadando and Mgila) had higher estimates 
of exposure. This was consistent for estimates obtained with both the density and catalytic models.  
One of the advantages of estimating the exposure rate using the density model rather than estimating the 
seroconversion rate using a catalytic model is that it makes fuller use of the continuous nature of the data, 
thus potentially increasing inferential power. The coefficient of variation of the estimated exposure rate 
(standard deviation of posterior/mean of posterior), which measures the precision of the estimates, is 
consistently smaller for the density model than for the catalytic model (Figure 4.9b). This result is more 
marked for villages with overall levels of lower transmission (i.e. those at higher altitude).  
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Figure 4.9: (a) Association between median estimates of exposure obtained with density model (y-axis) and 
catalytic model using European control (x-axis) for each village. (b) Coefficient of variation for both the density 
model (●) and the catalytic model (x). 
  
4.4.1.5 Correlation between exposure rate and derived EIRs 
Figure 4.10 shows that the estimates of exposure rate were also highly correlated with the two different 
estimates of the EIR available for the study villages, whether derived from altitude (Figure 4.10a) or derived 
from parasite prevalence (Figure 4.10b). It is worth noting that despite there being a strong correlation 
between the estimate of the force of infection and the two estimates of EIR (Figure 4.10c), the estimated 
values of EIR are substantially different in particular in lower endemicity settings. The range of EIR varies 
between ~0.03 and ~32 ibppy when derived from altitude, whereas its variation is between ~3 and ~20 
ibppy when derived from parasite prevalence. However, despite this, both methods rank the villages in a 
similar order of increasing endemicity. 
 
Figure 4.10: Association between exposure rate obtained from density model and EIR
1
 when derived from altitude 
(a) or derived from Parasite Rate EIR
2
 (b) and the correlation between both calculations (c). Coefficient of 
correlation, using Pearson method are denoted with r. If estimates were equal they would fall on black line in (c). 
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4.4.2 Estimates of the seroconversion rate  
Classical methods for estimating seroconversion rate as a measure of the force of infection consist in fitting 
a simple reversible catalytic model to the data with European sera used to specify seronegatives. This 
method was applied to the current data using a cut off value of 0.5 OD unit and the estimates are reported 
in Table 4.5. In a first development of this method, I used a mixture model to define seropositivity and 
distinguish between seropositive and seronegative individuals. A resulting cut-off value equal to 0.75 OD 
unit was obtained. In a second development of the method, I jointly estimated the cut-off using a mixture 
model and estimated the seroconversion for each village. Finally, in a third development of the method, I 
iteratively simulated seropositivity status as a data augmentation step whilst fitting the model to estimate 
the seroconversion rate. The estimates of the seroconversion rate for each village for each of these four 
methods are presented in Table 4.5. 
Table 4.5: Estimates of seroconversion rate SCR (λC) and rate of decay of antibodies (ρC) using 4 different methods.   
Posterior median and 95% credible intervals are presented for each village.  
Median(95%CrI) 
Seropositivity 
defined using 
European control 
Seropositivity 
defined by mixture 
model 
Estimation of SCR 
using mixture 
model 
Estimation of SCR 
using augmented 
data 
Exposure (λC)     
Kilomeni  0.0049 (0.0032-0.0072) 0.0041 (0.0026-0.0062) 0.011 (0.0081-0.014) 0.011 (0.0073-0.016) 
Lambo  0.011 (0.0076-0.015) 0.0071 (0.0046-0.01) 0.019 (0.014-0.025) 0.019 (0.014-0.027) 
Ngulu  0.095 (0.08-0.11) 0.079 (0.067-0.094) 0.2 (0.17-0.24) 0.2 (0.16-0.26) 
Kambia ya Simba  0.082 (0.069-0.096) 0.062 (0.052-0.073) 0.16 (0.13-0.19) 0.15 (0.12-0.21) 
Bwanbo  0.0045 (0.0028-0.0065) 0.0033 (0.002-0.0052) 0.0092 (0.0066-0.013) 0.0092 (0.0064-0.013) 
Mpinji  0.0069 (0.0049-0.0096) 0.0065 (0.0044-0.0091) 0.014 (0.011-0.019) 0.014 (0.01-0.021) 
Goha  0.026 (0.021-0.033) 0.019 (0.015-0.024) 0.046 (0.037-0.057) 0.045 (0.035-0.062) 
Kadando  0.11 (0.092-0.13) 0.09 (0.075-0.11) 0.23 (0.19-0.29) 0.23 (0.18-0.33) 
Kwadoe  0.0076 (0.005-0.011) 0.0049 (0.003-0.0076) 0.014 (0.0096-0.019) 0.014 (0.0096-0.021) 
Funta  0.12 (0.1-0.15) 0.097 (0.081-0.12) 0.28 (0.23-0.35) 0.28 (0.22-0.38) 
Tamota  0.068 (0.057-0.082) 0.057 (0.047-0.068) 0.11 (0.09-0.13) 0.11 (0.084-0.15) 
Mgila  0.16 (0.14-0.19) 0.13 (0.11-0.16) 0.31 (0.25-0.39) 0.31 (0.24-0.44) 
     
Seroreversion rate (ρC) 0.02 (0.015-0.026) 0.02 (0.015-0.027) 0.017 (0.011-0.024) 0.017 (0.0077-0.029) 
 
A comparison of these estimates is shown in Figure 4.11. The method using European controls (method 0), 
with a lower cut-off value, provides estimates of SCR that are higher than estimates obtained with the 
method using a mixture model to define seropositivity (method 1). For villages that are at low levels of 
endemicity, where the antibody levels are lower, the difference in the estimate of the seroconversion rate 
is not as substantial as in villages at higher endemicity levels where a large proportion of the population 
have antibody levels between the cut-off values defined in the two methods. Estimates derived from 
methods using cut-off values (method 0 & 1) appear to give lower estimates than the other methods. 
Jointly fitting a mixture model and estimating the SCR (method 2) or using the augmented data technique 
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(method 3) allows misclassification issues to be taken into consideration. Both methods (2 & 3) provide 
similar median estimates of the seroconversion rate, but with lower precision for the augmented data 
technique, reflecting the variability between individuals. By accounting for misclassification of the 
individuals, these methods appear more realistic than methods that define overall cut-off value as the 
models are also adjusted per age and per village. In addition, all methods resulted in high correlation 
between the estimated SCR, the derived EIR and the exposure rate estimated using the density model (see 
Figure 4.12). 
 
Figure 4.11: Seroconversion rate and associated 95% credible interval presented for each village and categorised by 
method used to derive SCR.  
Emilie Pothin | 111 
 
 
 
Figure 4.12: Correlation between multiple measures of exposure of each study village: SCR (yr
-1
) using 4 different 
methods described previously, EIR (ibppy) derived from Parasite Rate and from altitude and exposure rate, 
obtained from the density model (yr
-1
). Spearman correlations are presented in the upper panels.  
 
4.4.3 Validation of the density model using data from different villages in Tanzania. 
A validation study was performed for the density model by using dataset from 8 villages studied during the 
same survey in Tanzania but not used in the original fit. I tested whether the model developed provided 
consistent estimates of exposure and comparable biological parameters. The posterior distribution of the 
boost parameters obtained from the first 12 villages was used as a prior distribution to fit the model to data 
from these 8 different villages in Rombo and West Usambara regions. In each region, data from 4 villages 
with different altitude (exposure levels) were analysed. The distribution of the optical densities for anti-
MSP-1 antibodies in these 8 villages are represented in Figure 4.13. 
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Figure 4.13: Anti-MSP-1 antibody distribution for 8 villages from Rombo (first row) and West Usambara (second 
row) regions. Antibody density measured in Optical density and presented on log10 scale. Altitude decreasing from 
left to right. 
Seroprevalence was defined using the cut-off value obtained from European control (0.5 OD unit). A 
catalytic model was used to estimate seroconversion rates. The simple reversible catalytic model 
reproduces the age-stratified seroprevalence (Figure 4.14). The parameters for the 8 villages were 
estimated simultaneously with the rate of sero-reversion, estimated to be 0.039 years-1 (95% credible 
interval 0.025-0.056).  
 
Figure 4.14: Age specific seroprevalence for 8 villages. Data points are represented in black while median model fit 
is represented by the dashed line. λ: village specific annual rate of converting from MSP-1 seronegative to MSP-1 
seropositive, assuming a cut-off value for the density equal to 0.5 OD unit.   
Emilie Pothin | 113 
 
 
The antibody density model was used on the optical density for anti-MSP-1 antibodies from these 8 
villages. Figure 4.15 shows represented the optical densities by age for all the villages for both the data and 
the model fit. Despite some variability in the data, the median fit for optical density reproduces well the 
median from the data. As seen previously, antibody levels, measured with optical density increase with age 
and appear to be higher for villages with low altitude / high exposure such as Kileo and Mn’galo. However, 
some villages, despite being at higher altitude (e.g., Mokala: 1702m) than villages studied previously (e.g., 
Kilomeni: 1556m) have higher levels of antibodies from the youngest age with values around 10-0.75 OD unit 
and their levels do not increase much with age. 
 
Figure 4.15: Antibody levels associated with age and village altitude. Median fits (95% credible interval) for median 
antibody levels are represeted by the black dashed line (white area around median). Dark and light shaded area 
represent respectively 25
th
/75
th
 IQR and 2.5
th
/97.5
th
 IQR for the data.  
Parameter estimation for the model with this set of data for 8 villages was informed by the results from the 
model with 12 villages. Indeed an informative prior was used in the MCMC algorithm for the biological 
boost parameters (a, b ,S and η). Posterior distributions for those parameters were used to inform the prior 
while the exposure parameter had non-informative priors. The results from parameter estimation are 
presented in Table 4.6. 
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Table 4.6: Posterior median and credible intervals for each estimated model parameter 
 Posterior Median (95% Credible Interval) Prior  Mean (SD) 
Exposure (λ)   
Mokala 3.3  ( 3.1 - 3.5 )  - 
Machame Aleni 3.4  ( 3.2 - 3.5 )  - 
Ikuini 3.3  ( 3.1 - 3.5 )  - 
Kileo 4.1  ( 4 - 4.3 )  - 
Emmao 1.8  ( 1.6 - 2.1 )  - 
Handei 3  ( 2.8 - 3.1 )  - 
Tewe 3.3  ( 3.1 - 3.4 )  - 
Mn’galo 3.9  ( 3.8 - 4.1 )  - 
   
a 0.24  ( 0.23 - 0.24 )  0.24 (0.007) 
b 0.16  ( 0.15 - 0.17 )  0.09 (0.068) 
S 0.018  ( 0.018 - 0.019 )  0.02 (0.02) 
η 1.2  ( 1.1 - 1.3 )  0.03 (0.003) 
 
In order to assess the validity of this method, it is interesting to compare not only the estimates of the 
exposure rate with other metrics, such as seroconversion rate, parasite prevalence (PfPR) or EIR (derived 
from altitude) but also to visualize how the relationship between metrics compare with what was found 
previously with 12 villages. 
 
Figure 4.16: Association between exposure rates and seroconversion rate (a), parasite prevalence (b) and EIR 
derived from altitude (c) for the estimations of 8 (▪) and 12 villages (+). 
As shown in Figure 4.16a, a high correlation between exposure rate and seroconversion rate can be 
observed for the 8 villages (r=0.62). Similarly, there is also a high correlation between seroconversion rate 
and exposure rate for the 12 original villages (r=0.96).  However, if I assume a linear relationship between 
both metrics, the slope of regression is different for the fit to 8 villages (α=15.8) and for the fit of 12 villages 
(α=4.3). Nevertheless, the relationship between exposure rate and parasite prevalence (Figure 4.16b) is 
also strong for these 8 villages (r=0.31) as for the original 12 villages (r=0.82) and the slope of the regression 
line appears to be more similar when I compare estimates from 8 villages (α=0.01) with the original 12 
villages (α=0.04). If I compare the estimated exposure rate with EIR derived from altitude (Figure 4.16c) I 
also observe a high correlation between variables (r=0.71 for 8 villages vs. r=0.74 for 12 villages). Also, the 
slope of the regression line is comparable (α=0.47 for 8 villages and α=0.45 for 12 villages).  
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4.5 Discussion 
The utility of serological data to measure malaria transmission intensity has gained recognition in recent 
years [95, 97, 98] and is increasingly being incorporated in cross-sectional and longitudinal studies to 
monitor changes in transmission  [26, 41, 48, 82, 217], identify “hotspots” of transmission [72, 218, 219] 
and to identify high risk groups [11]. One of the key advantages of the methods is their ease of use in the 
field, with new laboratory techniques enabling serological responses to multiple antigens to be made from 
dried blood spots that can be stored and transported without the need for refrigeration [220]. Classically 
the approach to analysing such data has been to distinguish seropositives from seronegatives using a cut 
off value informed by unexposed European control populations [95, 97]. This has recognised limitations as 
the European control population may differ genetically in their immunological response to infection from 
the populations being analysed [211]. To avoid the need to incorporate a cut-off independent of the 
antibody background level, I developed and fitted a density model to serological data from a malaria 
endemic setting in Northern Tanzania. For comparison purposes, I also further developed methods based 
on catalytic model that uses seroconversion rates to measure transmission intensity. 
The results demonstrate that estimates of the exposure rate obtained from fitting the density model 
correlate highly both with previous estimates of the seroconversion rate obtained from the catalytic model 
as well as with traditional measures of transmission intensity (EIR) derived from altitude or from parasite 
prevalence data [93, 95]. The model therefore provides an alternative method to estimate transmission 
intensity from serological data that avoids the need to determine a cut-off between seropositivity and 
seronegativity. One alternative approach to using European controls to define a cut-off has been to using a 
mixture model, already broadly used in epidemiological studies in countries including Tanzania [98], 
Uganda [220], Somalia [99], Bioko Island [133] and Vanuatu [135]. The use of mixture models had already 
been explored by Irion and colleagues [168] who adopted an approach with latent class models to estimate 
prevalence of positivity. In this Chapter I have also further developed the use of mixture model to estimate 
the seroconversion rate without defining a cut-off value, either based on average proportion of responders 
or using each individual’s response (using augmented data techniques). All methods provided high 
correlation with indices of transmission. These mixture methods can also take into consideration the 
potential for misclassification of seropositive and seronegative individuals and do not require any external 
data for standardisation. Therefore, they provide alternative appealing methods for analysing serological 
data. However, one limitation of the mixture method approach is that its application in high transmission 
settings has limited validity as the antibody distribution of seropositive and seronegative individuals 
becomes impossible to distinguish. In contrast, the density model presented here performed equally well 
across all transmission settings. 
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An additional advantage of the density model demonstrated here is the improvement in the precision of 
the estimate of transmission intensity obtained by fitting a density model in comparison to those obtained 
by fitting a catalytic model. In particular, this was notably better in lower transmission settings. This result 
is not surprising, as with a density model a greater degree of information in the data was intrinsically used. 
However, such methods are also relevant from a practical perspective, as serological measures are likely to 
be of greatest use in areas of low transmission intensity where other commonly used measures (in 
particular parasite prevalence) lack precision. Thus by utilising the full data set, this increased precision will 
improve the ability to distinguish temporal and spatial trends in settings in which malaria has recently fallen 
to low levels [221, 222] as well as to monitor low-level transmission in countries working towards local 
elimination of the parasite [223, 224]. 
However, the application of the method to the different villages makes the assumption that there is no 
biological difference between the individuals/regions. Data from longitudinal studies from the same areas, 
if available, would alternatively be useful to calibrate the model for these biological parameters and assess 
the validity of these assumptions. 
The validation of the exposure rate as metrics for transmission intensity was based on values of EIR, either 
derived from altitude [214] or from parasite prevalence [93]. Derived EIR might not provide as accurate 
estimates as measured EIR. But, as SCR, based on anti-MSP-1 antibodies, had already shown high 
correlation with measured EIR in areas including Lower Moshi region in Tanzania [220], I expect similar 
correlations between measured EIRs and exposure rates. However, it would be of great interest if this 
approach could be directly validated against measured EIRs to further confirm that the exposure rate 
estimated by fitting the density model is truly an indicator of malaria exposure. 
 
Whilst the density model clearly has many advantages over the classical catalytic model, there are some 
limitations worth noting. Firstly the density model outlined here, whilst biologically grounded, is a simplistic 
representation of the true process of antibody-acquisition and loss: it does not take into consideration 
more complex immune responses (such as interaction between antibody responses to different blood-
stage antigens and/or between antibody- and cell-mediated immune responses [225]) or any ethnic or 
genetic difference between the different regions [210].  Nevertheless, it would be interesting to check what 
effect, if any, incorporating these factors would have on the estimates of transmission.  Also, while 
providing a simplistic representation of the complex process, the model does not consider age dependence 
in the affinity of the response [117, 226].  Whilst such aspects are clearly important, they cannot be 
estimated from cross-sectional data.   
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4.6 Conclusion 
In summary, the density model used in this Chapter provides a new method for analysing serological data 
that complements existing widely utilised tools for measuring malaria transmission intensity. These 
estimates are consistent with estimates of SCR, obtained using European controls or mixture models, and 
provide better precision. Further development of this method is needed to test it against a wider set of 
transmission settings, incorporate methods for assessing spatial and temporal variations in exposure and to 
assess its utility in capturing changes in transmission following scaling up of malaria interventions. 
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Chapter 5: Application of the antibody 
density model to assess malaria 
transmission intensity in diverse settings. 
In the previous chapters, I developed a density model capable of reproducing antibody levels and 
measuring malaria transmission intensity. The data used to measure malaria intensity in Tanzania 
originated from a study designed to assess the potential of measuring malaria transmission with serological 
data. If the density model I developed so far is to be re-used in other studies, it is of interest to further 
understand its range of applicability. In this chapter, I fit the same density model to data on antibody levels 
from four countries with diverse endemicity settings to estimate malaria transmission intensity. I also apply 
the density model to different antigens and compare their performance in measuring malaria transmission. 
Finally, I extend the density model to capture heterogeneity in transmission, the effect of age on 
transmission and to estimate temporal change in transmission. 
5.1 Introduction 
Malaria transmission intensity varies worldwide. As a result, the distribution of antibodies in different 
populations varies substantially. In addition to exposure to malaria, other factors could contribute to the 
differences in immunological responses that would give rise to different antibody distribution. It is 
therefore of interest to understand whether using an antibody density model to estimate exposure rate, as 
presented in the previous chapters, is valid across a range of different transmission settings and for 
individuals from different countries and hence ethnic backgrounds. As seasonal malaria might represent a 
target for interventions, it is worth exploring the performance of the model to assess malaria transmission 
just after the rainy season. Additionally, with the increasing number of control and elimination 
interventions, it becomes of interest to assess the applicability of this method in places in which 
interventions have been applied. In this Chapter, I therefore use the density model to estimate the 
exposure rate from age-stratified antibody data from Somalia, Bioko Island, The Gambia and Uganda. 
Somalia presents substantial spatial variation in malaria transmission intensity [221]. In some areas, the 
levels of transmission is so low that parasitaemia drops below the detection limits of microscopy [85]. The 
use of serological markers in such settings has already been demonstrated to be useful in predicting 
malaria exposure [99]. Due to the longevity of antibodies, serology measures exposure to malaria over time 
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and can therefore indicate the occurrence of malaria transmission in areas that report no parasite positive 
slides. I will apply the density model to data from Somalia to assess the performance of the method in low 
transmission settings. 
In Bioko Island, Equatorial Guinea, national malaria interventions have been scaled up since 2004. As a 
result, parasite prevalence has dropped following the application of intensified vector control and 
improved access to treatment [227]. However, transmission intensity has still not uniformly been reduced 
to very low levels. Serology has previously been used there to show recent changes in transmission and the 
heterogeneity in the effectiveness of these interventions [135]. I will use data from Bioko to assess 
transmission intensity when interventions have had an impact on transmission intensity. 
In The Gambia, parasite positive slides show a highly seasonal distribution of malaria infections that 
corresponds to the rainy seasons [41]. Transmission levels have significantly dropped in the last 20 years, 
setting The Gambia as an example for successful interventions. Indeed, areas of seasonal malaria might 
represent great targets to achieve reductions in malaria transmission intensity as levels of transmission 
drop substantially during the dry season [228]. However, in order to monitor the impact of these 
interventions, serology represents a useful tool for measuring malaria transmission intensity. I have used 
data from The Gambia to assess the performance of the density model to measure transmission intensity 
just after the wet season in areas of seasonal malaria. 
Despite on-going intensive interventions in Uganda, essentially bed nets distribution, efforts have been 
inefficient to reduce malaria transmission and the associated disease burden [229, 230]. Indeed, despite 
the free distribution of bed nets, the proportion of bed nets ownership is relatively low; when three ITNs 
per household would represent total coverage in Uganda, only 8% of the households has three or more 
ITNs [231]. Malaria remains predominantly holoendemic with intense and perennial transmission. Serology 
has been used to confirm the relative lack of impact of the interventions [136]. However, the use of 
seroprevalence in high endemicity settings is limited by the small number of unexposed individuals 
required to derive the cut off value. By using the full information contained in the antibody titre, the 
density model was applied in Uganda to assess transmission intensity in a high endemicity setting. 
The density model was fitted to data on antibodies against both AMA-1 and MSP-1 antigens. These are 
blood stage antigens and share some characteristics. Levels of antibodies to MSP-1 and AMA-1 antigens are 
strongly associated with increasing exposure to Plasmodium falciparum. However, the quality of these 
antibodies differs amongst individuals as antibody avidity shows some respectively negative and positive 
correlation with age for anti- MSP-1 and anti- AMA-1 [232]. By fitting the model separately and 
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simultaneously to both antibody types, the extent to which the density model can be used for any of these 
antibodies to measure malaria exposure is investigated.  
Malaria transmission is influenced by many different sources of heterogeneity, including genetic, 
behavioural and spatial factors [80]. For instance, the difference in exposure between individuals can be 
due to the distance to mosquitoes breeding site, the use of protective nets or antimalarial drug intake. 
Additionally, the diversity of host characteristics might affect the heterogeneity in biting [78] and the 
development of acquired and innate immunity that limits the frequency of infection [67], therefore 
reducing transmission. Thus, it is of interest to explore whether including heterogeneity in transmission in 
the density model improves the estimate of the exposure rate. 
Differences in human behaviour often contribute to heterogeneity of malaria transmission, in particular 
due to individual’s occupations. In South-East Asia, many studies have shown the effect of working in the 
forest on exposure [233–235]. Children starting to work in the forest become exposed to a much higher 
degree. This makes it difficult to differentiate the effect of age and cumulative biting, so a further 
development of the density model to account for a change in behaviour at a particular age would be useful 
to characterise forest malaria in specific areas. 
A consequence of the interventions is that temporal and spatial heterogeneity of malaria transmission 
might become apparent as transmission declines. Indeed, the impact of interventions can be spatially 
heterogeneous and happen at different time [133]. A classic method to assess the impact of any temporal 
change in transmission consists of conducting multiple cross sectional surveys (before and after the 
change). Some studies have shown that it was possible to detect a change in transmission by estimating 
two seroconversion rate (SCR) from a single cross-sectional survey [133, 135]. Accounting for a change in 
transmission in the density model would therefore increase the potential applications of the model. 
In the first section of this chapter, I summarise the epidemiology in the different settings used for the 
analyses. Next, I fit the density model to each of these data sets to obtain estimates of the exposure for 
each site. In the last section, I extend the density model to allow for an assessment of heterogeneity in 
transmission in the population, the effect of age on transmission and a temporal change in malaria 
transmission. Using simulations, I reproduce multiple scenarios to assess the ability of my method to 
estimate variation in transmission. These extended versions of the density model are then fitted to the data 
to assess temporal changes in transmission in Bioko Island and the effect of age on transmission in 
Cambodia.  
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5.2 Settings 
5.2.1 Data collection 
5.2.1.1 Somalia 
Located in the eastern part of Africa, Somalia is referred to as “the horn” of Africa (Figure 5.1). Somalia has 
a relatively semi-arid landscape and seasonal rivers.  In Somalia, the rainfall pattern is bimodal with peaks 
in April and August. Somalia is a country with very low malaria intensity. The parasite prevalence is below 
5% for most part of the North West Zone [221]. The dominant parasite species are both P. falciparum and 
P. vivax. 
A cross-sectional survey was conducted in August-September 2008 in Somaliland, in North Western 
Somalia. Three villages were selected randomly in the Gebiley district, Xuunshaley, Badahabo and Ceel-
Bardaale. The timing of the study corresponds to the end of the wet season. Each household was visited. 
Demographics characteristics and bednet use data were collected for households that agreed to 
participate. The presence of parasite was assessed using rapid diagnostic tests (RDT). The presence of 
Anopheles species were determined by larvae collections. The full description of the study is presented 
elsewhere [236]. Ethical approval for this study was granted by the Research Ethics Committee of the 
World Health Organisation and the Ethical Committee of the Ministry of Health and Labour, Republic of 
Somaliland. 
 
Figure 5.1: Map of Somalia 
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5.2.1.2 Bioko Island 
Bioko is an island in Equatorial Guinea, located around 30 miles west of Cameroon (Figure 5.2). The climate 
is characterised by peaks of rainfall towards September and October. The total rainfall is on average 2,000 
mm/year. Parasite prevalence is around 26% on average over the island but varies substantially between 
regions, from 5% in high altitude in the South East to 72% in the South West of the Island [237].  
A malaria control intervention program named Bioko Island Malaria Control Program (BIMCP), sponsored 
by Marathon Oil Company [227] was launched in 2004 with the intention of eliminating malaria from the 
island. Since the launch of this program, Malaria Indicators Surveys (MIS) were conducted annually in 18 
randomly selected sentinel sites, grouped in 5 geographical regions and covering most of the island. The 
surveys collected demographic data as well as data on household spraying, illness history and compliance 
with interventions. Children under 15 years old were tested for malaria parasitaemia using rapid diagnostic 
tests (RDT).  The research protocol was approved by the Equatorial Guinea Ministry of Health and Social 
Welfare. 
 
 
Figure 5.2: Map of Bioko Island 
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5.2.1.3 The Gambia 
The Gambia is a small West African country divided by the river Gambia (Figure 5.3). The country 
experiences highly seasonal rainfall with an average annual rainfall of 800 mm/year. A short rainy season 
takes place between July and October and a long dry season from November to June [238]. Malaria 
transmission in The Gambia is very low during the annual dry season and high during the wet season. The 
South bank has a longer malaria transmission season than the North bank due to a longer rainy season and 
its denser vegetation which provides breeding sites for mosquitoes. The three main mosquitoes’ species 
that transmit malaria in The Gambia are Anopheles Gambiae, Anopheles Arabiensis and Anopheles Malas. 
The biting rate for children is between 3 and 5 infective bites per person per year (ibppy), while an adult 
receives between 11 and 24 infective bites annually [239]. The predominant plasmodium species in the 
region was P. falciparum.  
Between 1990 and 1991, four cross-sectionnal surveys were carried out as an investigation in malaria 
immunology, epidemiology and control in this region [240]. Data presented here only focus on the survey 
carried out in November 1990, just after the wet season. Around 1,200 participants were recruited in two 
sets of hamlets on either side of the river. Each participant had to complete a survey form recording 
demographic characteristics. The collection of the data stopped when the expected sample size was 
achieved. Ethical approval for the study was obtained from the Scientific Coordinating Committee of the 
Medical research Council (The Gambia) and the Joint The Gambia Government Medical Research Council 
Ethical Committee. 
 
Figure 5.3: Map of The Gambia 
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5.2.1.4 Uganda 
Uganda is a landlocked country in eastern Africa with vast inland water bodies. Uganda experiences a dry 
season from November to February and two short rainy seasons from April to May and September to 
October. The Apac Sub-County, a district in Northern Uganda located between Kwania Lake and the Victoria 
Nile (Figure 5.4) reports the highest estimate of EIR in Africa [230] with EIR ranging from 4 to over 1,500 
infectious bites per person per year. As a consequence, parasite prevalence is also extremely high, with 
around 80% prevalence in children younger than 10 years old. Since 2001, a number of unsuccessful 
malaria control programs have been launched in order to control malaria and reduce morbidity and 
mortality [136].  
In October 2009, a survey was carried out by Proietti and colleagues to assess potential changes in 
transmission [136]. The study was conducted in four parishes: Apac District hospital, two health facilities in 
Abedi and Akere and a school in Atopi. Subjects were recruited per age category until the required sample 
size was reached (around 200-300 individuals per parish). Demographic characteristics, clinical information, 
use of antimalarial and prevention against mosquitoes were recorded through questionnaires. Presence of 
parasite was first detected using rapid diagnostics test (RDT) and confirmed by examination using 
microscopy and PCR. Ethical approval for the study was obtained from the ethical review committee of the 
London School of Hygiene and Tropical Medicine, the ethical committee of the Medical Biotech Laboratory, 
and the national ethical committee of Uganda. 
 
Figure 5.4: Map of Uganda 
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5.2.2 Laboratory methods  
In each of the studies, a fingerprint blood sample was obtained from each participant for malaria parasite 
examination and humoral assays. This sample was placed on filter paper as described by Corran [97] to 
measure antibody density. Filter papers were stored with dessicant until processed. Samples were diluted 
to a serum dilution equivalent of 1/1000 (1/750 in Uganda) for human immunoglobulin G antibodies 
against P. falciparum merozoite surface protein 119 (MSP-119) and 1/2000 for antibodies against apical 
membrane antigen 1 (AMA-1). Antibodies were detected by ELISA, as previously described in [220]. 
Antibody data were collected as optical density and converted to arbitrary titres using a standard curve 
based on dilutions of hyperimmune serum on each assay plate. 
5.2.3 Seropositivity definition 
Serological data were reported as antibody titre and will later be used in conjunction with the density 
model to characterise endemicity levels. However, in a preliminary descriptive analysis, seroprevalence was 
defined using a method widely used and presented in Chapter 4. Individuals were considered antibody 
positive when their antibody titre was above a cut-off value derived using a mixture model. In brief, the 
distribution of antibody titre was fitted as the sum of two Gaussian distributions using maximum likelihood 
methods. The cut-off value was then defined as the mean of the Gaussian corresponding to the 
seronegative population added with 3 standard deviation of the same distribution. I have assumed similar 
characteristics within countries and different characteristics between countries. As a result, cut-off values 
were derived at a country level but specific for each country. The resulting cut-off values are presented for 
each antigen in Table 5.1. Each country might present different genetic and ecological backgrounds that 
might explain country specific definition of seropositivity. However, in Uganda the number of seronegatives 
might be so low that the threshold obtained with a mixture model might over-estimate the real  one.  
Table 5.1: Cut off values obtained using mixture model 
 MSP-1 (units/mL) AMA-1 (units/mL) 
Somalia 40 86 
Bioko 87 233 
The Gambia 168 279 
Uganda 156 1006 
 
An overall summary of the malaria endemicity in the four countries that will be considered in the following 
analyses is presented in Table 5.2. Despite a lack of a standard method to compare the endemicity level of 
each country, Somalia and Uganda represent respectively areas of low and high levels of transmission while 
Bioko and Gambia had intermediate endemicity levels at the time of the survey (with endemicity in The 
Gambia expected to be marginally higher).  
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Table 5.2: Summary of studies and malaria transmission intensity for each studied country 
 Malaria transmission intensity Year of study Study reference 
Somalia Parasite prevalence: <5% 2008 Youssef et al. [236] 
Bioko Parasite prevalence: 26% - 72% 2008 Kleinschmidt et al.[227] 
The Gambia EIR:  -  3 to 5 ibppy (children) 
-   11 to 24 ibppy (adults) 
1990 Lulat [240] 
Uganda Parasite prevalence: 80% (children <10 years old) 
EIR: 4 to over 1500 ibppy 
2004 Proietti et al.[136] 
 
5.2.4 Descriptive analysis 
5.2.4.1 Overall seroprevalence and antibody titres 
The endemicity level in each country differs and this is reflected in the distribution of antibody levels in the 
population. Figure 5.5 demonstrates that with increasing transmission intensity (left to right), the 
proportion of individuals with high antibody levels increases, consistently for both antibody types. It 
appears that using a mixture model to determine seropositivity status is appropriate with the exception of 
Uganda where transmission intensity is high and therefore, it becomes difficult to distinguish between 
seropositive and seronegative individuals, in particular when considering the AMA-1 antigen. Using a 
density model which takes into account the full information contained in the antibody titre is therefore 
likely to be better able to characterise transmission intensity in this setting.  
Additionally, note that the anti- MSP-1 antibody distributions for The Gambia and Uganda are very similar 
(with a marginally higher proportion of seropositive individuals in The Gambia) despite a large differential 
of exposure between both countries (see Table 5.2 and Figure 5.5). As a result, in Uganda, it appears that 
the distribution of anti- MSP-1 antibodies is unexpectedly low. A number of plausible hypotheses for these 
observations could be suggested, including technical and biological explanations. 
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Figure 5.5: Antibody distribution in Somalia, Bioko, Gambia and Uganda (left to right) for anti- MSP1 (first row) and 
anti- AMA1 (second row). Cutoffs between seronegative and seropositive individuals are presented in red and the 
black line represents the Gaussian fit. 
In all four studied countries, data were collected in different geographical areas; three villages in Somalia, 
North and South river banks in The Gambia, six regions in Bioko and four parishes in Uganda. Figure 5.6 
illustrates the distribution of antibodies against MSP-1 and AMA-1 antigens for the different geographical 
areas in each country. Details of the summary statistics for antibody titres against MSP-1 and AMA-1 
antigens and the associated seroprevalence are provided in Table 5.3. 
 
Figure 5.6: Distribution of antibodies against MSP-1 (first row) and AMA-1 (second row) antigens for Somalia, Bioko, 
Gambia and Uganda (left to right) and presented per region. Note that the y-axes are on different scales.  
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Table 5.3: Summary statistics for anti- MSP-1 and anti- AMA-1 antibody titres and seroprevalence for regions of 
Somalia, Bioko, Gambia and Uganda.  
 # ind. 
MSP-1 AMA-1 
 
Seroprevalence 
%(no. positive/no. tested) 
Titre 
Median (IQR) 
Seroprevalence 
%(no. positive/no. tested) 
Titre 
Median (IQR) 
Somalia 
Badahabo 160 6.6 (7/106) 3.3 ( 0.1 - 11.7 ) 9.2 (13/141) 10.5 (1.7-30.7) 
Ceel-
Bardaale 
697 15 (95/634) 11.8 ( 2.5 - 26.8 ) 9.2 (60/653) 19 (4.5-46.3) 
Xuunshaley 271 5.1 (13/254) 5.6 ( 0.2 - 17.3 ) 5.6 (14/252) 14 (1.7-35.1) 
 
Total 
 
1128 
11.6 (115/994) 8.9 ( 1.3 – 23.1 ) 8.3 (87/1046) 17.2 (3.1-40.4) 
Overall Seroprevalence     % (no. positive/no. tested) 
17.7 (171/967) 
Bioko 
Malabo 2328 21.3 (473/2218) 20.9 (5.2-70.5) 44 (960/2181) 156.3 (18.1-574.3) 
 North East 1323 24 (299/1247) 30.5 (9.1-84.2) 42.3 (495/1171) 146.3 (30-509.8) 
North West 1749 37.3 (598/1604) 50.4 (16.1-162.7) 64.8 (1053/1626) 513 (100.7-1082.7) 
South East 700 23.8 (144/604) 29.1 (7.2-79.1) 37.3 (245/656) 150.7 (27.6-411.4) 
South West 588 23.2 (134/577) 25.5 (7.9-82.7) 40.7 (231/568) 163.1 (39.8-408.4) 
Other 699 16.7 (107/641) 19.1 (6-52.6) 34.5 (226/655) 109 (20.9-386.4) 
Total 7387 
25.5 (1755/6891) 28.7 (8.3-89.9) 46.8 (3210/6857) 196.4 (34.4-639) 
Overall Seroprevalence     % (no. positive/no. tested) 
54 (3663/6788) 
Gambia 
North Bank 841 52.7 (394/748) 195.6 (44.8-558.2) 50.5 (373/739) 285.1 (48.3-788.8) 
South Bank 344 33.8 (93/275) 79.6 (26.6-250.7) 64.5 (178/276) 454.7 (179.4-1009.2) 
Total 1185 
47.6 (487/1023) 151.2 (38.2-448.3) 54.3 (551/1015) 355.1 (64.7-865.7) 
Overall Seroprevalence     % (no. positive/no. tested) 
66.4 (675/1017) 
Uganda 
Abedi 251 41.1 (97/236) 107.7 ( 30.8 - 298.5 ) 49.2 (119/242) 989.9 (404.3-1561.1) 
Akere 217 42.1 (83/197) 123 ( 43.6 - 305 ) 48.8 (98/201) 999.9 (474.1-1485.6) 
Apac Town 213 49.4 (76/154) 145.1 ( 27 - 377.1 ) 50.6 (78/154) 1010.4 (382.8-1561.1) 
Atopi 202 48.7 (93/191) 146.1 ( 39.4 - 369.4 ) 59.2 (113/191) 1222.8 (616-1712.3) 
Total 883 
44.9 (349/778) 125.7 (36.3-337.5) 51.8 (408/788) 1045.8 (453.3-1603.6) 
Overall Seroprevalence     % (no. positive/no. tested) 
70 (545/779) 
*IQR, interquartile range (25th-75th percentile) 
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Despite some level of variation within each country, the major variability in antibody titre is observed 
between countries.   
In Somalia, the number of individuals taking part in the study differs between the three villages 
Xuunshaley (n=271), Badahabo (n=160) and Ceel-Bardaale (n=697). The seroprevalence of individuals in 
each of these villages is low (around 11.6% for MSP-1 and 8.3% for AMA-1) and so is the median titre (8.9 
units/mL for MSP-1 and 17.2 units/mL for AMA-1). Overall, only 17.7% of the population is seropositive to 
either MSP-1 or AMA-1 antigens, as seen in Figure 5.7. Data were collected in three villages from the same 
district. However, in Ceel-Bardaale individuals appear to have a higher antibody titre on average and the 
distribution of antibodies against both MSP-1 and AMA-1 antigens is wider than in other villages. This could 
potentially be explained by the fact that Ceel-Bardaale is a larger and wealthier village where households 
are located along the seasonal river [236] and therefore individuals might be more exposed to malaria and 
present with higher antibody levels. 
In Bioko, serum samples were collected from 7,387 individuals from the Malabo region (n=2,328), 
the North East region (n=1,323), the North West region (n=1,749), the South West region (n=700), the 
South East (n=688) and from other regions (n=700). More than half of the population (54%) were 
seropositive for antibodies against MSP-1 or AMA-1 antigens. The North West region has seroprevalence 
and median antibody titre for antibodies against MSP-1 and AMA-1 antigens much higher than the other 
five regions, and also a much wider distribution. If we assume that high antibody levels are associated with 
high exposure, then this result corroborates with what was already observed previously, i. e. high 
transmission in the North West region [241].  
In The Gambia, serum samples were collected from South (n=344) and North (n=841) banks of the 
river Gambia. Overall, a high seroprevalence was recorded for both MSP-1 (47.6%) and AMA-1 (54.3%) 
antigens, with a seroprevalence to either MSP-1 or AMA-1 antigen of 66.4%. The antibody titre was also 
relatively high with a median of 151.2 units/mL for MSP-1 and 355.1 units/mL for AMA-1. In The Gambia, 
the malaria transmission season is expected to be shorter in the North Bank, which would explain some 
heterogeneity in the distribution of antibodies in this region. Some individuals might get exposed and 
increase their antibody levels while some individuals might not get exposed at all.   
In Uganda, similar numbers of individuals were reported in each parish: Abedi (n=251), Akare 
(n=217), Apac Town (n=213) and Atopi (n=202). Around 70% of the overall population is seropositive to 
either MSP-1 (44.9%) or AMA-1 antigen (51.8%).  Seroprevalence was comparable for each parish, ranging 
from 41.1% in Abedi to 49.4% in Apac Town for MSP-1 and from 48.8% in Akere to 59.2% Atopi for AMA-1. 
The distribution of both antibodies types is very similar between the different parishes. These results infer a 
lack of local heterogeneity as the data were collected from four parishes geographically relatively close to 
each other.  
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Titres for anti- AMA-1 antibodies are much higher than for anti- MSP-1 antibodies in Uganda, The Gambia 
and Bioko while the difference is less marked in Somalia. Similarly, the prevalence of individuals with 
antibodies against MSP-1 antigens appears to be consistently lower than against AMA-1 antigens for most 
of the regions in each country, with the exception of Ceel-Bardaale in Somalia and the North Bank in The 
Gambia where prevalence of anti-MSP-1 is higher than prevalence of anti- AMA-1. The lowest and highest 
antibody titres for MSP-1 are associated with, respectively, the lowest and highest antibody titre for AMA-1 
within each country, with the exception of The Gambia. While seroprevalence for MSP-1 and AMA-1 ranks 
regions in the same order for Somalia and Bioko, there are some discrepancies in ranking in The Gambia 
and Uganda. 
In a country of low endemicity such as Somalia, most of the population is seronegative. As intensity 
increases between the different countries,  the prevalence of seronegative individuals decreases (Figure 
5.7). In Uganda, the proportion of seronegative individuals is similar to The Gambia when the exposure is 
exected to be much higher. As transmission increases, it also appears that the proportion of individuals 
with anti- MSP-1 antibody increases, with the exception of Uganda where seroprevalence to MSP-1 only is 
lower than in The Gambia. There is no clear pattern for the acquisition of AMA-1 with increasing 
transmission intensity.  
 
Figure 5.7: Prevalence of antibody types in each country 
There is an association between seroprevalence and antibody titres between the different countries. As 
expected, all villages in Somalia report the lowest seroprevalence/antibody titre, all regions in Bioko 
records medium seroprevalence/antibody titre and all areas in Uganda and The Gambia present higher 
seroprevalence/antibody titres. This consistent association between seroprevalence and median antibody 
titre is also observed within countries. In most of the regions, high seroprevalence is associated with high 
antibody titre and low seroprevalence is associated with low antibody titre. Figure 5.8 shows a linear 
relationship between seroprevalence and median log10 antibody titre for both anti- MSP-1 and anti- AMA-
1 antibodies. The correlation between seroprevalence and log10 antibody titre is significantly high with 
Spearman correlation coefficients of 0.87 for MSP-1 and 0.91 for AMA-1, with antibody titre which tends to 
increase as seroprevalence increases.  
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Figure 5.8: Association between seroprevalence and antibody titre for anti- MSP1 (left) and anti- AMA-1 (right) 
antibodies. Note that the y-axes are not on the same scale. Data are presented per region and categorised per 
country. 
5.2.4.2 Age structured seroprevalence and antibody titres 
Age is a significant determinant of malaria exposure and is an important factor when analysing serological 
data, as antibody levels vary with age. Individuals’ ages were recorded during the data collection and the 
age distribution of individuals included in the study in each country is presented in Figure 5.9. A large 
proportion of the data are from individuals less than 20 years old. In Somalia, the median age is 15 years 
old (IQR: 6-37), 14 years old (IQR: 6-30) in The Gambia, 12 years old (IQR: 4-30) in Bioko and 15 years old 
(IQR: 5-29) in Uganda. 
 
Figure 5.9: Age distribution in the studies in Somalia, Bioko, The Gambia and Uganda (left to right) 
Figure 5.10 illustrates age-specific seroprevalence for all countries for both MSP-1 and AMA-1 antigens for 
the data and model fit using the catalytic model (described in the Chapter 4) for the following 11 age 
classes (chosen to have comparable number of individuals in each class): 0-1, 1-3, 3-5, 5-8, 8-10, 10-15, 15-
25, 25-32, 32-40, 40-55, >55 years old. In all four countries, antibodies tested against both MSP-1 and AMA-
1 antigens show a clear increase in seroprevalence with a person’s age. In Somalia, The Gambia and Bioko, 
the catalytic model reproduces the data reasonably well for both antigens. The estimated seroconversion 
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rates are presented in Table 5.4. In Uganda, the model for antibodies against AMA-1 antigen provides a 
poor fit to the data with an under-prediction of seropositive individuals aged between 1 and 32 years old 
and an over-prediction for older individuals. In contrast, for the MSP-1 antigen, the model fit appears to be 
relatively good for individuals above 10 years old despite some lack of fit for younger children. Poor model 
fit may suggest some heterogeneity in the population, some changes in transmission intensity in time or 
some cross-reactivity of the antibodies. 
 
Figure 5.10: Seroprevalence for actual data (dots) and model fits (dashed lines) for Somalia, Bioko, The Gambia and 
Uganda (left to right) for both anti- MSP1 (black) and anti- AMA1 (red) antibodies. 
Table 5.4: Estimates of seroconversion rates (SCR) for the studied countries.  Mean and 95% confidence intervals 
are reported. 
 
MSP-1 SCR  
Mean (95% conf. interval) 
AMA-1 SCR 
Mean (95% conf. interval) 
Somalia 0.011 (0.005-0.016) 0.0059 (0.0034-0.0084) 
Bioko 0.032 (0.029-0.035) 0.091 (0.085-0.097) 
The Gambia 0.092 (0.07-0.11) 0.10  (0.084-0.12) 
Uganda 0.061 (0.045-0.077) 0.25 (0.18-0.32) 
  
The age-specific antibody titre distribution is presented in Figure 5.11. Antibody titre increases with age for 
all countries. In areas of low endemicity such as Somalia, the median level of antibodies only slowly 
increases between 0 and 15 units/mL for MSP-1 and up to 30 units/mL for AMA-1. However, for countries 
where transmission is much higher, a large proportion of the population have antibody titres exceeding 
values of 600 units/mL for MSP-1 in The Gambia and 1500 units/mL for AMA-1 in Uganda. The wide range 
around the median titre shows the variation in individual antibody titres in the population and is larger as 
age and exposure increase. Although in all countries while anti-MSP-1 antibody titres appear to 
continuously increase with age,  anti- AMA-1 antibody titres seem to increase steeply with younger age and 
around 20 years old, titres start to decrease, with the exception for Somalia where antibody titre increases 
monotonically with age. The difference in antibody acquisition against MSP-1 and AMA-1 could be 
explained by a difference in immunogenicity of the antigens. 
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Figure 5.11: Age structured antibody titres against MSP-1 (first row) and AMA-1 (second row) for studied countries. 
Median titre represented by lines and shaded areas correspond to 25
th
 and 75
th
 percentiles of the antibodies 
distribution (IQR). Note that the y-axes are on different scales. 
The prevalence of the parasite in human blood is indicative of malaria transmission. In areas of low 
exposure, parasite prevalence tends to be very low or equal to zero as it is the case in Somalia (0 parasite 
positive individuals / 1128 tested individuals). Parasite prevalence decreases with increasing age as 
expected, as shown in Figure 5.11. In high transmission settings, such as Uganda, the parasite prevalence is 
as high as 80% for young children and drops to 10% for older individuals. In The Gambia and Bioko, parasite 
prevalence appears to have a comparable pattern by age. For countries with medium to high transmission, 
it appears that the difference in exposure is noticeable in young children but for adults older than 20 years 
parasite prevalence becomes comparable. 
 
Figure 5.12: Parasite prevalence across age categorised by studied country 
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5.3 Methods  
5.3.1 Measuring malaria transmission intensity using density model 
The density model previously developed was fitted to data from Somalia, Bioko, The Gambia and Uganda to 
estimate malaria transmission intensity at country levels using both anti-MSP-1 and anti-AMA-1 antibodies. 
The laboratory methods were standardised across the four studies and reported antibody titres used for 
the analysis. The limit of detection was set to be 0.01 and antibody titres were log10 transformed. For all 
countries and both antigens, the model included N=51 compartments and . As before, the first class 
contained all individuals with log10 antibody titre equal to min 2x   and the last class all individuals who 
had antibody titre greater than 3.88 on a log10 scale. Country-specific parameters for the exposure rate 
were estimated and the model was fitted to all countries simultaneously with the other parameters not 
varying by country. The rate of decay of antibodies, ρ, was fixed to a constant value of 0.7 years-1 (half-life: 
360 days) for both MSP-1 and AMA-1 antigens. The model was identical to the one presented in Chapters 3 
& 4 (Sections 3.2.2.2 and 4.3.1.1 ):  
 
,
1
( )
( ) ( ) ( ) (t)      1
i v
v ij j i v hi i i
j i h i
dy t
k y t y t k y t y i N
dt
 
 
 
     
 
   (5.1) 
with , ( )i vy t  the proportion of individuals in country v  in antibody category i at age t and kij the probability 
that following exposure antibodies are boosted from antibody category j to category i, as defined 
previously. Let 0( , , ; , )vY y t   be the solution of (5.1) with 0y the initial state (i.e. the distribution of the 
population according to individual’s antibody level at the beginning of the exposure time, namely birth), v  
the exposure rate for country v , t  the age class, ρ the rate of decay of antibodies and { , , , }a b S  the 
set of boost parameters required to define ijk . 
As in earlier chapters (See section 4.3.1.2), the likelihood is given by: 
 
, , ,
0
log( ( | )) log( ( ))i t v i v
v t i
l P D n y t

 
 (5.2) 
with , ,i t vn the observed number of individuals in antibody category i in country v at age t. 
MCMC methods were used to sample from the posterior distribution of the parameters as described in the 
previous chapters. Because of the computational time required I ran two parallel chains with different 
starting points for MSP-1 (and three for AMA-1).  I performed 1,000,000 iterations respectively for each of 
the runs of the MCMC algorithm with a burn-in period of 250,000 steps (50,000 for AMA-1). The output of 
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each of the chains was then recorded every 500 iterations (1,000 for AMA-1) to generate an aggregated 
sample from the posterior distribution of size 3,000 (2,850 for AMA-1).  
5.3.2 Combining both MSP-1 and AMA-1 antigens to inform on transmission intensity 
The model was extended to simultaneously fit data on anti- MSP-1 and anti- AMA-1 antibody levels. I 
assumed the country-specific rate of exposure, v  was independent of the antibody type. The boost 
parameters i.e { , , , }a b S   and the rate of decay of antibodies  were assumed to be antibody-specific 
(presented in Table 5.5). Parameter estimation was performed fitting simultaneously to data from Somalia, 
Bioko, The Gambia and Uganda at country-level as described before but with the following likelihood: 
 
1 1 1 1
, , , , , ,
0
log( ( | )) ( log( ( )) log( ( )))MSP MSP AMA AMAi t v i v i t v i v
v t i
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with
1 1 1 1
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i t v i t v i v i vn n y t
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respectively the observed number and predicted proportion of 
individuals in anti-MSP-1 and anti-AMA-1 antibodies category i in country v at age t defined as: 
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 (5.4) 
with 
1 1
0 (0)
MSP MSPy y   and 1 10 (0)
AMA AMAy y   the antibody distributions observed in the data at age 0.  
However, in Bioko (where age was recorded in months for individuals younger than 1) and in The Gambia, 
there was a significant drop of anti- AMA-1 antibodies between the age of 0 and 1. Therefore, in order to 
discard maternal immunity, in those countries I assumed individuals start their life with the anti- AMA-1 
antibody level observed at age 1 and therefore
1 1
0 (1)
AMA AMAy y  . 
Here, I performed 150,000 iterations of the MCMC algorithm with a burn-in period of 25,000 steps and the 
output of the four chains was recorded every 200 iterations to generate an aggregated sample for the 
posterior distribution of size 2,500. 
 
 
  
Emilie Pothin | 136 
 
 
Table 5.5: List of model parameters 
Parameters Description 
λv Exposure rate for country v 
aMSP-1,aAMA-1 Maximum antibody boost size on exposure 
b MSP-1,bAMA-1 Slope of dependence of antibody boost on current log10 titre 
S MSP-1,SAMA-1 Standard deviation for boost size distribution 
η MSP-1,ηAMA-1 Mean boost for individuals with no current antibody 
ρ MSP-1,ρAMA-1 Rate of decay of antibodies 
 
5.3.3 Extension of the density model 
The density model can be further developed to address heterogeneity in exposure potentially attributable 
to spatial or temporal variations in transmission or any other factor. The effect of age on exposure can be 
accounted for by considering different exposure levels before and after a specific age. Also, any change in 
transmission that happened in the past can be additionally included in the model.  Spatial heterogeneity in 
transmission can be considered by simultaneously assessing specific exposures in different regions. Here, I 
present three extensions of the density model that respectively account for heterogeneity of exposure, 
age-effect in exposure and changes in transmission intensity.  
1. Heterogeneity in exposure 
Malaria transmission is rarely homogeneous in the population. Some individuals might be less 
exposed than other for instance due to genetic differences, individual’s behaviour, use of 
intervention or spatial variations. I made the assumption that the population is made of two 
subpopulations exposed to malaria at different levels (See Figure 5.13). A proportion p  of the 
population is exposed at a rate   (subpopulation A) and a proportion  1 p is exposed at a lower 
rate *  (subpopulation B), where [0,1]  . The model that captures heterogeneity in exposure 
can be written as:    
( ) ( ) (1 ) ( )A By t py t p y t       (5.5) 
 where 0( ) ( , , ; , )
Ay t Y py t   and 0( ) ((1 ) , * , ; , )
By t Y p y t      solutions of (5.1), 
represent the distribution of the proportions of individuals in each antibody class at age t in 
respectively subpopulations A and B. 
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Figure 5.13: Examples of scenarios for heterogeneity of exposure. (a) Houses closer to the forest might get higher 
exposure (λ) than houses that live further away exposed at λ*β (with 0≤β≤1). (b) Within a same community/house, 
individuals might be exposed at different rates.  
2. Age-dependent exposure  
In some countries malaria exposure can vary between children and adults due to a number of 
different reasons including use of bed nets preferred for children only or occupational malaria with 
increasing exposure when children start to work. Here, I assumed that individuals older than   
years old (referred as adults) are exposed at a rate  and individuals younger than   years old 
(referred as children) to be exposed at a lower rate *  , where [0,1]   (See Figure 5.14A). The 
distribution of individuals in each antibody class at age t can be modelled as: 
 
( (0), * , ; , )         if t
( )
( ( ), , ; , )           if t>
Y y t
y t
Y y t
    
    

 

 (5.6) 
with the distribution of the population according to an individual’s antibody level at the beginning 
of the exposure time being at birth ( (0)y ) for children and at age   for adults ( ( )y  ). 
3. Changes in transmission intensity 
Due to interventions put in place or other environmental factors, in some areas malaria 
transmission intensity can vary through time. Here I extend the density model to assess whether a 
decline in transmission can be detected. I assumed a sudden change, reflecting effective control 
interventions, happened Ω years before the survey and the exposure rate dropped from   to 
*  , [0,1]   (See Figure 5.14B). So individuals, aged t  years old at the time of the survey, 
were exposed from birth to -t   at rate   and at rate *  for the last Ω years between the 
change and the time of the survey. Individuals born after the change (less than   years ago) were 
exposed at a single rate *  . The distribution of individuals in each antibody class at age t can be 
modelled to account for the change in transmission as: 
 
( (0), * , ; , )                if  
( )
( ( ), * , ; , )          if       where   ( ) ( (0), , ; , )
           
Y y t t
y t
Y y t t t y t Y y t
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 
 
     (5.7) 
(a) (b) 
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Figure 5.14: Schematic representation of the variability in exposure due to age and time. (A) At age ω, children who 
were exposed at rate λ*β are now exposed at rate λ, indifferently of the time. (B) A change in transmission, due to 
successful intervention for instance, happened Ω years ago. Before the change all individuals were exposed at rate 
λ and since the change individuals are exposed at the reduced rate λ*β.  
A summary of the model parameters for the three extensions of the density model is presented in Table 
5.6. 
Table 5.6: Summary of the model parameters related to exposure for the three extended models 
Scenarios Parameters Description Prior Distributions 
Heterogeneity 
λ Exposure Rate (years-1) Uniform on [0,100] 
β Scaling for exposure Uniform on [0,1] 
p Proportion of individuals exposed at rate λ Uniform on [0,1] 
 
Age Effect 
λ Exposure Rate (years-1) Uniform on [0,100] 
β Scaling for exposure Uniform on [0,1] 
ω Age at change in transmission (years) Uniform on [1,100] 
 
Changes in 
transmission 
λ Exposure Rate (years-1) Uniform on [0,100] 
β Scaling for exposure Uniform on [0,1] 
Ω Time since change in transmission (years) Uniform on [1,100] 
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5.3.4 Fitting extended models to simulated data 
To assess the performance of the method to quantify transmission intensity in complex settings, I designed 
simulations based on the following three scenarios:  
1. Heterogeneity in exposure 
I assumed that data were collected in a survey where the population had heterogeneous exposure 
of transmission with a proportion 0.8p   (subpopulation A) exposed at a constant rate
13.5 yrs  while the other individuals (subpopulation B) were exposed at a constant rate
* ,  with  =0.2   .  
2. Age-dependent exposure  
I made the assumption that data were collected in an area where adults, after the age of 15  , 
were exposed at a rate
13.5 yrs  , while children younger than 15   years old were exposed 
at a rate * ,  with  =0.8    
3. Changes in transmission intensity 
A change in transmission was assumed to have happened 15 years ago. Before the change, 
individuals were exposed at a rate
13.5 yrs  and since the change individuals are exposed at a 
rate * ,  with  =0.8   . 
For these three scenarios, biological parameters modelling the boost of antibodies are assumed to be 
constant with the maximum size of the boost of antibodies 0.75a  , the slope of dependence of the boost 
size 0.5b  and the standard deviation 0.02S  . “Seronegative” individuals had an average boost size of 
0.01  and the rate of decay of antibodies was set to 0.7 years-1. I used the same age structure that was 
used for the simulation in section 3.3.1, based on the Cambodian data set. The number of individuals in 
each antibody level category was drawn from a multinomial distribution with its associated probability 
corresponding to ( )iy t , where ( ) ( ( ))i iy t y t  is described in Section 5.3.3 for each of the scenarios. I also 
assumed that at birth no individuals presented with antibodies, thereby ignoring maternal immunity. For 
each scenario 50 datasets were simulated and parameter estimation was performed for each of them using 
MCMC approach using the following multinomial log-likelihood:  
,log( ( | )) log( ( ))i t i
t i
l P D n y t   (5.8) 
with ,i tn and ( )iy t  respectively the observed number and modelled proportion of individuals in antibodies 
category i at age t. Only parameters related to exposure (the exposure rate  , the scaling factor  , the 
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proportion p , the age of change  and the time since the change  ) were estimated and their associated 
uninformative priors are presented in Table 5.6. The biological parameters (the maximum boost size a , the 
slope of dependence b , the standard deviation S , the maximum boost size for “seronegative” individuals 
  and the rate of decay of antibodies  ) were set to the values used for the simulation. I performed 
40,000 iterations for each run of the MCMC algorithm with a burn-in period of 1,000 steps. The output was 
recorded every 10 iterations to generate a sample from the posterior distribution of size 3,900. 
5.3.5  Confidence regions from profile likelihood  
So far, Bayesian methods have been used to provide inference on model parameters. However, classic 
methods such as estimation by maximum likelihood were also used in this chapter, as the use of Bayesian 
methods becomes computationally intensive when exploring temporal heterogeneity in transmission. Here, 
I present the use of profile likelihood methods [242] to construct the confidence intervals for the 
parameters of interest . Let   be the other parameters of the model, also termed nuisance parameters. 
Denote by ( , )L   the likelihood function and by ˆ  the maximum likelihood estimates. The profile 
likelihood ( )lP   is defined by ( ) max ( , )lP L   . Confidence regions are based on likelihood ratio 
test. Indeed, the likelihood ratio test statistic of the hypothesis 0 0:H   (where 0  is a fixed value), 
given by  
0( )2log
ˆ( )
l
l
P
P


  follows a 2p distribution with p the dimension of  .  So the profile likelihood-based 
confidence interval is given by: 
2 2
,1 ,1
1 1ˆ ˆ: log ( ) log ( ) : log ( ) log ( )
2 2
l l p l l pP P P P         
   
       
   
 
with 
2
,1p   the (1- ) percentile of 
2
p distribution.   
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5.4 Results 
5.4.1 Measuring malaria transmission intensity in Somalia, Bioko, Gambia and Uganda 
5.4.1.1 Measuring malaria transmission intensity analysing each antibody separately 
The fitted model for each separate antibody is presented in Figure 5.15 and Figure 5.16 respectively for 
MSP-1 and AMA-1 and the parameter estimates are shown in Table 5.7. 
In all countries the model reproduces the data relatively well for both anti- MSP-1 and anti- AMA-1 
antibody levels.  
Around 15 and 5 years old, respectively for Bioko and Uganda, anti-AMA-1 antibody levels appear to 
plateau and then decrease with age. The model is not able to capture these trends. Instead, in Bioko, while 
the model fits the levels of anti- AMA-1 antibodies between birth and 10 years old well, they are under-
predicted for individuals between 10 and 50 years old and over-predicted for individuals older than 50 
years. In Uganda, the fitted model overestimates anti- AMA-1 antibody levels from the age of 25 onwards. 
There is also a decrease in anti- AMA-1 antibodies observed in the data but this is less marked than for 
Bioko. The fitted model tends to over-predict the number of individuals with no circulating antibodies, due 
to the low estimates of the average boost size for these individuals,  . Nevertheless, the age-specific 
distribution of antibodies does not appear to show these results. This might be due to the overall number 
of individuals with high levels of anti- AMA-1 antibodies being over-predicted to balance the under-
prediction of lower antibody levels.  
 
Figure 5.15: Anti- MSP-1 antibody distribution. Overall (first row) and age specific (second row) antibody 
distributions for Somalia, Bioko, Gambia and Uganda (left to right). Median fit  ( 95% prediction interval) for median 
antibody levels are represented by the red (black)  dashed lines. Dark and light shaded area represent respectively 
25th/75th IQR and 2.5th/97.5th IQR for the data. Solid red lines represent 25th/75th IQR for the model fit.  
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In the age specific antibody distribution (Figure 5.16), the median fit of the median antibody level and its 
associated 95% credible interval are represented with respectively red and black dashed lines while the 
median fit of the 25th and 75th percentiles (IQR) are represented by the solid red lines (no credible intervals 
presented for the IQR model fit).  
 
Figure 5.16: Anti- AMA-1 antibody distribution Overall (first row) and age specific (second row) antibody 
distributions for Somalia, Bioko, The Gambia and Uganda (left to right). Median fit ( 95% credible interval) for 
median antibody levels are represeted by the red (black) dashed lines Dark and light shaded area represent 
respectively 25
th
/75
th
 IQR and 2.5
th
/97.5
th
 IQR for the data. Solid red lines represent 25
th
/75
th
 IQR for the model fit. 
It is important to note that, despite a good fit of the model to the data for AMA-1, the posterior 
distributions found for the parameters were bimodal (See Appendix VI), suggesting either a high rate of 
exposure and a small mean antibody boost or a low rate of exposure with a large mean boost. Given the 
available data on anti- AMA-1 antibodies the model was not able to distinguish between these hypotheses. 
Exposure rate estimates for each country are presented in Figure 5.17A for anti- MSP-1 antibody and the 
bimodal distribution is presented in Figure 5.17B for anti- AMA-1 antibody. Countries are shown according 
to their expected level of transmission increasing from left to right. The exposure rate estimates increase 
with increasing expected level of transmission. However, the estimated exposure rates differ depending on 
the antibody type fitted to. For example, the estimated rate of exposure in Uganda is lower than that in The 
Gambia when the model is fitted to anti- MSP-1 antibody data. However, when fitted to the anti- AMA-1 
antibody data the exposure rate for Uganda is much higher (considering either of the two modes). Despite 
the bimodal distribution of exposure for AMA-1, either of the parameter sets corresponding to these two 
modes remains correlated with increasing level of transmission between countries. 
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Figure 5.17 Estimates of exposure rate for anti- MSP-1 (left) and anti- AMA-1 (right) antibodies. Median and 
posterior 95% credible intervals are represented by the black square and error bars. Individuals estimates from the 
MCMC algorithm are presented in colours: Somalia (orange), Bioko (blue), The Gambia (green) and Uganda (purple). 
Nothe that the y-axes are on different scales. 
Despite expected biological differences between MSP-1 and AMA-1 antigens, the estimates of the 
parameters modelling the antibody boost are somewhat comparable, but with a higher standard deviation 
for AMA-1 (See Table 5.7). Also, “seronegative” individuals tend to have higher anti- AMA-1 antibody boost 
size, but for both antigens, following the first exposure, individuals are estimated to remain “seronegative”. 
Indeed given the lognormal distribution of the boost with mean size η and standard deviation S, only a 
negligible proportion of the “seronegative” individuals will increase their anti-MSP-1 antibody level (2% for 
MSP-1).  
Table 5.7: Parameter estimation for estimation using respectively anti- MSP-1 and anti- AMA-1 antibodies. 
Parameter 
MSP-1 AMA-1 
Median (95% CrI) Median 1 Median 2 (95% CrI) 
Exposure rate λ     
Somalia 4.7 (4.5-4.8) 2.1 2.8 (1.9-3.2) 
Bioko 6.1 (5.9-6.1) 3.7 4.7 (3.4-5.2) 
The Gambia 7.3 (7.1-7.5) 4 5.1 (3.7-5.7) 
Uganda 6.8 (6.7-7) 5.3 6.7 (4.9-7.4) 
Maximum boost size a 0.75 (0.69-0.86) 1.3 0.86 (0.73-1.4) 
Slope of dependence b 0.52 (0.5-0.55) 0.42 0.38 (0.36-0.43) 
Standard deviation S 0.02 (0.017-0.033) 0.15 0.14 (0.11-0.18) 
Maximum boost size for 
“seronegative” η 0.021 (0.007-0.045) 0.044 0.034 (0.028-0.049) 
Note here that the modes for the parameter distribution for anti- AMA-1 antibodies were clearly 
distinguishable; therefore the posterior distribution was split in two subsets to derive the median for each 
mode.  
 
(A) (B) 
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5.4.1.2 Measuring malaria transmission intensity analysing simultaneously both antibody 
types  
The model was next extended to simultaneously estimate parameters associated with the acquisition of 
multiple types of antibodies. The estimates obtained are presented in Table 5.8.  
The estimates obtained for the boost parameters are comparable to those obtained when fitting the model 
separately to the different antigens. The estimates of the exposure rates are similar to those obtained by 
fitting the model to the MSP-1 antibody data with the exception of Uganda, which is estimated to be 7.2 
years-1 (95% CI: 7.0-7.4), higher than the exposure rate in The Gambia equal to 6.8 years-1 (95% CI: 6.7-6.9).  
Table 5.8: Parameter estimation when both antibody types are simultaneously included in the model. 
Estimates    Median (95% CrI) 
Exposure  MSP-1  AMA-1  
Somalia 4.1 (4-4.2) a 0.93 (0.85-1) a 0.57 (0.53-0.61) 
Bioko 5.9 (5.8-6) b 0.57 (0.55-0.59) b 0.35 (0.33-0.36) 
The Gambia 6.8 (6.7-6.9) S 0.021 (0.018-0.021) S 0.082 (0.074-0.093) 
Uganda 7.2 (7.0-7.4) η 0.025 (0.009-0.042) η 0.020 (0.018-0.021) 
 
The model fits reproduce well the overall and age-specific distributions of both anti-MSP-1 and anti-AMA-1 
antibodies (See Figure 5.18). Nevertheless, the model tends to overestimate the number of individuals with 
no circulating antibodies (as the model predicts “seronegative” individual to stay “seronegative”). The 
model fits (Figure 5.18) suggest similar predictions to those obtained by fitting the model to the two 
antibodies independently. 
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A comparison of the estimated exposure rates is presented in Figure 5.19A with their association with 
estimates of seroconversion rates (SCR) obtained using the catalytic model. A high degree of correlation is 
observed between seroconversion rates derived using a catalytic model and exposure rates obtained fitting 
a density model (Spearman correlation r=0.94 between density model using both antigens and SCR derived 
using MSP-1). However, the models fitted to the different antibodies independently rank the exposure 
from each country in different orders to those fitted to the two antibodies together. It is worth noting here 
that this difference is also observed when exposure is assessed using seroconversion rates. In addition, 
when both antibodies are analysed in a single model, the ranking of villages based on exposure correspond 
to the expected ranking (Table 5.2), also found considering anti-AMA-1 alone (Uganda has higher exposure 
than The Gambia). As seen in Figure 5.19B, using both antibodies in the evaluation of transmission intensity 
improves the precision of the estimations. Note that the precision of the estimated exposure rate using 
density models is relatively consistent for each country, while precision for SCR highly depends on the 
endemicity level (here country). 
 
 
Figure 5.19: (A) Association between exposure rate from the density model and seroconverion rate (SCR). Median 
estimates of exposure and their associated posterior 95% credible interval are presented for each country when 
density model used simultaneously both anti- MSP-1 and anti- AMA-1 antibodies (first column), separately anti- 
MSP-1 and anti- AMA-1 antibodies (second and third columns). Estimates of SCR are presented when anti-MSP-1 
(fourth colum) and anti- AMA-1 (last colum) antibodies are considered.  (B) Coefficient of variation for exposure 
rate derived for each country categorised by the different methods.  
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5.4.2 Simulation study 
A total of 50 datasets were generated for each of the scenarios described in the methods section using 
extended versions of the density model. In the first scenario, antibody levels are modelled assuming that 
the population is exposed to two different levels (scenario A). In the second scenario children and adults 
are assumed to be exposed at different rates (scenario B). In the third scenario a change in transmission is 
assumed to have occurred in the past (scenario C). For all the simulations, the “true” parameter value used 
in the simulation fell within the 95% credible interval obtained from fitting the model to the simulated data 
in 96.8% of the cases for scenario A, 90.7% for scenario B and 97.3% in scenario C. Details of these 
probabilities are given for individual parameters in Table 5.9.  
Table 5.9: Probability of correctly estimating each of the parameters 
Scenarios Param. Description 
Probability of correctly 
estimating individually  each 
parameter 
(A) 
Heterogeneity 
λ Exposure Rate 92% 
β Scaling for exposure 100% 
p 
Proportion of 
individuals exposed at 
rate λ 
98% 
  
(B) 
Age Effect 
λ Exposure Rate 78% 
β Scaling for exposure 94% 
ω 
Age at change in 
transmission 
98% 
  
(C) 
Changes in 
transmission 
λ Exposure Rate 96% 
β Scaling for exposure 96% 
Ω 
Time since change in 
transmission 
100% 
 
Figure 5.20 illustrates the results from the simulation studies. These scenarios do not necessarily provide a 
clear pattern in the data that would clearly indicate the underlying simulated heterogeneity or change in 
transmission. When individuals experience a high degree of heterogeneity in exposure in the population 
(across all age classes) as in simulation A this is noticeable in the wide range of the antibody levels.  
However, even this would be difficult to determine without the comparison dataset. The parameter 
estimation was able to recapture the model parameters and therefore the model fits the data extremely 
well. 
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Figure 5.20: Simulation study results for models considering heterogeneity in exposure (A), the effect of age on 
exposure (B) and a change in transmission intensity (C). For each scenario, the distribution of the antibody levels in 
each of the simulated dataset is presented in the left panels. The middle panels illustrate the model fit for a set of 
simulated data  (25
th
/75
th
 IQR in grey and median in white) against the median fit obtained using the posterior 
median of the model parameters (red line) with its associated credible interval (black dashed lines). The right 
panels represent the posterior 95% credible intervals and median for each of the parameters estimates for each 
simulated dataset. The red line corresponds to the value of the parameter used during the simulations. 
Note also that only 50 simulations were performed here, therefore it is likely that the confidence on the 
proportion of simulations in which the parameters are correctly estimated might increase by increasing the 
number of simulations.   
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5.4.3 Applying the extended models to real data 
5.4.3.1 Assessing changes in transmission intensity in Bioko Island  
Malaria control interventions have been put in place in Bioko Island since 2004. Multiple studies have 
shown that since the implementation of the interventions, a heterogeneous impact has been recorded 
around the island [135, 237, 241]. I therefore extended the density model to be able to capture any change 
in malaria transmission that has happened in the different areas on the island. Due to the computational 
complexity of the model, I did not attempt to estimate change in transmission. Instead, I used the posterior 
median of the boost parameters obtained when applying the model to both MSP-1 and AMA-1 antigens 
separately (See Table 5.10) and I used profile likelihood methods to explore how different combinations of 
the parameters (the exposure rate  , the scaling factor  and the time since the change  ) influence the 
fit of the model (as measured by the likelihood). By analysing each region separately, I accounted for 
heterogeneity in exposure between the regions and assumed that the exposure, the impact and the time of 
the change are specific for each region. To construct the grid, I used the ranges of exposure rate obtained 
with a regional analysis performed in Bioko (not presented) i.e. between 4 and 8 for MSP-1 and 2.5 and 5 
for AMA-1. Additionally, I assumed that a change could have happened between 1 and 20 years ago. As a 
consequence, the likelihood was computed annually for 10 values of the scaling factor   equally spaced 
between 0 and 1, and 15 values of exposure rate for each of the antigens, resulting in a grid of 3,000 points. 
The likelihood, function of the scaling factor   and the time since the change in transmission   are 
illustrated in Figure 5.21. Additional results presenting both of these factors against the exposure rate 
(presented in the Appendix VI) show that the precision associated with the exposure rate is relatively good 
for both antigens.  
Table 5.10:  Parameter values used for nuisance parameter for derivation of likelihood for both MSP-1 and AMA-1 
data. 
Parameter MSP-1 AMA-1 
Maximum boost size a 1.7 1.3  
Slope of dependence b 0.69  0.42  
Standard deviation S 0.025  0.017  
Maximum boost size for “seronegative” η 0.034 0.055 
Rate of antibody decay ρ 0.7 0.7 
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Figure 5.21: Log Likelihood computed for varying values of the exposure rate  , scaling factor  (y-axis) and the 
time since the change of transmission intensity  (x-axis) for both MSP-1 (A) and AMA-1 (B) antigens for various 
regions in Bioko 95% confidence intervals are represented in red. Only the maximum likelihood for the different 
values of exposure rates is presented. 
The results with MSP-1 antigen suggest that in most of the regions, it was not possible to detect any change 
in transmission by fitting to MSP-1 antibodies (scaling factor   is around 1). For the South East and South 
West regions, the results suggest that there might have been a change in transmission which happened at 
least 2 years before the survey when transmission dropped up to 30%. Results obtained with anti- AMA-1 
antibodies show that a change in transmission happened between 2 and 7 years before the survey, 
resulting in a drop of transmission intensity between 20 and 40%. The results for AMA-1 also show that in 
Malabo, South East, South West, North West and Other regions, there might have been a change in 
transmission which happened at least 2 to 3 years before the survey when transmission dropped up to 30% 
in certain regions. In the study carried out by Cook and colleagues [133], a drop of transmission intensity 
was also recorded in the North East region. In addition, their reported magnitude for the drop in 
transmission intensity was around 83% when measured with SCR, 79% when measured with parasite rate 
and 65% when measured with under 5 mortality rate. Note that in their study, a change of transmission 
was detected in all regions except the North West, while my results suggest there might have been a 
change but the uncertainty around its date is rather high. 
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5.4.3.2 Assessing age-dependent exposure in Cambodia 
In Cambodia, malaria exposure is thought to depend on age since adults working in the forest are at high 
risk through exposure to vector populations residing in the forest fringes. Therefore, to test whether age-
dependent factors can be estimated from these data, I made the assumption that when children reach the 
age to work in the forest their exposure level changes. This model was fitted to a subset of data collected in 
Cambodia (previously presented in Chapter 2), with a domain known to be less exposed (Chris Drakeley – 
personal communication) disregarded.   
I assumed that exposure was constant in the different areas and hence that only age determines a change 
in transmission. I made the assumption that children start to work in the forest between the age of 9 and 
18 (used as uniform prior for ) and children have lower exposure than adults, therefore I used a uniform  
prior on [0,1] for the scaling factor  . I performed 180,000 iterations for the MCMC algorithm with a burn-
in period of 50,000 steps. The output was recorded every 100 iterations to generate a sample from the 
posterior distribution of size 1,300. The parameter estimates (See Table 5.11) were comparable to those in 
Chapter 3. However, an effect of age on transmission was recorded around 13 years old. Additionally, it 
was found that children are 10% less exposed than adults (See Figure 5.22). As suggested before, the 
change in exposure can be due to children starting to work in the forest or benefiting less from bednets. 
Table 5.11: Parameter estimates for model using age effect in Cambodia 
Parameter Estimates    Median (95% CrI) 
Exposure for adults       λ 5.4 (5.3-5.5) 
Scaling factor for exposure for children β 0.9 (0.87-0.92) 
Age of change               ω 13 (9.7-15) 
Maximum boost size     a 0.6 (0.56-0.67) 
Slope of dependence     b 0.48 (0.46-0.5) 
Standard deviation       S 0.29 (0.26-0.33) 
Maximum boost size for “seronegative” η 0.0029 (0.0014-0.0084) 
 
Figure 5.22: Exposure rate and age of change. Median estimates of exposure and their associated posterior 95% 
credible interval are presented for children and adults. The median age of change is presented in red and the grey 
box represents the posterior 95% credible interval.  
Emilie Pothin | 152 
 
 
5.5 Discussion 
Several studies [95, 197, 243] have observed an association between blood stage antibodies and exposure 
to malaria. Different countries have different transmission intensities and this is reflected in antibody 
levels. The results presented here demonstrate that the density model developed in the previous chapters 
can be used to estimate malaria exposure across a range of different transmission settings.   
My fitted model was able to reproduce anti MSP-1 and anti-AMA-1 antibody levels in all the studied 
countries.  Additionally, no major differences in quality of model fits were observed between the different 
countries. In The Gambia, for instance, the fitted model underestimated the anti-MSP-1 antibody levels. 
However, the predictions for anti- AMA-1 were qualitatively good, suggesting that the poor fit is not due to 
the country or the endemicity level. Similarly, despite the fact that anti- AMA-1 antibody levels are 
systematically higher, no substantial differences in the quality of model fits were observed between AMA-1 
and MSP-1 antigens. As noted, the model fit is better for anti-AMA-1 antibodies in The Gambia while in 
Bioko, the fit is worse with anti- AMA-1 antibodies, suggesting that the antibody type is not responsible for 
the marginal lack of fit. However, in Bioko and Uganda, the lack of fit for anti- AMA-1 antibody levels is very 
likely due to the decrease in antibody levels in adults, as the model cannot reproduce this phenomenon. 
Indeed, the model assumes that the exposure rate and the acquisition and decay of antibodies are constant 
over age (and time), which might not be valid. An age-dependent rate of exposure might be less likely as an 
explanation than age-dependency in the acquisition or decay as we would also expect to observe it with 
anti- MSP-1 antibodies. The available data does not allow us to identify the reason for this decrease of anti- 
AMA-1 antibodies over the age of the surveyed population in Bioko and Uganda. 
My results demonstrate that the density models can be used to estimate transmission intensity from anti- 
MSP-1 antibody levels. A high degree of correlation was observed between the exposure rates estimated 
using the density model and seroconversion rates, typically used to estimate transmission intensity from 
serological data. The results showed a bimodal distribution for the results using AMA-1 antibodies. In other 
words, the results suggest that individuals have their current antibody level either because they have been 
often exposed but had a small boost each time or because they have less often been exposed but had a 
bigger boost each time. The available data on AMA-1 did not allow me to distinguish between two of those 
modes. However, either of the obtained modes was correlated with transmission intensity. This re-
emphasizes that the results of the model should be regarded as relative results rather than absolute ones 
and in that case the model applied to AMA-1 data can also be used to compare transmission intensities. 
Additionally, it is important to note that I found that the different antigens ranked Uganda and The Gambia 
in reverse order of transmission intensity, and the same result was obtained with SCR using catalytic 
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models. If antibody distribution is mainly determined by transmission intensity, we would not expect to 
observe a different result for different antibodies. Thus there must be some other reason that explains a 
low antibody level in The Gambia. Some unlikely explanations, such as antigenic variation or variation in 
laboratory assays could simply be at the origin of these results. However, a more likely explanation could be 
an immuno-regulation. A saturation of the immune system in high transmission setting, such as Uganda, 
could stop the production of antibodies. The reasons for such phenomenon remain unclear, it could be due 
to immune-suppression caused by malaria infection or the control of blood stage antigen might happen 
through other mechanisms and would control the infection without anti-merozoite responses. Individuals 
would therefore naturally lose their current antibodies and this would explain why anti- MSP-1 antibody 
level measurements are lower in Uganda than in The Gambia (where the transmission is lower). The same 
phenomenon was also observed in a more recent survey in Uganda (Chris Drakeley – personal 
communication). Another explanation could therefore be that there might be some cross-reactivity of the 
antibodies during co-infection with Plasmodium malariae and Plasmodium ovale, also reported in Uganda. 
Despite its low anti- MSP-1 level, the analysis using both antibody types correctly identifies Uganda as the 
country with the highest transmission level. As a result, using both antigens in a single model might reduce 
the bias introduced by any antibody-specific effects.  
Furthermore, there is a growing interest in measuring simultaneously antibodies against multiple malarial 
antigens (rather than single antigens) with multiplex assays [244–246]. Such methods allow a faster 
assessment of the reactivity of antibodies to a panel of antigens and may provide novel information on the 
immune response that might not be identifiable when antigens are considered individually [247]. As a 
result, with its capability to analyse simultaneously multiple antigens, the density model might represent a 
useful tool to measure of transmission more accurately with the results of multiplex assays. 
Here again, I have shown that the precision associated with exposure rates was better using density models 
in comparison with catalytic models. The full information contained in the continuous titre has the property 
to better inform the estimate of transmission in comparison with a binary measurement such as the 
seroprevalence used to derive SCR. The model here was not able to distinguish a single mode for exposure 
rate and therefore the precision associated with its estimate could not be assessed. However, In order to 
assess malaria transmission in low endemicity settings, AMA-1 antigen was shown to present some 
advantages (as it is highly immunogenic) while in high endemicity setting MSP-1 was shown to work better 
(as it is less immunogenic and provides better precision for estimates of exposure) [97]. Further work would 
therefore need to be conducted if the use of AMA-1 antibody increases. Indeed, a better understanding of 
the reason of the incapability of singularly identifying the exposure rate with AMA-1 would be essential. 
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The exact function of antibodies to merozoite surface antigens are not perfectly understood, but the role of 
anti- MSP-1 and anti- AMA-1  antigens have been characterised [248, 249] and their acquisition is therefore 
not expected to be similar. However, the results here demonstrated that, whether antibodies were 
analysed separately or simultaneously, the difference of acquisition of antibodies was mainly different due 
to the variability between individuals. Fitting the model to all countries simultaneously has allowed me to 
explore a wide range of antibody levels. However, by doing so, I have assumed no differences in acquisition 
of antibodies for all the individuals, ignoring ethnic and other differences that might influence the antibody 
response for individuals from each country. Somalia, The Gambia, Bioko and Uganda are countries 
spreading from West to East Africa and therefore there might be a high level of genetic variability between 
these countries that would affect antibody response [250]. Therefore conclusions on the biological 
parameters might not be completely valid. 
Concerning the size of the average boost for “seronegative” individuals, estimates remain very low, 
indicating that “seronegative” individuals tend to stay below the limit of detection once they get exposed 
to infection. This result might not be a complete representation of reality as the model over-predicts the 
number of “seronegative” individuals in each country (with the exception of Somalia for the analyses with 
AMA-1). Such small values are very likely to be influenced by the number of “seronegative” individuals that 
never get exposed. In Chapter 3, I considered a model of the population of “seronegative” individuals as a 
mixture of individuals who never get exposed and those who are exposed and developed an antibody 
response. At the time, a more parsimonious model was chosen as model predictions were very similar 
between model results, in Cambodia, where endemicity is low. However, in areas where transmission 
intensity is much higher, such a model might present some advantages. Indeed, non-exposed populations 
would be accounted for in settings where the current model assumes everyone is highly exposed. Despite 
the high level of transmission in some countries, some individuals might never have been exposed, due to a 
number of different reasons including ecological and environmental factors such as variations in 
attractiveness to mosquitoes [251], damaged or unused bed nets [252]. Therefore taking into consideration 
some heterogeneity of exposure in high endemicity settings and accounting for non-exposed populations 
might be a better representation of what is really happening. 
I also extended the original density model to take into consideration some specific characteristics of 
transmission. Heterogeneity in malaria transmission is relatively common. I therefore extended the model 
to account for heterogeneity in exposure which could indifferently be attributed to different settings such 
as spatial and temporal heterogeneity in mosquitoes distribution [253], heterogeneity due to age [78] or to 
vector control interventions [237]. The estimation method applied to 50 simulated cross sectional datasets 
showed that the specific parameters related to exposure, i.e. exposure rate, scaling factor for exposure rate 
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and proportion of the population exposed at a specific level can be correctly estimated. By setting the 
scaling factor to zero, this model would account for a proportion of the population that would never be 
exposed to malaria infection. This differs from the model presented in Chapter 3 as a specific proportion of 
the population, regardless of an individual’s current antibody level, would not be exposed, and not only the 
“seronegative” individuals, as was assumed there.  
Spatial heterogeneity can be modelled by applying the model to different regions, whereas heterogeneity 
due to an age effect can be represented by assuming a difference in exposure before and after a certain 
age. The model was therefore extended to account for an age effect on exposure. Simulation studies have 
shown that the parameters related to exposure, i.e. exposure rate, scaling factors and the age of change, 
can be correctly estimated. I fitted the extended model incorporating an age effect to a subset of the data 
from Cambodia. An age effect was detected around 13 years old. Children are expected to be 10% less 
exposed than adults. The results therefore imply that when children start working (in the forest), they 
increase their exposure level. Indeed, Cambodia is known to experience occupational malaria, i.e. 
individuals working in the forest represent a high risk group [254]. The results of the model have therefore 
corroborated with this hypothesis. 
In the context of elimination of malaria and with the increasing number of malaria control interventions, it 
is of interest to assess any change in malaria transmission intensity. For this purpose, I have extended the 
model and tested it with simulated datasets. Results show that we can correctly estimate the parameters 
related to exposure, i.e. the exposure rate before the change in transmission, the scaling factor assessing 
the change and the time since the change. As an example, I applied the model to the data from Bioko. My 
results identify some change in transmission, in particular using AMA-1 antigen. These results corroborate 
with what was previously found using seroconversion rates for the same area [133]. However, in their study 
Cook and colleagues identified all the regions, with the exception of North West, as having experienced 
changes in transmission. The density model only clearly identified the North East as having a significant 
change in transmission. The other regions had a high uncertainty around the date of the change. This latter 
parameter could potentially be overestimated due to the babies born after the interventions who lose their 
antibodies relatively quickly. Indeed, the model had assumed a constant loss of antibodies that might not 
be a valid assumption. Additionally, the impact of the interventions measured by the ratio of 
seroprevalence in their study also ranked the North East region as the region that experienced the most 
substantial drop in transmission. The discrepancies in the magnitude of the drop of transmission intensity 
measured with SCR and exposure rate (using density model) can easily be interpreted as a difference in 
methodology. Indeed, SCR measures an incidence, the number of individuals that become seropositive i.e. 
that increase their antibody level above a cut-off value. In contrast, the exposure rate measures the 
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number of individuals that get their antibody level boosted and is therefore driven by the magnitude of the 
change in antibody distribution. As illustrated schematically in Figure 5.23, SCR would characterise the 
change presented in the figure as a substantial drop in transmission intensity while the extended density 
model might not even detect the small change in transmission. 
 
Figure 5.23: Schematic representation of antibody distribution during a decrease in transmission intensity. Antibody 
distribution before (black solid line) and after (blue dashed line) the change are discretised by the cutoff value (red 
vertical dashed line) that defines seroprevalence. 
Historically, changes in transmission intensity have been assessed with multiple cross-sectional surveys or 
longitudinal surveys. Recently, there has been an increase in the use of a single survey that can detect 
changes in transmission using profile likelihood methods [98, 133, 135]. The results have shown that the 
density model can also be used to detect changes in transmission intensity from a single cross-sectional 
survey. Despite being computationally intensive, this method might more accurately capture the 
magnitude of the change in transmission. Additionally, these methods are more likely to detect a sudden 
change in transmission, with successful intense implemented interventions, and not if there has been a 
slow and continuous decrease in transmission over time.  
5.6 Conclusion 
In this chapter, I have applied the density model to four countries with very diverse endemicity settings and 
I was able to reproduce antibody levels for both anti-MSP-1 and anti- AMA-1 antibodies and to measure 
malaria transmission intensity. I then extended the original density model to explore three different 
scenarios: heterogeneity in exposure, an effect of age on exposure and a change in transmission intensity.  
The latter scenario was applied to data from Cambodia and Bioko, and identified respectively an age effect 
and some changes in transmission intensity. It would be beneficial to use longitudinal data to inform 
biological parameters so that the model can adequately assess changes in exposure. Some further 
validation might be required for the extended models but such methods have good potential for multiple 
applications in the context of malaria elimination.  
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Chapter 6: Discussion 
In the current context of malaria control and elimination, measuring malaria transmission intensity is a key 
element for monitoring changes in transmission, planning and assessing the impact of the interventions. 
Recent advances in malaria control have highlighted the importance of serology as a method of quantifying 
malaria transmission, in particular for areas of low endemicity. In this thesis I have developed a new 
method for estimating malaria transmission intensity from antibody levels. This chapter summarises the 
key results, indicates the implications of the research, highlights the limitations of the method and finally 
points out some future directions for research in this area.  
6.1 Summary of findings 
In Chapter 2, I presented a method extended from the classic catalytic model as a “proof of concept” to 
show the association between levels of antibody and malaria exposure. I discretised the population into 
multiple arbitrary compartments according to the individual’s level of antibodies. This discretised density 
model permitted the separation of the effect of exposure and antibody kinetics on the immune response. 
The model was fitted to data from Cambodia and showed a high correlation between seroconversion rates 
and exposure rates (from the density model) for both MSP-1 and AMA-1 antigens. Given the simplicity of 
the model only qualitative conclusions indicating a density- dependency of acquisition of antibodies could 
be established.  
In Chapter 3, I further extended the model presented in Chapter 2 to include a larger number of 
compartments in order to approximate a continuous density of antibodies and therefore a continuous 
model. A variety of different models were tested to mimic individual’s acquisition of antibodies and 
account for heterogeneity in the “seronegative” population. When these models were applied to 
Cambodian data, results indicated that age specific antibody titres, collected from cross-sectional surveys, 
could be reproduced using a density model that assumes a constant exposure rate, a constant loss of 
antibodies and density-dependent acquisition of antibodies. The model retained for the rest of the thesis 
assumes that individuals produce exponentially decreasing amounts of antibodies as their current antibody 
titre increase and the size of this boost is log-normally distributed. Additionally, “seronegative” individuals 
are assumed to have a single specific antibody response. Using this model, estimated malaria transmission 
intensity was correlated with distance to the forest in Cambodia, which can be thought of as a proxy for 
exposure in this setting.  
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In Cambodia the level of endemicity is very low, which might limit the applicability of the density model. 
Moreover, malariometric indices were not available to allow a direct comparison with transmission. To 
validate the density model as a tool for measuring malaria transmission intensity, in Chapter 4 I presented 
analyses of previously published data from Tanzania where an association between serological data and 
transmission intensity has already been identified across a wider range of endemicity settings [95]. The 
model was also validated by informing the biological parameters with informative priors. To provide an 
additional comparison, mixture methods were used to further developed catalytic models so that they do 
not require cut-off values and take into consideration misclassification of seropositive status of the 
individuals. The estimates obtained with the density model were consistent with estimates of 
seroconversion rates, obtained using European controls or mixture models, and provided better precision.  
In Chapter 5, I further tested the density model by applying it to data from four countries with diverse 
endemicity settings. The model was fitted to data from Somalia and Uganda where transmission is 
respectively extremely low and high, from The Gambia, where malaria transmission is seasonal, and from 
Bioko Island which has a successful control programme. The model was able to reproduce antibody levels 
for both P. falciparum anti-MSP-1 and anti- AMA-1 antibodies and to measure malaria transmission 
intensity using anti-MSP-1 antibodies. The use of anti- AMA-1 antibodies to singularly determine malaria 
exposure would require further work. Estimates of exposure were indeed correlated with estimates of SCR. 
However, the data showed similar distributions of anti- MSP-1 antibodies for The Gambia and Uganda, 
resulting in similar estimates of exposure rates for both countries,  whereas Uganda is known to experience 
a much higher intensity of transmission [230]. When both antigens were considered simultaneously in a 
single model, the estimates of exposure provided the correct ranking for estimates of transmission 
intensity. The results suggested that the combination of these two antigens offers higher precision for 
measuring malaria exposure and removed antibody specific effects. Finally, I further developed the density 
model to assess variations in exposure, to investigate an age dependent exposure (that could be associated 
with occupational malaria) and to assess the utility of the model in capturing changes in transmission 
following scaling up of malaria interventions. Results from simulation studies showed that the true 
parameters from these extended models could be retrieved. The application of an extension of the density 
model on data from Bioko captured a temporal change in transmission, confirming what was found in a 
previous study [133]. Additionally, the extension of the density model that accounts for an age effect on 
transmission was tested on data from Cambodia, presented in Chapter 2, and detected a significant 
difference in exposure between children and adults around the age of 13. Further work and validation of 
the extensions of the density model might however be required. 
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In summary, throughout the thesis, I have developed a density model capable of reproducing antibody 
levels reported in cross sectional surveys according to the intensity of parasite exposure. These model 
derived estimates of exposure appear to be a valid tool for measuring malaria transmission intensity in a 
wide range of transmission settings.  
 
Overall interpretation of the findings 
The model assumes that individuals lose their antibodies at a constant rate ρ, fixed during the thesis to 0.7 
years-1 (half-life of 1 year), regardless of the antibody type. The model also makes the assumption that 
individuals produce exponentially decreasing amount of antibodies as their current antibody titre increase. 
Additionally, “seronegative” individuals are assumed to have a single specific antibody response η. As 
malaria transmission increases (measured with exposure rate  ), the number of “seronegative” individuals 
tend to decrease while the antibody distribution for “seropositive” is shifted towards higher antibody 
values (Figure 6.1).  
 
Figure 6.1: Effect of increasing malaria transmission intensity (  ) on overall antibody distribution (A) and age 
specific median antibody level (B). 
In most settings tested the number of “seronegative” individuals appears to be an over-estimate. This 
result is due to low estimates of the parameter mainly driving the number of seronegative individuals,  , 
corresponding to the size of the boost for individuals who do not have circulating antibodies. These 
estimates might not provide an accurate description of the actual biological mechanism as this would infer 
a substantial difference of the size of the boost for “seronegative” individuals and individuals who have 
antibody levels just above the detection limit, corresponding to parameter a . A plausible explanation for 
this phenomenon might be the fact that the density model does not take into consideration the non-
exposed individuals. Indeed the density model makes the assumption that all individuals are exposed while 
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individuals with no circulating antibodies (“seronegative”) are very likely to be individuals who have not 
been exposed (rather than have acquired and lost antibodies). Kinyanjui and colleagues [200] had already 
suggested a similar hypothesis for clinical outcomes implying that individuals who do not get clinical 
episodes are very likely to be individuals who have not been exposed (rather than have mounted clinical 
immunity against malaria).  However, it could be argued that in areas of moderate to high transmission 
intensity, there might be few individuals who are truly unexposed. An alternative explanation for 
individuals to be “seronegative” might be that there is another immune mechanism that reduces the 
number of blood stage parasites and therefore individuals do not mount an antibody response. In the same 
way that they suggest removing unexposed individuals, in areas of high endemicity (where submicroscopic 
infections are less frequent) estimates for the kinetics of antibodies for “seronegative” individuals in the 
density model could benefit from removing individuals who are not carrying parasites or did not experience 
a malaria episode (denoting exposure). The extended density model that considers heterogeneity in 
transmission could also be an alternative method to account for non-exposed individuals. Indeed, the 
density models I have further explored to assess variations in transmission (heterogeneity in transmission, 
effect of age on exposure and temporal change in transmission) are useful tools to measure malaria 
transmission intensity in more specific settings. 
 
The density model developed during the thesis is a novel method for measuring malaria transmission 
intensity using serological data. To my knowledge, this is the first method that reproduces antibody levels 
from cross-sectional survey with mechanistic models based on exposure levels. Instead, antibody levels are 
often reproduced using longitudinal studies and statistical models [255], with no consideration of the 
biological mechanisms. The longevity of antibodies has been the focus of considerable research to better 
understand immune mechanisms. As a result, the decay of antibodies has been studied using longitudinal 
data [132, 192], whereas the acquisition of antibodies remains understudied mainly due to the logistic and 
ethical difficulties in pinpointing the time of an infection and measuring its associated boost of antibodies. 
Measuring transmission intensity from serological data, typically involves the use of seroprevalence data 
and rarely the full information contained in antibody titre. Moreover, I have shown that a better precision 
in estimates is obtained when continuous antibody titre are considered for exposure rate in comparison 
with estimates for SCR. Recently, Bretscher and colleagues developed a model to measure SCRs from 
individual-level longitudinal data on antibody titres [137]. Their method, as well as other mixture model 
approaches, use antibody titres but ignore the acquisition of antibody levels after seroconversion. 
Additionally, their method requires data from longitudinal studies which are logistically and ethically more 
demanding than cross-sectional studies and might not be useful for routine surveillance. I have also shown 
the possibility to extend the density model to account for more complex scenarios of exposure, which was 
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already possible with catalytic models [133, 134]. This makes the density model a useful tool for measuring 
malaria transmission intensity that can be used, for instance, to assess the impact of the interventions or to 
monitor elimination during routine surveillance. 
6.2 Implications of the findings 
In the current context of malaria elimination, there is a need to develop and use robust, accurate and 
precise tools for measuring malaria transmission intensity. Given the advantages that serological methods 
offer for measuring malaria transmission intensity and in particular in areas where transmission intensity 
has fallen to low levels, serological methods have attracted much attention. The renewed interest and 
importance of serological methods in the context of malaria elimination activities has already been 
discussed in detail in Chapter 1. As transmission intensity decreases, parasitological and entomological 
methods become less reliable and more logistically difficult. This makes measurements of anti-malarial 
antibodies, which integrate malaria exposure over time, a more preferred method for estimating exposure. 
Methods outlined in the PhD have the advantage over existing models in that they do not require an 
(arbitrary) cut-off value to differentiate between seropositive and seronegative individuals. As a result, 
these methods, as opposed to catalytic models that require European data for control [95, 97], do not need 
external data to be analysed and in high endemicity settings, the issue of differentiation between 
seropositive and seronegative individuals when mixture models are used (Chris Drakeley – personal 
communication), are not problematic with a density model.  
 
In areas where malaria intensity is low / inexistent, collecting large number of blood samples becomes 
logistically and ethically challenging. Serology has the advantage of a less invasive alternative method of 
collecting saliva samples to determine antibody levels [256]. Serology could also be used to evaluate 
transmission blocking interventions which will shortly be entering phase II and III trials [257]. It is thought 
these will work best in areas of low transmission [258, 259], where standard metrics may not be sensitive 
enough and serology would be preferred. The number of applications and needs for serology is indeed 
increasing, in particular as malaria declines, therefore the improved precision of transmission intensity 
provided by the density model will complement  the current techniques already in place. Serology can be 
used to define malaria endemicity and detect past exposure when parasite rates are zero [27] and as a 
consequence has an important role in surveillance, also considered to be an intervention to achieve malaria 
elimination [11]. The density models outlined in this thesis will complement existing serological methods 
which have already been used to confirm elimination of malaria, assess the impact of interventions and 
monitor changes in transmission intensity [8, 9, 133, 135].  
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The current methods applied to interrupt local transmission include killing the parasite with appropriate 
treatment and vector elimination activities [27]. If these interventions are successful, the absence of 
interaction between parasite/vectors and humans imply that individuals will lose their current antibody 
levels and young children will not produce anti-malarial antibodies [197]. The density models will be able to 
detect such phenomenon, indicating the effectiveness of the interventions, either during multiple cross 
sectional surveys (before and after the interventions have been put in place) or using an extended version 
that account for changes in transmission. An absence of significant decrease of antibody level where 
interventions have been put in place might indicate that the interventions have not worked.  
 
In this thesis, I have developed a model that predicts antibody levels for a cross sectional survey based on 
exposure and kinetics of antibodies. Antibody responses to blood stage antigens induce protective immune 
response to natural infection and are associated with clinical protection. Antibodies are indeed crucial 
components of protective immune response. However, the strength of the association between antibodies 
and protection against malaria remains poorly understood [200]. Some studies have shown that high 
density of antibodies and notably against MSP-1 and AMA-1 antigens could play a major role in the immune 
responses [260, 261]. If further research validates the association between the antibody levels and the level 
of protection, then the density model might represent a useful tool for predicting antibody levels at a 
population-level and could therefore infer on the potential for protection in a population. 
6.3 Limitations of the density model 
The use of mathematical models typically involves a simplification of the actual phenomenon to only 
include characteristics of interest to answer specific scientific questions. In the context of the development 
of a model to reproduce antibody levels from cross-sectional surveys based on exposure levels and kinetics 
of antibodies, a number of biological and epidemiological assumptions have been made. 
 
Simplification of complex biological processes 
 
The process of loss of individual’s antibodies assumes a constant rate of decay of antibodies fixed to 0.7 
years-1 corresponding to a half-life around 360 days. This value, which originated from a longitudinal study 
[192], made the assumption that antibodies detected for serological studies produced by long lived plasma 
cells. However, short lived antibody responses to merozoite antigens are mostly observed [116, 117, 197]. 
Therefore by ignoring the short lived antibody response, the model might over-estimate antibody levels 
when estimates of the rate of decay are based on long lived antibodies. Additionally, the model assumes a 
constant rate of decay of antibodies; the reality is somehow different with the persistence of antibodies 
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differing with age [243, 262]. In the absence of reinfection, children have a more rapid decay in antibody 
levels in comparison with adults [225, 263]. As a result, the antibody levels for young children might be 
overestimated while they might be underestimated for adults. A similar assumption of age-independent 
seroreversion rate is, nevertheless, usually made with classic catalytic models. It is important to note that 
rate of seroreversion from the catalytic model and rate of decay of antibodies measure different quantities. 
Indeed, the seroreversion rate assumes the population is discretised between seropositive and 
seronegative and it therefore measures the rate at which individuals revert back to seronegative, i.e. their 
antibody level drops below the cut-off value. In the density model the rate of decay of antibodies 
corresponds to the decay of antibody levels experienced by individuals. 
 
In the density model, the acquisition of antibodies is based on the simple assumptions that, as individuals 
increase their antibody levels, the amount of antibodies they produce upon infection decreases. In reality a 
number of immune mechanisms, which are not all modelled, are triggered by the presence of the parasite 
in humans, including pre-erythrocytic immune responses and non humoral immune responses for example. 
The immunological processes modelled here are assumed to be constant with time and age. However, 
there is evidence that the development of the antibody response is age-dependent due to the maturation 
of the immune system with age [264]. Additionally, the model does not account for current infections, 
which are generally associated with higher antibody levels [199]. Therefore, any subsequent infection is 
considered to be the same [265], ignoring the theory that superinfections might significantly boost the 
antibody response [266]. As the result, the levels of antibodies predicted by the density model might be 
underestimated in areas where superinfections are more likely (high endemicity). 
 
A number of other biological assumptions have been made to simplify a complex reality. For instance, 
infants are known to be protected against malaria during at least the first few months of life due to the 
transfer of maternal antibodies [62, 267], which was ignored in the model. Also, there might be some 
biological differences in the acquisition and loss of antibodies between individuals or ethnic communities 
due to genetic makeup. Some studies have shown that unidentified genes contribute to variations in 
individual’s inherent susceptibility to malaria [200, 268] and individuals also present differences in 
attractiveness to the mosquitoes [269]. Therefore the assumption of identical antibody kinetics between 
communities might not be the most accurate representation of reality. The model accounts for some 
variations between individuals with a lognormal distribution of the size of the boost though further work 
will be required to determine whether this is sufficient. 
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Epidemiological limitations 
Variations in individual’s antibody levels are mainly attributed to exposure. However, malaria exposure is 
rarely homogeneous. Heterogeneity in malaria transmission contributes to the challenges to achieve 
successful malaria elimination. It is believed that, similarly to other diseases [107], 20% of the endemic 
populations bear 80% of the transmission and more specifically more than 90% for malaria infections [270]. 
The models presented here were used to explore the heterogeneity of the seronegative population and an 
extended version of the density model  also accounted for heterogeneity in transmission that could be 
attributed to identifiable subpopulations (according to, for example, spatial clusters or drug uptake) or 
temporal changes. However, heterogeneity in exposure can be attributed to unmeasurable determinants 
including non-random biting, travelling history, ethnicity or socio-economic differences which haven’t been 
accounted for by the models presented in this thesis.  
 
The age of an individual will influence their antibody level. In addition to its effect on maturation of the 
immune system, age also affects the force of infection [271]. However it is often difficult to distinguish 
between the actual role of age, the length of exposure and the difference in body size resulting in a larger 
exposed body surface [78]. The density model developed here assumes a constant rate of exposure which 
is likely to be an oversimplification. An age-dependent exposure rate was assessed with an extended 
version of the density model though only a non-continuous difference before and after a specific age was 
considered. A more realistic representation of reality would set the exposure rate as a function dependent 
on age (and time).  
 
The increasing progress of malaria vaccines, notably the pre-erythrocytic vaccine RTS,S [272] might have 
some implications for the use of a model that considers levels of antibodies to determine malaria 
transmission intensity. In contrast to naturally acquired immunity that predominantly targets blood stage 
infections, the RTS,S vaccine induces pre-erythrocytic immune response, which in turn will influence blood 
stage immune responses. The observed reduction of levels of blood stage immune markers might be due to 
reduced number of merozoites invading red blood cells (due to pre-erythrocytic immunity induced by the 
vaccine). Indeed, this vaccine does not directly target blood-stage antigens and therefore does not directly 
trigger blood-stage antibody response[273]. The model would therefore correctly associate reduction in 
antibody levels to reduction of blood stage exposure. However, this would not be the case for blood stage 
vaccines, which would enhance the production of anti- merozoite antibodies, without necessarily reflecting 
the level of blood stage exposure. The variations of antibody levels due to the impact of other interventions 
such as vector control or treatment should correctly reflect variations in blood stage exposure.  
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Limitations for the use of serology to measure malaria transmission intensity 
As for other methods that use serological data to infer the force of infection [95, 97, 139, 140, 274, 275], 
the density model assumes that the exposure rate is a measure for the force of infection, i.e. the rate at 
which an infectious mosquito bite successfully causes a blood stage infection. Seroconversion and exposure 
rates, determined respectively by catalytic and density models, have been used to indicate transmission 
intensity. However, it is important to note that serological markers strictly provide information on blood 
stage exposure but are not a direct measurement of mosquitoes exposure. These only approximate a 
mosquitos’ exposure as a number of factors including pre-erythrocytic immune response could prevent 
injected sporozoites developing into blood stage infections [76]. Using the density model with pre-
erythrocytic antibody data would provide a more accurate estimate of malaria exposure as it reflects 
exposure to sporozoites [120]. However, as pre-erythrocytic immune responses do not last as long as blood 
stage immune responses, this might be difficult to achieve. 
As anti-malarial antibodies are highly determined by exposure then most people in areas of high 
endemicity will have high antibody levels. This makes it difficult to distinguish between seropositive and 
seronegative individuals and therefore limits the applicability of catalytic models. Despite the fact that 
antibody levels saturate at high values, the density model is capable of assessing exposure rate provided 
that enough information is collected for individuals who experience variations in antibody levels, i.e. young 
children. Therefore the design of the study in areas of high endemicity is of great importance in order to 
assess malaria transmission intensity accurately.  
The density model was developed to predict the levels of antibodies produced upon exposure. However, 
the avidity of the antibodies is also of importance. Indeed, it is believed that antibody avidity increases with 
repeated exposure [276]. If this is the case, with increasing exposure fewer antibodies might be produced 
during each infection but would be of better quality. The antibody levels would therefore underestimate 
the level of exposure. However, the understanding of the avidity of the antibodies remains poorly 
understood with some studies finding no evidence of an association between antibody avidity and 
exposure [232]. 
Serological methods have been shown to represent useful tools for assessing malaria transmission in the 
context of experimental surveys [95]. However, some operational limitations remain for serology and 
therefore for the density model to be routinely used. The sample collection is easy but most malaria 
programs are currently not equipped to analyse serological samples [27]. An additional limitation comes 
from the computational complexity of the method. Despite having shown advantages of the density model 
over classic catalytic models, the implementation of the method using the full information in the antibody 
Emilie Pothin | 166 
 
 
levels is computationally intensive, which may limit its wider utility. However, this can to some extend be 
overcome given the wider availabilities of statistical packages that can be used to perform such analyses 
and through sharing of code. To this end the R code used for this analysis is available on request. 
6.4 Further evaluations and potential applications 
The significance of the developed density model will be determined by its usefulness in measuring malaria 
transmission intensity to help guide the prevention, control and surveillance of malaria. This thesis has 
shown that there is a wide scope for further developing models that could account for (1) heterogeneity of 
exposure; (2) changes in transmission intensity and (3) the use of multiple antigens as markers of exposure. 
Further studies including longitudinal data could further improve our understanding of antibody kinetics 
and help to better parameterise the model. Additionally the association between exposure rates could also 
be directly compared with measures such as the Entomological Inoculation Rate (EIR) to establish the 
relationship between mosquito and blood stage antigen exposures. Additionally, it would be important to 
calculate the sample size required for the model to provide valid estimates and to detect changes in 
transmission intensity of different magnitudes. The continuous model was mainly applied for P. falciparum 
antibodies. Despite some difference in the life cycle of the parasite, it would be interesting to further 
explore the applicability of the density model for P. vivax. 
 
The density model was developed for anti-malarial antibodies though there is scope for applying this 
methodology to other diseases that present similar epidemiological and biological characteristics.  
Indeed, the model could be applied to infections with a relatively constant transmission rate and decay of 
immunity, antibody levels mainly depending on exposure level and antibody kinetics, and with a systematic 
acquisition of antibodies upon infection that last long enough to be assessed in cross-sectional survey. 
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Appendix I - Details on Metropolis Hastings algorithm 
In a Metropolis Hasting algorithm, the probability of accepting a new value for a parameter   is: 
 
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with * the candidate value,   and  Q  respectively the posterior and proposal distributions. 
Here, I suggest deriving the ratio of the proposals: 
Q( */ )
 
Q( / *)
 
 
 
Let Z*=log( *) , hence 
*
dZ*=d(log( *))=
*
d


 
Therefore, if
2* ~ ( , )Z Norm Z  then 
2
2
( * )
2
2
1
( * / )
2
Z Z
Q Z Z e 



  
The proposal is therefore: 
dZ*
Q( */ )=Q(Z*/ )                               as Q( * / )d *=Q(Z* / )dZ*
d *
1 *
             =Q(Z*/ )                                as dZ*=
* *
1
             =Q(Z*/e )                               a
*
Z
d
      



 



2 2
2 2
2
2
( * ) ( * )
2 2
2 2
(log( *) log( ))
2
2
s Z=log( )
1
             =Q(Z*/ )
*
1 1 1
             =                     as Q( * / )
* 2 2
1 1
            =              as Z=log( )
* 2
Z Z Z Z
Z
e Z Z e
e
 
 



  

 
 
 



 

 
The proposal is log-normally distributed with parameters 
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As a result, the acceptance ratio becomes: 
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However, the posterior distribution is defined as:     ( / ) ( )P D P     
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And, in the implementation, a new value is accepted if: 
 
 
/ * *
<U     
/
P D
P D
 
 
where ~ [0,1]U Uniform  
Or precisely if 
 
 
 
/ * *
log <log U    
/
P D
P D
 
 
  
 
  
 
equivalent to      log / * log / log( *) log( )<log UP D P D       
 
  
Emilie Pothin | 188 
 
 
Appendix II - Deriving antibody levels from the outputs of the model 
As I have discretised the continuous antibody level for the implementation of the density model, I want to 
retrieve an estimated density level from the proportion of individuals whose antibody level falls within the 
51 defined intervals. This requires interpolation to determine the antibody level qz associated with a 
percentile q of the population. In other words, I want to find the antibody level for which q % of the 
population has an antibody level below that level qz  (See Figure 7.1). 
Let iQ be the cumulative proportion of individuals that has a level below level iz , with level iz being the 
median antibody level of the interval 1( , ]i ix x and 1,i ix x the lower and upper bounds of antibody class i , 
with {2,..., }i N  and 1 min 2z x   .  iQ is then defined as:       ,
1
i
i j t
j
Q y

  
Let uQ and 1uQ  be the lower and upper cumulative proportion of individuals that contains the percentile of 
interest q therefore 1( ; ]u uq Q Q   for the intervals 1( , ]u ux x  and 1 2( , ]u ux x   and 1,u uz z   be the 
associated antibody level medians for those intervals. 
 The antibody level below which q % of the population is, is defined as: 
1
1
( )* uq u u u
u u
q Q
z z z z
Q Q



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
 
Note if we are interested in the median antibody level for an specific age range we use q=0.5 
 
Figure 7.1 :  (A) Schematic representation of the derivation of antibody levels from proportion of individuals in 
antibody class i. (B) Schematic representation of the interpolation to determine antibody level based associated 
with the percentile q. 
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Appendix III - Impact of the number of compartments for 
discretisation 
The density model developed in Chapter 3 was a continuous model discretised by dividing the range of the 
antibody titre into N=51 compartments. It is worth assessing whether changing the number of 
compartments and therefore the size of the intervals would affect the estimates of exposure rate. For this 
purpose, I carried out the parameter estimation using both N=41 and N=61. The resulting estimates are 
shown in Figure 7.2. The change in the number of compartments appears to not significantly affect the any 
of the biological parameters (the maximum boost size a , the mean boost size for individuals with no 
circulating antibodies   and the variability amongst individuals, S ). The exposure rate does not seem to 
be influenced by the number of compartments. As long as it is large enough, the number of compartments 
(and therefore the size of the intervals) does not significantly affect the exposure rate estimates. 
 
 
Figure 7.2 : Posterior 95% credible intervals for all the parameters of the model estimated with models using 
different numbers of compartments for the discretisation of the continuous antibody titre. The original 
discretisation being N=51(●), with results also shown for N=41(■) and N=61(▲). 
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Appendix IV - MCMC diagnostics for Tanzania dataset 
In Chapter 4, I estimated simultaneously all exposure parameters assuming all other parameters were 
constant across villages. A total of 16 parameters were estimated, namely 12 for exposure rate for each 
village, the maximum boost size a ,the slope of the decrease b, the standard deviation S and the average 
antibody boost size for individuals with no current antibodies η. Figure 7.3 presents the MCMC outputs 
with the trace and the posterior distribution for each parameter. Visual inspection indicates convergence of 
the markov chains. The marginal posterior distributions obtained were informative with relatively narrow 
credible intervals and an approximately normal distribution. 
 
Figure 7.3: MCMC posterior distribution and trace for exposure rate (yrs-1) for each village and maximum boost size 
(a) , slope of the decrease (b), standard deviation (S) and the average antibody boost size for individuals with no 
current antibodies (η).  
Emilie Pothin | 191 
 
 
Appendix V - MCMC diagnostics for anti- AMA-1 antibodies 
In Chapter 5, I performed the parameter estimation using anti- AMA-1 antibody data from Somalia, The 
Gambia, Bioko and Uganda. A total of 8 parameters were estimated, namely 4 for the exposure rate for 
each country, the maximum boost size a ,the slope of the decrease b, the standard deviation S and the 
average antibody boost size for individuals with no current antibodies η. Figure 7.4 presents the MCMC 
outputs with the trace and the posterior distribution for each parameter. Visual inspection indicates 
convergence of the Markov chains but the posterior distribution of some of the parameters appears to be 
bimodal. The marginal posterior distributions obtained around both modes are relatively well 
distinguishable. These results imply that, given the data, the model is not capable of distinguishing between 
the two modes. These modes appear to suggest that either the exposure is high and the maximum size of 
the boost is low or vice versa (correlation between λ and a). 
 
Figure 7.4: MCMC posterior distribution and trace for exposure rate (yrs
-1
) for each country and maximum boost 
size (a) , slope of the decrease (b), standard deviation (S) and the average antibody boost size for individuals with 
no current antibodies (η). 
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Appendix VI - Additional results for change in transmission in Bioko 
Figures 7.5 and 7.6 present the surface profile likelihood when a change in transmission is assessed for each 
of the six regions in Bioko. Each figure present two of the three parameters for which the likelihood was 
evaluated and the maximum value of the likelihood over the third parameter was reported. 
 
Figure 7.5: Log Likelihood computed for varying values of the exposure rate (x-axis), scaling factor (x-axis) and the 
time since the change of transmission intensity for both MSP-1 (A) and AMA-1 (B) antigens for various regions in 
Bioko. 95% confidence intervals are presented in red. Only the maximum likelihood for the different values of the 
time since exposure was presented.  
 
The uncertainty around the parameters is relatively small for the exposure rate λ and the scaling factor β. 
However, the uncertainty around the date at which the change happens is relatively high for all regions 
except for the North East, when looking at AMA-1 results. 
The multiple modes for the exposure rate could be simply explained by the fact that the grid requires more 
points to explore the likelihood surface. Or this result could also be explained by multiple or continuous 
drops in transmission that the model is trying to cast in a single change in transmission. For the most 
interesting result, in the North East, using the AMA-1 antigen, the distribution is however uni-modal. 
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Figure 7.6: Log Likelihood computed for varying values of the exposure rate, scaling factor (y-axis) and the time 
since the change of transmission intensity (x-axis) for both MSP-1 (A) and AMA-1 (B) antigens for various regions in 
Bioko. 95% confidence intervals are presented in red. Only the maximum likelihood for the different values of the 
scaling factor was presented.  
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